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This thesis is focused on the in vitro reconstitution and optimization of the 
multienzymatic biosynthetic pathways to produce isoprenoids and isoprenoid 
precursors.  
A significant challenge in a multi-enzymatic reaction is the need to 
simultaneously optimize the various steps involved to obtain high-yield of a 
product. In this study, statistical experimental design was employed to test the 
hypothesis that an optimal multienzymatic composition can be identified rapidly 
for high-yield in vitro biosynthesis. We demonstrated the synthesis of amorpha-
4,11-diene (AD), a key precursor to artemisinin, from mevalonic acid (MVA) by 
assembling seven enzymatic steps in one-pot. Guided by Taguchi method, the AD 
yield was significantly improved from 5% to 20%, when the multienzymatic 
concentrations were optimized. Meanwhile, an inhibitory step, farnesyl 
pyrophosphate synthase (IspA), was identified where its product precipitated 
when accumulated to a sufficiently high concentration. To mitigate this limitation, 
the subsequent enzymatic reaction, amorphadiene synthase (Ads), was found to be 
a critical step whereby increasing the enzymatic activity resulted in a remarkable 
improvement of AD yield to approximately 100%.  
Next, mechanistic investigation of the interplay among the enzymes and 
metabolites was carried out to unravel the regulatory behavior of in vitro 
reconstituted AD synthetic pathway.  With the aid of Lin-log approximation, a 
hitherto unrecognized inhibition of ATP on Ads activity was identified. Further 
structural analysis indicated that the polyphosphate moiety elicited the inhibitory 




effect. Hence, another novel product inhibitor, pyrophosphate, was identified that 
potently inhibited the Ads activity. Therefore, an ATP-recycling enzyme 
(pyruvate kinase) and pyrophosphate-hydrolysis enzyme (pyrophosphatase) were 
included in the reaction to minimize the inhibitor concentrations. As a result, the 
kinetics was significantly enhanced by more than 3 fold.  
Recycling the pathway enzymes is cost-effective, and able to enhance the 
specific AD yield. Enzyme immobilization is a desirable strategy often exploited 
in industrial bioprocesses. Therefore, the multi-biocatalysts were co-immobilized 
onto immobilized nickel resins via engineered histidine-tags. Based on the 
regulatory topology of the AD synthetic pathway, a rationally designed bi-
modular system was implemented, which successfully improved the AD yield 
from 40% to ~100%. Furthermore, the multienzymes can be effectively reused for 
7 cycles of reaction. Taken together, approximately 2.2g/L of AD was produced 
within 4 days, which was greater than 6-fold enhancement of AD specific yield as 
compared to the free enzymatic system.  
Furthermore, the oxidation of AD to downstream artemisinic acid was 
explored with yeast whole-cell biotransformations. A hybrid in vivo and in vitro 
platform was demonstrated to produce the cytotoxic compounds, 
dihydroartemisinic acid and artemisinic acid and achieved ~80% conversion.  
Finally, the non-mevalonate pathway was reconstituted and co-
immobilized in vitro to produce 2C-methyl-D-erythritol 2,4-cyclodiphosphate 
(MEC). The first committed step, 1-deoxy-D-xylulose-5-phosphate synthase 
(Dxs) suffered from interfacial inactivation. By omitting Dxs and co-




immobilizing the other pathway enzymes, ~50% of substrate was converted to 
MEC within 10 minutes.  
The findings in the thesis highlighted the advantages of cell free 
biosynthesis which are flexible, easily controlled and manipulated, and 
transcending the cellular barrier. The thesis study significantly contributed to 
optimizing and balancing the multienzymatic system in vitro, by first rapidly 
identifying the optimum enzymatic ratio via statistical experimental design, 
subsequently identifying the bottleneck step and its regulations, and lastly devise 
specific strategies to minimizer inhibitors’ concentrations and de-bottleneck the 
multienzyme pathway. The strategies demonstrated are applicable to other in vitro 
multienzyme biosynthesis system beyond the scope of study. This bottom-up 
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Chapter 1 Introduction 
1.1 Motivation 
1.1.1 In vivo metabolic engineering and its challenges 
Isoprenoids are a diverse class of natural products that have many 
important biological functions. There are at least 55,000 different isoprenoids 
identified to date, but only a limited number of these has been shown to have 
biological functions [1]. This is because many of these compounds accumulate in 
trace amounts in their natural host, making it difficult to extract at sufficient 
amounts for further purifications and applications [2]. The quantum leap in the 
development of recombinant DNA technology has offered an opportunity to 
produce these valuable natural products in surrogate producers such as the robust 
microorganism Escherichia coli (E. coli) with high titers [3, 4]. Substantial 
experience in manipulating the multi-component biosynthetic pathway inside the 
microbes has been achieved in the last few decades. For example, Ajikumar and 
co-workers demonstrated multivariate-modular approach to balance the non-
mevalonate pathway in vivo and successfully produce 1 g/L taxiadiene, an 
important precursor to the anti-cancer drug, Taxol [4]. Despite the recent 
successes in designing novel genetic circuits and in re-directing intracellular 
carbon flux for high yield production of metabolites, major challenge remains. 
The daunting complexity of cells, the unpredictable interference between native 
and synthetic parts, and the fact that cells adapt and evolve are some of the 
significant barriers yet to be resolved [5].  




1.1.2 In vivo metabolic engineering and its challenges 
One way to overcome these challenges in using cells as bioreactor is the 
exploitation of cell-free synthesis. In vitro cell-free synthesis plays a critical role 
and is re-emerging as a powerful platform to optimize and understand the 
biosynthetic pathways without the need to be concerned with cell viability [6, 7]. 
Therefore, it renders the freedom and flexibility to manipulate and adjust its 
components and abiotic environment at levels that may be intolerable to living 
organisms. Moreover, in vitro multienzymes synthesis ensures the regio- and 
stereo- selectivity of the products, and is able to direct metabolism to produce 
desired compounds at mild conditions [7, 8]. One successful application of in 
vitro multienzyme biosynthesis was the production of hydrogen (H2) from the 
pentose phosphate pathway intermediates [9]. The central metabolism 
intermediates that would otherwise be efficiently utilized by microorganisms to 
produce biomass was directed to synthesize the user-defined product. As a result, 
the yield surpassed the theoretical yield by anaerobic fermentation from 4 H2 per 
glucose (in vivo biosynthesis) to 12 H2 per glucose (in vitro biosynthesis). 
Another well-cited application of in vitro multienzyme system was the production 
of the bacteriostatic agent, enterocin [6]. The cytotoxic compound was 
synthesized by assembling 12-enzymatic steps, and achieved 25% conversion. 
However, to successfully assemble a network of multiple biocatalysts to 
synthesize the products at the optimal productivity requires fundamental 
understanding of the system and extensive optimization. For example, even when 
each step of the enzymatic reaction can achieve a yield of 90% conversion, the 




overall yield would be equal or less than 25% for a pathway consisting of 12 
enzymatic steps. To balance the enzymatic fluxes in the multienzyme system is 
paramount to minimize the accumulation of inhibitory intermediates and 
byproducts, improve the life span of enzymes and enhance the productivity of the 
system. To our best knowledge, very few studies on systematic optimization of 
multienzymatic reaction was demonstrated in the literature before the project was 
initiated. Therefore, this thesis study aims to demonstrate strategies to 
systematically optimize and balance the isoprenoid, amorpha-4,11-diene (AD), 
biosynthetic pathway in vitro. Novel industrial optimization tools and system-
level modelling approach were explored to improve the AD titer to near 
theoretical yield. The insights gained and strategies employed will be valuable 
and applicable to other in vitro multienzymes biosynthesis beyond the scope of 
the study. 
 
1.2 Thesis Objectives 
The main objective of the thesis was to assemble and optimize 
multienzymes reactions in vitro so as to produce isoprenoids and isoprenoid 
precursors. The important mevalonate pathway was used as an exemplary 
pathway to be reconstituted and optimized to produce amopha-4,11-diene (AD), 
an important precursor to the antimalarial drug artemisinin.  Mathematical 
modelling and predictions were extensively utilized to aid in addressing three 
important research questions: (1) is there an optimal enzymatic compositions 
present in this multienzymatic biosynthesis system? (2) Are there any regulations 




present among the metabolites and the enzymes? (3) How to improve the kinetics 
and specific yield of the system after understanding its fundamental behaviours? 
They are elaborated specifically as follows.  
(1) We aim to identify the optimum enzymatic ratio of the seven 
enzymatic steps, in order to balance the metabolic flux, and understand 
how each enzymatic activity would affect the final yield of AD. 
Moreover, we hope to identify the key rate-limiting step(s) that its 
concentrations need to be fine-tuned. In the field of cell-free 
multienzymatic biosynthesis, the concept of optimizing and balancing 
multienzymatic activities were often under represented as compared to 
designing unnatural biochemical pathways and producing the final 
product. The conventional method to adjust the enzymatic 
concentrations was by trial-and-error method, which was iterative, 
time-consuming and sometimes failed to capture the true optimum 
condition. Therefore, the purpose of the first study (Chapter 3) was to 
demonstrate the important concept of balancing multienzymatic flux in 
vitro by combinatorial approach and rapidly identify the optimum 
enzymatic levels.  
(2) Following the pathway balancing in vitro, we was able to achieve 
~100% conversion of AD from 5mM mevalonic acid within 12 hours 
of incubation. However, theoretical calculations based on the turnover 
rate of the key rate-limiting step, amorphadiene synthase (Ads), 
revealed that to convert 5mM mevalonic acid required only 3-4 hours. 




Therefore, we hypothesized that the critical step Ads was inhibited in 
the course of reaction. To unravel the limiting factor, we aim to study 
the regulatory network topology present in the multienzyme system. 
Single enzyme analysis is advantageous to unravel the molecular 
interactions between the inhibitor and the enzyme. However, this 
approach entails too many factors and experimental runs and might not 
accurately depict the multienzymatic system behavior. Therefore, we 
pursued a system approach to rapidly quantify an important parameter 
in metabolic control analysis: elasticity coefficient, which reflects the 
biological interactions among the metabolites and the pathway 
enzymes, to some extent. The insights we learnt would guide us for 
further optimization. 
(3) Based on in-depth understanding of the multienzyme pathway system, 
we aim to develop specific strategies to shorten the reaction cycle and 
improve the specific AD yield (mg AD per mg of enzyme). 
Immobilization strategies were also explored in order to save the 
costly purification process and recycle the multienzymatic system. As 
a result, it would render the system industrially favourable.  
(4) Extending from the AD synthesized pathway, we further aim to 
explore semi-in vitro multienzymatic biosynthesis, which potentially 
could be scaled-up and used for industrial applications. Since in vitro 
multienzymatic reaction is flexible and transcends cellular barrier, we 
seek to mix different in vitro reaction formats together in single vessel 




to further convert AD to downstream oxidized artemisinin precursors. 
The membrane-bound cytochrome enzyme, CYP71AV1, was 
perturbing the upstream AD production in vivo. Therefore, a novel and 
integrated in vivo and in vitro hybrid reaction system was proposed 
and aimed to surpass the conversion yield (~60%) achieved in the 
literature. 
(5)  The non-mevalonate pathway is not only valuable for the production 
of the key building blocks of isoprenoids but also intensively studied 
for novel drug discovery. Therefore, we aim to isolate the pathway 
enzymes in vitro, reconstitute them in a single vessel, and develop a 
recyclable platform to study and screen for novel antibiotic drugs in a 
multienzymatic fashion.     
 
1.3 Thesis Organization 
This thesis consists of eight Chapters. Chapter 1 provided a brief 
introduction and the objectives of the thesis, while Chapter 2 reviewed the 
literature related to the thesis topics. In Chapter 3, statistical experimental design 
methodology was employed to optimize the enzymatic ratio of the pathway. It 
successfully predicted an inhibitory enzymatic step, farnesyl pyrophosphate 
synthase (ispA) by which its product farnesyl pyrophosphate (FPP) would 
precipitate in the reaction. Moreover, amorphadiene synthase (Ads) was shown to 
be a critical enzymatic step in order to achieve almost 100% conversion of 
substrate to the product. Chapter 4 described the comprehensive investigation of 




the components in the in vitro multienzyme system to identify interactions among 
the metabolites and the enzymes. Lin-log approximation was used and predicted a 
novel inhibitory effect of ATP on amorphadiene synthase (Ads). It is due to the 
polyphosphate moiety of ATP that resembles the by-product of Ads, 
pyrophosphate, which was found to be a novel, potent inhibitor of Ads.  An ATP 
recycling system and pyrophosphatase were used to maintain a low concentration 
of ATP and the removal of pyrophosphate, respectively. The strategies 
successfully improved the rate of AD production to near theoretical productivity. 
The same strategy was used to devise a bi-modular co-immobilized multienzyme 
system that could effectively reuse the enzymes for 7 cycles of reactions, (Chapter 
5). Chapter 6 extended the study on the pathway so as to convert amorphadiene to 
artemisinic acid (AA) and/or dihydroartemisinic acid (DHAA). A whole cell yeast 
biocatalysis was also explored, which by mixing different formats of in vitro 
system (whole-cell, cell lysates), approximately 80% of AD was converted to the 
downstream products (AA and DHAA). Chapter 7 reported the assembly of the 
non-mevalonate pathway on heterologous surface to produce an important 
intermediary metabolite 2C-methyl-D-erythritol 2,4-cyclodiphosphate (MEC). 
Chapter 8 summarized the important findings of the thesis and provided some 
recommendations for future work. 




Chapter 2 Literature Review 
2.1 Metabolic engineering of isoprenoids 
Natural products represent a rich source of therapeutic agents to defend 
against human disease. Despite the advancement in synthetic combinatorial 
chemistry, natural products and their mimics are still the dominant forms used in 
drug development and disease treatment. Of 155 small molecules used for cancer 
treatment, 47% of them were derived from natural products [10].  Their 
remarkable chemical diversity has motived intense scientific interest in mining 
natural products and identifying their novel functions [1].  Among them, 
terpenoids is the largest and most diverse class of natural products that possess 
many important biological functions [11]. There are more than 55,000 terpenoids 
identified so far, and many of them have functions that are yet to be explored [1]. 
One barrier that curbed the wide utility of terpenoids is their extreme scarcity in 
their natural producing host; some of them were only present in parts per million 
(ppm) level. Therefore, to obtain sufficient amount of a specific kind of 
terpenoids will require massive harvesting and extensive extraction. This space- 
and time- consuming process inevitably limit the supply of high-therapeutic-value 
terpenoids for downstream analysis, and is definitely not sustainable to supply 
global demands. De novo chemical synthesis of many of these terpenoids are not 
industrially viable due simply to the complex chirality of the chemical structures 
and chemical synthesis often result in undesirable side product contaminants. 
Thus, cells as surrogate producers that redirect the metabolite flux towards 
terpenoids production would provide an innovative means to circumvent these 




challenges. Fortunately, despite the structural diversity of terpenoids, they share 
common building blocks- the 5-carbon molecules, isopentenyl pyrophosphate 
(IPP) and dimethylallyl pyrophosphate (DMAPP). The two precursors are 
condensed to form various lengths of hydrocarbon scaffold. According to the 
number of carbons in the skeletal structure, typically in units of five carbons, the 
terpenoids can be classified into hemi- (5 carbon), mono- (10 carbon), sesqui- (15 
carbon), di- (20 carbon), and triterpenes (30 carbon) [12, 13]. Over the past 
decade, metabolic engineering and synthetic biology, using microbial hosts to 
enhance IPP / DMAPP production, have significantly improved the yield and 
numerous useful tools to better control the microbial production were developed 
[14]. Ajikumar et al. employed a multivariate-modular approach to metabolic-
pathway engineering and successfully increased the titer of taxadiene—precursor 
to taxol—to 1 g/L in E. coli strain [4]. Moreover, Paddon et al. combined the 
genetic engineering and fermentation strategy to create a high-producing yeast 
strain and achieved 25 g/L artemisinic acid production [3].  These emerging 
technologies using microbial fermentation (Figure 2.1) is replacing conventional, 
less environmentally friendly chemical processes, and are becoming industrially 
viable [15].   
 
Figure 2.1. From natural processes to fermentation based production of natural 
products.  





In the field of metabolic engineering, pathway balancing is paramount to 
ensure high yield, since it is well accepted that metabolic pathways are not limited 
by a single rate-limiting step and that optimized pathways require the balanced 
expression of several enzymes [16]. Accumulation of pathway intermediates may 
result in compromised productivity and lead to growth retardation [13]. Therefore, 
numerous innovative combinatorial and rational design strategies were devised to 
control and balance the pathway flux, such as using global transcriptional 
machinery engineering (gTME) [17] and co-localization of pathway enzymes 
[18]. However, biology is complex, and our ability to rationally redesign 
biosynthetic pathways is often limited by our understandings of the interplay 
among biomolecular networks [19]. Moreover, the enzymatic levels are hard to 
control when overexpressed in heterologous hosts as these proteins may be 
insoluble when overexpressed and attempt to predict the solubility of the proteins 
is still a significant challenge [20]. Due to the complexity with in vivo based 
production, in vitro multienzyme synthesis (Figure 2.2) has emerged as powerful 
alternatives to cellular based metabolic engineering [21]. Recently, Cheng et al. 
had successfully reconstituted the polyketide pathway in vitro, achieving an 
approximately 25% overall yield, which in vivo production had limited success [6, 
21]. Walsh and co-workers have produced terrequinone A, an antitumor fungal 
agent, in three enzymatic steps, and revealed a novel function of TbiE, that was 
not identified in vivo [21, 22]. Therefore, in vitro multi-enzyme synthesis not only 
provides an alternative route for natural products synthesis, but also provides 




additional insights into identifying regulatory pathways that may assist in both in 
vivo and in vitro biosynthesis.  
 
Figure 2.2. Different platforms for biosynthesis [23].  
Majority of metabolic engineering and synthetic biology projects are performed in vivo. In vitro 
systems are emerging as a complementary technology. In vitro systems can be further subdivided 
into cell free synthesis and multi-enzyme assembly. The former was obtained by lysis of cells and 
mainly used for biomolecules production, whereas multienzyme assembly is obtained with lysis 
and purification, and mainly used for small molecules production. (Reproduced with permission 
from Elsevier.) 
 
2.2 Cell-free and multienzyme biosynthesis in vitro 
The power of in vitro biotransformation was first appreciated over a 
hundred years ago. In 1897, Eduard Buchner used yeast extract to convert sugar 
to ethanol and carbon dioxide for which he won the Nobel Prize (1907 Chemistry) 
[23]. Since then, cell-free synthesis has gained exciting advancement both in 
academic research and commercial applications. Indeed, successful in vitro 
biotransformation have been achieved for several decades, due largely to rapid 
developments of genomic tools and high-throughput engineering techniques [24, 




25]. Majority of in vitro biocatalytic transformation has focused on single 
transformations. One classic example is the polymerase chain reaction, developed 
by Nobel Prize winner Kary Mullis in 1983, that involved only one heat-stable 
DNA polymerase from Thermus aquaticus. It has become an indispensable 
technology in molecular biology and have revolutionized modern biological 
research [26].  Another noteworthy application of single-enzyme is their ability to 
modify the backbones of natural products [13, 27, 28].  Britstol-Myers Squibb 
Pharmaceutical Research Institute has developed an enzymatic process to add an 
acetyl group to C-10 position hydroxyl group of 10-deacetylbaccatin III, and 
convert it to  baccatin III (Figure 2.3), an important precursor to taxol,  with 51% 
yield [29]. Due to the specific action of enzyme, protection of other free hydroxyl 
groups is unnecessary (Figure 2.3). With protein engineering and directed 
evolution, enzymes are now able to accept a broader spectrum of substrates, thus 
expanding its capability in serving as novel catalysis to diversify the structures of 
natural products further [30, 31]. 
 
 
Figure 2.3. Schematic representation of conversion of 10-deacetylbaccatin III (1) 
to baccatin III (1) by C-10 deacetylase, which is an important precursor to taxol 
(3) [29]. 








On the other hand, a vast number of cascade enzyme reactions has been 
developed in the past decades, ranging from the simple combination of 
oxidoreductase with a suitable cofactor regeneration system to highly complex 
multienzymatic synthetic systems [32]. Importantly, many enzymes are fairly 
compatible with each other within certain ranges of operating conditions, as they 
are able to co-exist inside living organisms [32]. For example, an alternative route 
with alcohol dehydrogenase and NAD(P)H cofactor recycling enzyme has been 
used to enrich alcohol enantiomers instead of lipase-catalyzed method [32].   
Monti and co-workers elegantly applied the co-factor specificities rule of certain 
oxidoreductase, and combined 5 enzymatic oxidation and reduction reactions in a 
single vessel for the synthesis of 12-ketoursodeoxycholic acid from cholic acid 
(Figure 2.4); this was not possible by conventional chemistry synthesis [33].  
 
Figure 2.4. Multienzyme synthesis of 12-ketoursodeoxycholic acid from cholic 
acid using sequential oxidation and reduction [33]. 
(Permission to o reproduce the Wiley Materials) 
 
This thesis is focused mainly on multienzymatic cascade reactions. A 
common workflow for multienzyme reaction is shown in Figure 2.5 that 
comprises of the overexpression of each enzyme in a microbial host cell, 
purifying the overexpressed enzymes from host cells, and reassembling them in a 
reaction vessel for biocatalysis.  







Figure 2.5. The common workflow of multienzyme reaction. 
 
2.2.1 Advantages of in vitro multienzyme synthesis 
As part of their inherent property, enzymatic catalysis is regio- and stereo- 
specific, and operate under mild reaction conditions. Many natural products 
contain several chiral centers, hence, resulting in low yield when synthesized 
through traditional chemical synthetic process [34]. For example, the total 
chemical synthesis of taxol resulted in a yield of ~0.4% [4]. Therefore, 
biocatalysts are increasingly favoured by industries to synthesize and modify 
complex target molecules [35-37].  In addition, the use of multienzymes in one-
pot fashion is particular appealing since it saves time from the laborious process 
of isolating the intermediates and hence effectively preventing the loss of yield 
during purification [32]. Sometimes, the auxiliary reaction, such as co-factor 




regeneration, would further enhance the yield by providing thermodynamic drive 
towards product formation and/or irreversibly removing by-products [38].  
In contrast to in vivo production, in vitro multienzyme based technology 
successfully bypassed cellular barriers [23]. Thus, resources could be entirely 
channeled towards synthesis of user-defined products, and the substrates could be 
added freely without a need to consider toxicity. The main advantage of in vitro 
multienzymatic systems as compared to engineered cellular systems is their much 
reduced complexity and therefore ease of controlling the reactions [39].  The 
process could be easily optimized by varying enzyme and substrate 
concentrations, addition of co-substrates and solvents, and by varying pH and 
temperature. Due to the simplified network, mathematical modeling of in vitro 
multienzyme reaction is made easier; the recent modeling methods will be 
reviewed in section 2.3.2. Lastly, for in vitro multienzyme reaction, the purity of 
the final products is much higher as compared to cellular systems where 
competing side reactions and cell metabolites may result in a mixture of 
contaminating compounds [39]. A comparison between in vivo and in vitro 














Table 2.1. Comparison of multienzyme in vivo and in vitro process [40]. (Reprint 
with Permission) 
Characteristics In vivo process In vitro process 
Cell/Biocatalysis Constrains   
Substrate inhibition Possible Possible 
Product inhibition Possible Possible 
Catalytic stability Low High (if immobilized) 
Cost production Low High 
Reaction Constrains   
Reaction reproducibility Variable Reproducible 
By products Possible Unlikely 
Operating conditions High dependence High dependence 
Process Modeling   
Process understanding Mechanism not fully 
understood 
Possible 






Potential Process Controllability 








Process Monitoring   
Online measurements Possible Possible 
Intermediate products Unlikely Possible 
Downstream Processes   
Product recovery Possible  Possible 
Recycling (cell / biocatalysis) Possible Possible (immobilized) 
Others   
Green / renewable process Yes Yes 
Current research activity High Low 




2.2.2 Applications of in vitro multi-enzyme pathway assembly 
There are three major applications in the field of in vitro multi-enzyme 
reaction: directed synthesis of user-defined products (Section 2.2.2.1), screening 
for inhibitors (section 2.2.2.2In vitro multienzyme pathway assembly for drug 
screening), and biochemical analysis of pathway (section2.2.2.3).  
 
2.2.2.1 Directed synthesis of user-defined products 
In vitro multienzymatic synthesis is versatile enough to stop at any step 
along the enzymatic pathway. Pathway intermediates are important to study the 
biochemical properties of the downstream enzymes. Most of the time, isotope-
labelled intermediates served as a good tracker to identify downstream pathways. 
As compared to cell based biosynthesis, multienzyme synthesis would be more 
efficient to obtain such intermediates at high quantity. Schuhr et al. assembled the 
first five 1-deoxy-D-xylulose 5 phosphate (DXP) pathway enzymes together with 




C- labeled 2C-methyl-D-erythritol 2,4-cyclodiphosphate (MEC) with a 
80% conversion yield from pyruvate [41]. They emphasized the importance of 
multienzyme reaction that enabled them to introduce isotope labels at specific 
positions with the same procedure as well as the high efficacy of the process that 
allow them to scale down the reaction so that the products were not diluted. The 
isotope-labeled MEC is important to elucidate the mechanism of downstream 
ispG and ispH enzymes, which have been recently identified as bottleneck steps 
in the DXP pathway [42, 43].  




In addition, in vitro enzyme synthesis is highly tractable, allowing the 
assembly of enzymes from different metabolic pathways and creation of novel 
pathways, as shown in Figure 2.6B. Zhang et al. has demonstrated an unnatural 
synthetic enzymatic pathway to produce hydrogen from economical starting 
material [9]. They assembled 13 enzymes, consisting of enzymes from pentose 
phosphate pathway, and successfully produced hydrogen at a much higher 
theoretical yield than would be achieved in vivo (Figure 2.6B). The entropy 
gained when hydrogen was produced in the gas phase resulted in a negative 
thermodynamic drive and hence making the unnatural process spontaneous. This 
would be challenging for in vivo production since the substrates used such as 
glucose-6-phosphate would be easily diluted inside a living cell. There are many 
more examples demonstrating the capability of in vitro multienzyme synthesis 
which surpasses nature [6, 44-47].  
 
Figure 2.6. Examples of in vitro multienzyme biosynthesis.  
(A) synthesis of 2C-methyl-D-erythritol 2,4-cyclodiphosphate (MEC) by the 1-deoxy-D-xylulose 
5 phosphate (DXP) pathway. (B) The unnatural synthetic pathway to produce hydrogen 




2.2.2.2 In vitro multienzyme pathway assembly for drug screening 
Microorganism have unique and essential pathways that are absent in 
eukaryotic cells. Many of them serve as valuable targets to develop anti-bacterial 
and anti-infective agents. Moreover, due to increasing cases of drug resistance in 
various pathogenic strains, drugs targeting multiple enzymatic sites would be 
preferred to elicit more potent anti-bacterial effect. Therefore, in vitro 
multienzymes assembly provides a focused platform to screen for drugs inhibiting 
multiple pathway enzymes simultaneously. Potential drug leads can be added at 
will without concerning its transport across the cellular membrane. Peptidoglycan, 
for example, is a unique structure in bacteria and is not found in mammalian 
system. Its biosynthetic pathway serve as attractive drug targets. However, the 
lack of pathway intermediates severely hampered the screening process [48]. 
Therefore, El Zoeiby and co-workers reconstructed the peptidoglycan 
biosynthetic pathway of 6 Mur enzymes, for the purpose of developing inhibitors 
to the pathway [49].  The shikimate pathway is an important pathway found in 
plants, fungi and microorganisms, but not in animals, for the synthesis of 
ubiquinone and folate [50]. Deletion of the pathway is lethal to the host cell, so its 
constituent enzymes are valuable drug targets. By means of in vitro assembling 
the purified pathway enzymes, a promising high-throughput assay was developed 
to screen for inhibitors to any of the enzymes simultaneously [51].  
 




2.2.2.3 Understanding of biochemical properties of the pathway 
In a much simplified setting, in vitro multienzyme synthesis is critical to 
understand the fundamental biochemical properties of the metabolic pathway, 
such as the steady-state kinetic behavior as well as the interplay among enzymes 
and metabolites. Yu and colleagues have reconstituted the E. coli fatty acid 
synthase (FAS) using 10 purified protein components, and did a detailed kinetic 
analysis of the in vitro system [52]. By doing so, they were able to deduce an 
optimal molar ratio of the 10 protein components based on the influence of 
individual FAS subunit concentrations on FAS activity. One interesting 
observation made by them was the unusual dependence of FAS activity on some 
but not all of the subunits. Another example is the elucidation of polyketide 
pathway. Sun et al. has been able to identify the biosynthetic pathway to produce 
tetronate RK-682, which is a potent inhibitor of protein phosphatases and of HIV-
1 proteinase [53]. Their work found an unusual enzyme RkD which played a 
central role that is responsible for the synthesis of RK-682. 
 
2.2.3 Challenges of in vitro synthesis 
Despite the many advantages, there are also a number of limitations of in 
vitro systems. A major limitation for in vitro reaction is the need for enzyme 
catalysts that must be obtained in sufficient quantities for refolding and 
reconstitution,  functional and stable under in vitro reaction conditions [39]. To 
tackle the problem, different ways of enzyme synthesis has been demonstrated; 
one promising technology is in vitro translation system where 32 purified 




enzymes from cellular translation machinery are known to be dedicated entirely to 
producing target enzyme at a rate of 160 µg/ml/h  [54]. Innovative reaction 
formats have been devised and implemented to enhance the performance of 
biocatalysts. This is reviewed in section 2.4. Moreover, co-factor dependent 
enzyme reactions involving dehydrogenases, oxidases, kinases, and phosphatases 
require an enzymatic co-factor regeneration system that continuously replenishes 
expensive co-factors by catalyzing the opposite reaction using an inexpensive 
substrate [39]. Majority of the enzymatic steps are reversible in nature, which 
would limit the conversion yield of a multienzyme reaction. With co-factor 
recycling system, the reaction could be further driven to completion [38, 55].  
 
2.3 Mathematical tools aided in vitro multienzyme process optimization  
To engineer a biological system, the application of mathematical tools is 
invaluable in the design process. One of the biggest fine chemicals producer, 
LONZA, routinely applies modeling to avoid formation of inhibiting by-products 
of  biotransformation and also as tools for industrial bioprocess integration [56]. 
Therefore, mathematical simulations are increasingly applied industrially to 
devise the most cost-effective process and maintain control over the process.  
Two kinds of mathematical tools are important here for in vitro 
multienzyme process optimization: (1) statistical experimental design 
methodology; (2) kinetic and dynamic process modeling. They have been widely 
used independently as well as in combinations to identify the optimum process 
conditions in order to achieve the user-defined objectives [57-59].  




2.3.1 Statistical experimental design methodology for process optimization 
The conventional method of process optimization involves the study of 
one variable at a time, which is not only cost and labour intensive but also ignores 
the interactions between the confounding factors [60]. Statistical modeling and 
experimental design methods overcome the limitations and have been extensively 
applied for standard industrial process optimization. It is a “black-box” modeling 
strategy that views experiment as simply connecting inputs (factors) and output 
(responses), and predicts the best relationship between the inputs and outputs 
[61]. Generally, in the design of a statistically based experiment, it involves 
several steps: (1) selection of responses; (2) identification of the confounding 
factors; and (3) choice of the different levels or treatments [62].  Usually, partial 
factorial design is carried out to reduce the experimental efforts.  
One important design methodology was formulated by Dr Genichi 
Taguchi, and is now known as, “Taguchi Methods” [62]. They were first 
introduced as a means to design robust products and processes, and is now widely 
used in many interdisciplinary areas including biotechnology. Taguchi methods 
use orthogonal arrays to minimize and randomize the experimental runs, and 
ensure all the levels of a factor appear at equal number of times [62]. Moreover, 
the methods have flexible structures that can be applied for  two-, three- and 
mixed- level fractional factorial designs, and accurately acquire highly reliable 
technical information [62].  For example, Taguchi method has been successfully 
applied to fermentation processes that produce recombinant proteins as well as 
metabolites [63-66]. Sirisansaneeyak and co-workers have used an L18 orthogonal 




array, one factor at two levels and seven factors at three levels, to increase the 
lactic acid production by 7 fold, and identified the main factor contributing to the 
yield increment was the yeast extract levels [66].  
The strategy adopted by Taguchi method is vastly different from classical 
design of experiments (DOE); it involves the empirical minimization of an 
expected loss function over an uncontrollable “noise space” to determine the best 
design of the controllable factors / variables [67]. The uncontrollable noise space 
could include all the external conditions (such as human operator skill levels) that 
deviate the outcome from the target values [67]. Target values are specified by the 
experimentalists, and are fixed in the following three types: (1) the closer to some 
nominal value the better; (2) the bigger the better; (3) the smaller the better. 
Normally, to improve the production yield, the second target, ‘the bigger the 
better”, is applied. The statistical model would then be able to determine the main 
contributing factor(s), and generalize how individual controllable factor would 
affect the yield by average effect analysis. Analysis of variance (ANOVA) will be 
conducted to access the significance of main controllable factors on the yield. 
Prediction of optimal combinations of the factors would be calculated to guide 
further designs and validations.   
Recently, Taguchi method has been compared with response surface 
methodology (RSM), and artificial neural network (ANN). Aggarwal and co-
workers have noted that RSM requires much more experimental efforts than 
Taguchi methods, while they predicted nearly similar results [68]. However, in 
certain applications, Taguchi methods would lead to non-optimal solutions, since 




the central objective was to reduce variations. Therefore, Taguchi method and 
RSM were often used in sequence to reduce the experimental efforts and identify 
the optimum condition. Teng and co-workers [69] adopted the strategy to 
optimize the culture condition for whole-cell lipase production process. They used 
L18 Taguchi method to narrow down the 8 controllable factors into 4 main factors, 
and further optimized the concentrations of the four key factors by RSM. The 
process effectively reduced the experimental efforts from 80 to 35 experimental 
runs, and improved the yield by 2.2 fold [69].  
 
2.3.2 Kinetic and dynamic modeling for network description 
Understanding the underlying mechanisms of a multienzyme network 
would definitely offer distinctive advantages for better process design and 
optimization. Mathematical modeling is the art of describing the essentials of a 
system in mathematical terms [70]. It digitized a complex biological system into a 
simplified analogue that is easier to analyze, interrogate, predict, manipulate and 
optimize than the biological system itself [71].    Despite the long history of 
modeling, describing in vivo system in models has achieved limited success due 
to the complex multilevel nature of the system. Instead, in vitro multienzyme 
system is much more simplified with known components, and hence, a 
mathematical model can be composed. A spectrum of models is available ranging 
from mechanism driven to data intensive models. Despite the multitude of 
modeling methods, they typically encompass nine phases to construct such 
models: (1) data selection; (2) collection of information on network structure and 




regulation; (3) specification of assumptions and simplifications; (4) selection of a 
mathematical modeling framework; (5) estimation of parameter values; (6) model 
diagnostics; (7) model validations; (8) model refinements; and (9) model 
application [71].  
 
2.3.2.1 Mechanism-based modeling 
One very important mechanism in biochemical analysis is the Michaelis-
Menten Rate Law (MML) (Equation 2.1). which assumes that the enzyme and 
substrates interact transiently, and hence a steady state would be achieved [71]. 
Therefore, defined rate equations could be constructed if the kinetics parameters 
such as Km and Vmax are known. Moreover, the equation is important to study the 
allosteric effects of enzymes by determining the change in Km and Vmax when an 
inhibitor is present.  Ideally, an in vitro multienzyme system could be represented 
by a set of ordinary differential rate equations, governed by MML, to simulate the 
dynamic behavior of the system. However, there are certain limitations that make 
the modeling method less practical. Firstly, many of the kinetics parameters (Km 
and Vmax) have to be determined experimentally. Although they are “constants” 
for individual enzyme, they vary across species and different microenvironment 
[72]. This variation is important to generate diversity in populations and behavior 
adaptations. Secondly, the validity of the assumption may be challenged when 
substrate concentration become very low, especially when the networks involve 
protein-protein interactions [73] and multienzymatic complex formation. Lastly, 
the MML equations become very complex and difficult to analyze when there are 




multiple substrates and mechanisms involved; many enzymes would interact with 
more than one substrate, and their mechanisms are not fully unraveled [74].  
 
Equation 2.1. The Michaelis Menten Equation.  
The symbols are as follows: v is the rate of enzymatic reaction. S: the substrate concentration. 
Vmax is the maximum enzymatic activity. Km: is the Michaelis Menten constant. 
 
In view of the shortcomings of MML, theoretical biologists have made 
effort to modify the equation. Equation 2.2 described the extended version of 
MML, which would be able to capture reversible one-substrate-to-one-product 
reaction mechanism. Moreover, Hill equation [75] attempts to describe the 
cooperative and allosteric interactions between substrate and enzyme. This stems 
from the observation that in vivo substrate concentration did not vary drastically 
but could elicit drastic change in enzymatic activity [76]. 
 
 
Equation 2.2. The extended Michaelis Menten equation.  
The symbols are as follows: v is the rate of enzymatic reaction. Vf and Vr are the forward and 
reverse rate of reaction respectively. Cs  and Cp are the concentration of the substrate and product 
respectively. Km,S and Km,P are the Michaelis Menten constant for substrate and product 
respectively.  
 
To capture the multi-substrate / product characteristics of enzymes, more 
sophisticated rate equations have been developed, such as the Monod-Wyman-
Changeux (MWC) model [77]. However, mechanism driven model requires a 
priori knowledge of the biochemical pathway structure. Therefore, quite limited 
applications have been demonstrated for complex in vitro multienzymatic reaction 




system. Ku and co-workers have attempted to model a C30 carotenoid pathway 
comprising farnesyl pyrophosphate synthase (ispA) and 4,4’-diapophytoene 
(DAP) synthase (crtM) [78]. Detailed kinetics for individual enzyme has been 
carried out under optimized reaction conditions. They were then combined with 
mass balance equations to model the two-step in vitro reaction. With the aid of 
modeling, Ku et al. was able to identify the product DAP is unstable in aqueous 
medium. Hence, they introduced a novel two-phase reaction system, and achieved 
a quantitative conversion from isopentenyl pyrophosphate (IPP) to DAP.   
 
2.3.2.2 Canonical modeling: lin-log approximation 
An alternative approach to modeling dynamic behavior of multienzyme 
systems is canonical modeling method; in particular the lin-log approximation 
approach proposed by Visser and Heijnen which have gained importance and 
attention [79]. It is an extension of Metabolic Control Analysis (MCA), but allows 
larger perturbations of enzyme and metabolite concentrations around the steady 
state [79]. Hence, it is technically feasible to collect the experimental data. 
Moreover, Lin-log approximation is able to capture the nonlinear dynamics of the 
enzymatic reactions while keeping the model relatively simple [71]; the reaction 
rate (Equation 2.3) is a nonlinear function of metabolite concentrations and is 
proportional to enzyme levels [80]. The detailed mathematical descriptions will 
be presented in chapter 4. The objective of lin-log approximation was to estimate 
the elasticity, an important parameter in MCA that describes the effect of a 
metabolite on enzymatic activity around the pre-determined steady state. 




Therefore, elasticity would shed light on the allosteric interactions among the 
metabolites and enzymes; negative elasticity would normally represent an 
inhibitory effect, while positive elasticity correspond to a stimulatory effect [79, 
80]. Wu et al. demonstrated the use of lin-log modeling method to understand a 
linear reconstituted pathway for pyruvate production from glycerate-3-phosphate 
(part of glycolysis pathway) , and were able to estimate elasticities that were 
consistent with biological knowledge [80].  Costa et al. did a comprehensive 
comparison among the available models by using E. coli central metabolism as a 
benchmark and concluded that Lin-log approximation would be the most suitable 
approach to model complex large-scale networks [81].  Therefore, lin-log 
approximation is a powerful method in structure identification and multienzyme 
network topology elucidation; it provides an initial screen of any possible 
regulations present in an in vitro multienzyme system, and hence narrowing down 
the search space. 
 
Equation 2.3. The lin-log approximation equation.  
The symbols are as follows: v and vo are reaction flux and steady state flux respectively. e and eo 
represent the enzyme concentrations and steady state enzyme concentrations respectively. ε0 is the 
elasticity around the steady state which represent the relative change in the reaction rate due to a 
relative change in metabolite level [79]; the mathematical representation is given, too. x is the 
metabolite concentrations. i and m represent the number of reactions and the number of 
metabolites in the multienzyme reaction system respectively.  
 
The drawback of lin-log modeling is that substantial error would be 
resulted if the substrate concentrations are very close to 0, due to the inherent 
property of logarithm operations that log(x) approaches negative infinity when x 
value approaches 0  [82]. Hybrid models, combining both MML rate equations 




and canonical modeling method, might be a better strategy for modeling in 
biological systems [83].  
 
2.4 Formats used in in vitro multienzyme reaction 
Another exciting aspect of engineering in vitro multienzyme reaction is 
the creative reaction formats developed to further enhance the performance of the 
system. The interdisciplinary applications of material research and synthetic 
biology have overcome some limitations of in vitro multienzyme system (section 
2.2.3Challenges of in vitro synthesis) and significantly improved the 
biotransformation efficiencies [39]. For example, the industrially important 
enzyme lipases, when immobilized on hydrophobic solid support, showed 
interfacial activation [84].     
 
2.4.1 Co-immobilization of purified multienzyme system 
Enzyme concentration is much more diluted in vitro as compared to the 
densely packed environment in vivo. Diffusion of substrates into the catalytic sites 
is a significant limitation to reaction kinetics. Increasing enzyme / substrate 
concentration effectively increased the proximity of the catalytic sites and hence 
enhanced the productivity of the multienzyme reaction. Nature has its ways of 
bringing the enzymes closer by creating multienzyme complexes and synthetic 
biology has exploited such strategies recently. There are many ways of bringing 
enzymes into close proximity such as chemical-crosslinking, genetic fusion and 




co-immobilization. Here three particularly interesting strategies would be 
reviewed.  
 
Figure 2.7. Co-immobilization techniques. 
(A) cross-linked enzyme aggregates (CLEA), (B) DNA-directed co-immobilization [85]. (C) 
mRNA display [23]. (Reproduced with permission from Elsevier.) (D) His-tag and Ni-NTA 
interactions. (Reprinted by permission from Macmillan Publishers Ltd) 
 
2.4.1.1 Cross-linked enzyme aggregates (CLEA) 
Inspired by the idea of cross-linked enzyme crystals (CLEC), initially 
developed for X-ray diffraction study, cross-linked enzyme aggregates (CLEA) is 
a facile way of immobilizing enzymes without any physical support. The method 
does not require laborious protein crystallization, which required enzymes to be 
highly purified [86].  The enzymes can be easily precipitated out of solutions by 
simple addition of salts, a concentration step that is commonly applied [86]. Then 
the aggregates is treated with cross-linkers such glutaraldehyde to increase its 
mechanical stability (Figure 2.7A). Additives and modifiers can then be co-
precipitated with the enzymes to further enhance the biocatalytic efficiency. 




Several industrially important enzymes, such as lipases have been immobilized by 
CLEA and has effectively enhanced its activity in organic solvent by 12 fold [87].  
For cascade enzymatic reactions, combi-CLEA is used, namely multiple 
enzymes were co-precipitated together to form the insoluble but functional 
agglomerate. Mateo et al. [88] demonstrated the utility combi-CLEA method on a 
bienzymatic system to produce enantiomerically pure (S)-mandelic acid. They 
reported that the product of combi-CLEA was 98%, which was higher than that of 
individual CLEA particle (94% ee).  They attributed to the substrate channeling 
effect of combi-CLEA that prevented diffusion of intermediate into aqueous 
phase and hence possible racemization [88]. The limitations of the method are 
that the enzymatic function may be affected after precipitation and the inter-
enzymatic distance is difficult to control. 
2.4.1.2 DNA-directed immobilization (DDI) 
To have a spatial arrangement of multienzymes, DNA-directed co-
immobilization is another increasingly important method for in vitro multienzyme 
system. The strand specificities of DNA primers are able to self-assemble into 
scaffolds with nanometer-scale dimensions, termed “DNA origami” [89]. Wilner 
et al. reported a DNA-scaffold activated enzyme cascade reaction, comprising of 
glucose oxidase (GOx) and horseradish peroxidase (HRP) (Figure 2.7B)  [85]. 
Without the DNA scaffold, there would not be any reactions observed. Since the 
dimensions of a DNA strand are defined, they were able to control the inter-
enzymatic distance and hence control the product formation rate.  




Inspired by the idea of RNA display (Figure 2.7C), Jung et al. devised a 
functional protein chip using hybridization between mRNA and DNA to capture 
five enzymes to produce trehalose [90]. They found a linear concentration range 
that the amount of enzymes captured correlated with its catalytic efficiency. 
Therefore, by using the novel chip, the five-enzyme pathway for trehalose 
production in vitro could be effectively optimized.  
A significant technical limitation is to link DNA with the enzymes. 
Although the sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (Sulfo-SMCC) chemistry is efficient in cross-linking, the ratio of 
DNA amount per protein requires careful titration. Moreover, the orientation of 
the protein on the chip is difficult to control, which might affect the enzymatic 
activity. There have been many modifications to both DNA and proteins as 
suggested in literature to overcome these issues. This include the use of aptamer 
[91-93], fusion proteins [94, 95] and chemical modifications to protein [96]. One 
interesting strategy was to modify DNA strand with Ni-NTA, a metal chelating 
group that would non-covalently interact with proteins engineered with 
polyhistidine-tag [97]. This strategy would be reviewed in the following section 
2.4.1.3. 
 
2.4.1.3 Immobilized metal affinity chromatography (IMAC): His-tag and Ni-NTA 
IMAC was invented a decade ago [98] and is extensively used in protein 
purification and immobilization (Figure 2.7D). The advantage of this method is 
that the orientation of the immobilized protein can be controlled, since the his-tag 




can be engineered at either C-terminal or N-terminal of the protein of interest. 
Correct orientation of the enzymes was shown to be critical to enzymatic 
activities on solid support [99, 100]. Moreover, IMAC essentially combines the 
purification and immobilization into one single step, which is a cost-effective way 
to immobilize enzymes [101, 102]. By this method, Shao et al. co-immobilized a 
five-enzyme biosynthetic pathway for uridine 5’-diphosphate N-
acetylglucosamine production, and achieved gram-scale productivity [103]. Liu 
and co-workers [104] demonstrated the direct immobilization of seven enzymes 
onto Ni-NTA agarose beads from cell extracts for UDP-galactose production. 
They were able to alter the spatial arrangement of the enzymes by either 
immobilize one enzyme on one bead or co-immobilize seven enzymes onto one 
bead. They showed that the co-immobilized multienzyme system was able to 
achieve higher product titer than the free enzymes after incubating for 48h. 
A drawback of the method is the weak, non-covalent interaction between 
his-tag and Ni-NTA, which is approximately in submicromolar to micromolar 
range [105]. Therefore, high surface density of Ni-NTA was used to modify the 
solid support [106].  
 
2.4.2 Semi-in vitro synthesis and whole-cell Biocatalysis 
To scale-up the in vitro multienzyme synthesis, other semi-in vitro method 
was explored (Figure 2.2), such as whole-cell Biocatalysis [107], permeabilized 
whole-cell Biocatalysis [108] , and cell-free synthesis [109, 110]. These methods 
omit the enzyme purification step and enable the scale-up of in vitro system. The 




development in the technology has increased dramatically (Figure 2.8), with 
production in the industrial scale (>100L).   
 
Figure 2.8. Milestones in the scalability of batch E. coli extract cell-free protein 
synthesis reactions [23].  (Reproduced with permission from Elsevier.) 
 
Recently, Zawada et al. reported successful scale-up of cell-free cytokine 
production from microscale to 100L scale and achieved 700mg/L by using E. coli 
cell extracts [111]. In their study, they showed almost linear extrapolation when 
the reaction size was scaled-up. Their method has been applied for industrial 
antibody and vaccine production. This study successfully dispelled the myth that 
in vitro system is not scalable, and showed a great promise for the technology to 
be industrialized.  
 
2.5 Amorpha-4,11-diene and Artemisinic acid synthesis pathway 
Artemisinin is the most effective drug ingredient to combat the deadly 
disease malaria [112]. Recently, its potential applications in cancer treatment are 
promising and attract international attentions [113]. It is naturally derived from 
the leaves of the sweet wormwood, Artemisia annua. However, the yield was 
extremely low, ranging from 0.03-0.3%. Moreover, the supply of artemisinin 




fluctuates owing to the weather and overall harvest [114]. Therefore, metabolic 
engineering of microorganism to produce the precursor, artemisinic acid, from 
glucose was developed and achieved approximately 25g/L yield in 7 days [3]. To 
our best knowledge, the production of dihyroartemisinic acid (DHAA) has not 
been demonstrated in vivo or in vitro. Therefore, we would like to explore the 
multienzyme biosynthesis technology to optimize the production of AD and 
DHAA in vitro.   
DHAA is shown to be the immediate precursor to artemisinin, which can 
be easily converted by sun light [115]. It was biosynthesized through a series of 
oxidation reactions from the key precursor amorphadiene (AD), as shown in 
Figure 2.10. AD, which is the first key cyclization product from the ubiquitous 
precursor farnesyl pyrophosphate, represents a key branching point from the 
upstream pathways. As stated in section 2.1, all isoprenoids shared the common 
building blocks: isopentenyl pyrophosphate (IPP) and Dimethylallyl 
pyrophosphate (DMAPP), which both are derived from either the mevalonate 
(MVA) pathway or the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway. 
Recently much attention has been given to the DXP pathway, since the enzymes 
are promising targets for anti-infective and anti-bacterial agents [55, 116]. 
Moreover, the pathway has higher theoretical carbon yield with balanced co-
factors, which are advantageous for industrial IPP / DMAPP based isoprenoids 
production [117]. Nevertheless, MVA pathway is also very important, and it is 
involved in many research areas dealing with hypercholesterolemia and metabolic 
bone diseases [118].  




2.5.1 The mevalonate (HMG) pathway 
The mevalonate (HMG) pathway for the biosynthesis of isoprenoids from 
acetate represents the initial steps in a series of enzymatic reactions for production 
of polyisoprenoids (e.g. dolichol) and sterols (e.g. lanosterol, ergosterol, 
cholesterol) in fungi, plant cytoplasm, animals, most other eukaryotes, archaea 
and some eubacteria [119, 120]. The study in this thesis was focused on the 
production of amorphadiene, a sesquiterpene from mevalonic acid shown in 
Figure 2.9.  
 
Figure 2.9. The schematic representation of the amorphadiene synthesis pathway.  
The enzymes are as follows. Erg12: mevalonate kinase. Erg8: Phosphomevalonate kinase. Erg19:  
Mevalonate diphosphate decarboxylase. Idi: Isopentenyl diphosphate isomerase. IspA: Farnesyl 
diphosphate synthase. Ads: amorphadiene synthase. 
 
Mevalonate kinase (Erg12, EC 2.7.1.36) is the first enzyme that transfers 
γ-phosphate group of ATP to mevalonic acid and form mevalonate 5-phosphate. 
The enzyme from different genomic background has been amplified and studied 
extensively. Despite the fact that they catalyze the same reaction, their allosteric 
property differs significantly. Erg12 from both human and S. cerevisiae was 




demonstrated to be potently inhibited by the downstream diphosphate compounds, 
such as farnesyl pyrophosphate (FPP) [121, 122]. On the contrary, Primak et al. 
[123] recently reported a feedback resistant mevalonate kinase from archaeal 
organism Methanosarcina mazei. Structural insight and basic biochemical 
analysis revealed that FPP would compete with the ATP binding site [124]; there 
is a region of several hydrophobic amino acid side chains positioned near the ATP 
binding site, which would then interact with the polyisoprenoid chain of FPP. 
Changes in orientation and solvent exposure of the region resulted in different 
feedback inhibition pattern of Erg12 [124]. 
Phosphomevalonate kinase (Erg8, EC 2.7.4.2) is the subsequent enzyme 
that catalyzes the reversible reaction of mevalonate 5-phosphate and ATP to form 
mevalonate-5-diphosphate and ADP. Distinctive biochemical and structural 
property exist with Erg8 isolated from higher eukaryotes or from fungi and 
bacteria [125]. Bloch et al. discovered and isolated Erg8 from yeast extracts 
[126], and found the enzymatic activity decreased when ATP concentration was 
increased above 10mM.  Although the enzyme contains an ATP binding site, it is 
not regulated by downstream pyrophosphate compounds. Biochemical analysis of 
Erg8 from Streptococcus pneumonia suggested a random sequential reaction 
mechanism [127].  
Mevalonate diphosphate decarboxylase (Erg19, EC 4.1.1.33) is the last 
enzyme in the mevalonate pathway that catalyzes the ATP dependent 
decarboxylation of mevalonate 5-diphosphate. The enzymatic reaction is essential 
for yeast viability [128]. It has been suggested that Erg19 is regulated since sterol 




production decreased when Erg19 was overexpressed [128]. Therefore, metabolite 
analogs such as 6-fluoro-MVAPP was developed as an potent inhibitor to block 
sterol biosynthesis [129].   
Isopentenyl diphosphate isomerase (Idi, EC 5.3.3.2) catalyze a crucial 
activation step in the isoprenoid biosynthesis pathway [130].  Although this 
enzyme may seem not to be important in the DXP pathway, it is a critical enzyme 
for the mevalonate pathway to produce the electrophile dimethylallyl 
pyrophosphate (DMAPP). It has been reported that Idi plays an important role in 
control of the isoprenoid flux [131]. Structure of E. coli Idi was recently 
unraveled and revealed the unusual mechanism involving protonation of an 
unactivated carbon-carbon double bond, a reaction rarely encountered in nature 
[130]. Several inhibitors to Idi have been developed in the literature, such as the 
epoxide of isopentenyl pyrophosphate which is also a stimulator of γδ T cells 
[132].   
Farnesyl diphosphate synthase (IspA, EC 2.5.1.10) represents one 
important enzyme for condensation of IPP and DMAPP into C10 and C15 
isoprenoid backbone [133]. The enzyme was found to be remarkable in 
differentiating the isomers IPP and DMAPP and to initiate the chain elongation 
with very high stereoselectivity [133]. Single site mutation of IspA can catalyze 
the formation of GPP and GGPP [134]. Detailed kinetics analysis of FPP reaction 
with IPP and GPP revealed an ordered bi-bi reaction mechanism [135]. Recently, 
this enzyme has been a target to treat bone diseases and cancer treatment, because 




nitrogen-containing bisphosphates are effective blockers of IspA, and are also 
inhibitors of osteoclastic bone resorption [136, 137].  
 
2.5.2 Terpene synthase: Amorphadiene synthase  
Terpene synthase is a class of important enzymes that produce some of the 
diverse isoprenoid structures. The crystal structure of taxadiene synthase was 
reported recently, and revealed the structural resemblance among the terpene 
synthases [138]. Yet, terpene synthases showed remarkable product selectivity 
and specificity despite using the same substrate. The availability of amorpa-4,11-
diene synthase (Ads, EC 4.2.3.24) gene has opened up the possibility of 
genetically engineering microbes to produce amorphadiene (AD) [139, 140]. Ads 
acts on a critical branch point that cyclizes FPP into AD. The structure of Ads is 
not yet available, but reaction mechanism involving a shift in the diphosphate 
group has been proposed based on NMR studies [141].  Similar to other tepene 
synthase, Ads exhibited extremely low catalytic efficiency [142], which would 
probably be due to the slow release of hydrophobic product into aqueous medium 
[143]. Therefore high-throughput assay has been developed to screen for terpene 
synthase with improved catalytic efficiency [144].  Since accumulation of FPP is 
toxic to host cells, Zhao et al. developed a screening method based on cell 
viability to screen for variants of terpene synthase [145].   
 




2.5.3 Cytochromes P450: CYP71AV1 
Cytochrome p450 enzyme catalyzes a critical biotransformation of 
terpenoids, which enabled downstream functionalization of the terpenoids. The 
thermodynamically unfavorable addition of oxygen atom to hydrocarbon bond 
has always been an interest to organic chemists. The cytochrome p450 
(CYP71AV1, EC 1.14.13.158), responsible for amorphadiene oxidation, has been 
isolated recently, and shown to catalyze three consecutive oxidation of 
amorphadiene to form artemisinic acid (AA) (Figure 2.10) [146].  The membrane 
bound enzyme is NADPH dependent and requires a redox partner, cytochrome 
p450 reductase (CPR), which was also isolated from Artemisia annua. Komori et 
al. has reported a key cysteine residue in CYP71AV1 that without which the 
stereoselectivity of the enzyme would be compromised [147]. CYP71AV1 has 
been overexpressed together with the amorphadiene synthesis pathway in 
different host cells, such as tobacco [148] , E. coli [149] and Yeast [3], and high 
production of artemisinic acid is successfully obtained in yeast. It was observed 
that overexpression of CYP71AV1 would affect upstream AD production [3]. 
Therefore, a novel semi-biosynthetic route was suggested; instead of using 
CYP71AV1, the substrate promiscuous p450BM3 was used to add an epoxide 
group on AD and subsequently converted to AA (Figure 2.10) [150]. Another 
biosynthetic route was also proposed, comprising three other enzymes, alcohol 
dehydrogenase (ADH1) [3], aldehyde dehydrogenase (ALDH1) [151], and 
double-bond reductase (Dbr2) [152]. Dihydroartemisinic acid would be produced 
with the combined action of the three enzymes and CYP71AV1 (Figure 2.10).    






Figure 2.10. Schematic representation of downstream pathways that convert 
armorphadiene to artemisinic acid and/or dihydroartemisininc acid.  
The enzymes are as follows: CYP71AV1: amorphadiene oxidase. Adh1: alcohol dehydrogenase. 










Chapter 3 Statistical experimental design guided optimization of a 
one-pot biphasic multienzyme total synthesis of amorpha-4,11-
diene  
3.1 Introduction 
Malaria is a contagious disease that has claimed millions of life annually, 
and continues to infect more than 0.5% global population, especially in less 
developed nations [153]. Artemisinin is the key ingredient of the most potent 
treatment to Malaria [112]. It belongs to the diverse class of isoprenoids that are 
derived from the building blocks: IPP and DMAPP. Traditional supply of 
artemisinin solely depended on extraction from the leaves of the sweet 
wormwood plant Artemisia annua [154]. Since the growth of crops is slow and 
seasonal, this method inevitably results in supply fluctuation of artemisinin [155]. 
Efforts in metabolic engineering and synthetic biology have made some promises 
to even out the supply cycle by engineering fast growing microbes to produce 
artemisinin and its precursor, artemisinic acid [146]. Recently, a multistep semi-
synthesis of artemisin has been reported where yeast cell was used to produce 
precursors for further chemical conversions [3]. Invariably, the complex cellular 
environment renders any optimization process a challenge to control and 
maximize productivity [39].   
In vitro multienzyme pathway assembly is a useful approach 
complementing in vivo metabolic engineering [156]. As mentioned in Chapter 2, 
Cheng et al. demonstrated the feasibility of producing polyketide by enzymatic 
total synthesis [6].  They assembled 12 pathway enzymes from different 
production hosts and were able to achieve an overall yield of 25% from simple 




raw material. This bottom-up method successfully bypasses cellular barriers and 
allows a higher degree of freedom for pathway manipulation. At the same time, it 
still ensures regioselectivity and enantioselectivity of the product. Moreover, 
enzymatic reactions involve fewer chemicals that can simplify purification and 
reduce the cost of downstream process. In vitro multienzyme biosynthesis has 
been touted as a promising technology that may replace many chemical synthesis 
processes due to its high efficiency [8].   
A significant challenge in a multi-enzymatic reaction is the need to 
optimize the various steps involved simultaneously so as to obtain high-yield of a 
product. Here we demonstrated the synthesis of amorpha-4,11-diene (AD), a key 
precursor to artemisinin, from mevalonic acid (MVA) by assembling seven 
enzymatic steps in one-pot with two-phase reaction condition (Figure 2.9). 
Subsequently, we set to optimize the pathway productivity by means of Taguchi 
orthogonal array design in an attempt to balance the enzymatic levels under pre-
determined reaction conditions. The information gained led us to identify an 
inhibitory step of farnesyl pyrophosphate synthase (IspA), the critical factor Ads 
and significantly improved the AD yield. Therefore, this technique developed in 
the present study demonstrated a complementary way of producing valuable drug 
precursors with the ability to identify the limiting steps and balance the enzymatic 









3.2 Results  
3.2.1 Enzymatic purification and characterization 
Individual enzyme was overexpressed in E. coli strains. Sodium 
dodecylsufate polyacrylamide gel electrophoresis (SDS-PAGE) results showed 
that the enzymes were expressed at high levels. However, the yield of purified 
individual enzymes obtained by immobilized metal affinity chromatography 
differed significantly (Table 3.1). This was mainly due to the differences in the 
solubility of the enzymes (Figure 3.1A) [20]. In particular, there was almost no 
detectable soluble fraction of Ads (Figure 3.1B). This led us to extensively 
optimize the strains, growth conditions and enzyme extraction methods for Ads. 
Repeated freeze-thaw method [157] was found to be effective in isolating Ads 
(1.6 mg/L) from cells with high purity as compared to detergent based lysis 
method. An initial attempt was made by mixing equal mass of the six enzymes in 
one pot with an overlay of dodecane phase where amorpha-4,11-diene was found 
to be produced in trace amounts (results not shown).   
 
Figure 3.1 Solubility study of the pathway enzymes.  
A: solubility of the pathway enzymes measured based on the method described previously. The 
amount is estimated and normalized by the cell number, which is equivalent to 0.1ml of cell 
OD600=1. [20]. B: western blot of the supernatant and pellet of the bacterial strains 
overexpressing ADS, by anti-his6 primary antibody.   




In order to better understand and optimize the in vitro system, steady-state 
kinetics of each enzyme was initially measured. The results were summarized in 
Table 3.1. The enzymatic concentrations were determined to ensure the 
measurement of the initial rate of reaction were linear in the first 15 mins.  From 
the results, Ads displayed a significantly lower turnover number, a 2 orders of 
magnitude lower than the other five enzymes. It seemed to be an intrinsic property 
of terpene synthases, which was proposed to be limited by the release of the 
product [142, 143, 158]. Therefore, Ads was identified to be the bottleneck step in 
the multienzyme synthesis reaction.  
 
Table 3.1. Purification and characterization of each pathway enzyme. 








































4.2.3.24 64624 43.7±10 0.05±0.01 0.3-1.6 
The bracket contains the specific substrate that the Km is measured for.   
*The enzyme yield is defined as the final amount of enzymes obtained after 
purification from a liter bacterial culture. The results have been repeated 3 times.  




**The molecular weight (MW) of the enzyme was calculated based on its amino 
acid sequence.  
 
3.2.2 Tuning enzymatic levels by Taguchi orthogonal array design 
Table 3.2. Taguchi L16 (4
5
) orthogonal arraray design and results. 
 
Levels*  






1 2 3 4 1 2 11% 34 
2 2 4 3 2 1 12% 62 
3 1 2 2 2 2 9% 63 
4 1 4 4 4 4 18% 16 
5 1 1 1 1 1 5% 49 
6 1 3 3 3 3 10% 29 
7 2 1 2 3 4 8% 15 
8 4 2 3 1 4 14% 24 
9 3 3 1 2 4 13% 27 
10 4 3 2 4 1 24% 33 
11 2 2 1 4 3 16% 23 
12 3 4 2 1 3 9% 39 
13 3 2 4 3 1 10% 22 
14 4 4 1 3 2 26% 72 
15 3 1 3 4 2 13% 19 
16 4 1 4 2 3 16% 32 
Predicted Max AD yield 1 (P1) 4 4 4 4 2 15% 17 
Predicted Max AD yield 2 (P2) 4 4 4 4 1 2% 2 
Experimentally Max AD yield 4 4 1 3 2 20% 56 
        
Analysis of variance  







* Refer to Table 3.3 for the actual enzyme concentrations corresponding to the 
coded levels. A: mevalonate kinase (Erg12), B: phosphomevalonate kinase 
(Erg8), C: diphosphomevalonate decarboxylase (Erg19), D: isopentenyl 
pyrophosphate isomerase (Idi), E: farnesyl pyrophosphate synthase (IspA). 
** Specific AD yield is a dimensionless parameter measuring mg/L product 
produced by mg/L of enzyme. (refer section 3.5.6 for the detailed description). 
 




To balance the enzymatic flux and to analyze the contribution of the other 
five enzymes to the final yield of AD, a combinatorial approach was carried out 
assisted with Taguchi orthogonal array design [67, 159]. The reaction conditions 
were fixed at pH 7.4 and 30 
o
C, with a constant Ads concentration of 100 mg/L 
(1.5 μM). The results were summarized in Table 3.2, and the corresponding 
enzyme concentrations were shown in Table 3.3. Remarkably, we observed 
divergent AD yield with varying amounts of enzymes, where the best enzymatic 
ratio (run14) produced 5 fold more of AD as compared to the lowest ratio (run 5) 
in which the enzymes had equal activities.   
Table 3.3. Actual enzyme concentrations corresponding to the coded levels in 
Taguchi orthogonal array design. 
 
Coded levels 
Variables (mg/L) 1 2 3 4 
A: Erg12 0.8 4 20 80 
B: Erg8 0.2 1 5 20 
C: Erg19 1.5 7.5 37.5 150 
D: Idi 1.8 9 45 180 
E: IspA 1.8 9 45 180 
 
To further examine the influence of each enzyme on AD yield, the average 
effects analysis was determined. Figure 3.2A and B showed the average values of 
each level of the five enzymes on the AD yield. The five enzymes could be 
classified into two main groups: A (Erg12), B (Erg8) and D (Idi) positively 
enhanced AD yield when their activities were increased (Figure 3.2A). However, 
varying the activities of Erg19, and IspA did not have appreciable effect over AD 
yield (Figure 3.2B). Moreover, the half normal plot (Figure 3.2C) clearly 
indicated that Erg12, Erg8 and Idi were three main factors that had stronger 




influence to maximize AD yield. Therefore, among the 16 runs, higher AD yield 
was obtained from combinations where all the three main enzymes were at higher 
activities (run 14 and run 12). The model predicted the maximum AD yield would 
be achieved when the first four enzymes were at their highest activities (Table 
3.2). Attempt to validate this finding showed no significant improvement over AD 
yield (results not shown), suggesting that the activity ratio of 
Erg12:Erg8:Erg19:Idi:IspA:Ads of 100:100:1:25:5:1 (run 14) was near the local 
optimum. Further improvement of AD yield may require a change in the pre-
determined reaction conditions. More importantly, this combination of enzymatic 
levels resulted in the highest specific AD yield among all the experimental runs 
designed by Taguchi method. Therefore, this enzymatic ratio was chosen as the 
reference condition to further optimize the multienzymatic synthesis system. 
 
Figure 3.2. The Taguchi orthogonal array design results.  
To examine the influence of each enzyme on amopha-4,11-diene (AD) yield, the average effects 
analysis was determined. The five enzymes can be classified into two main groups. A: Average 
values of each level of factors Erg12, Erg8 and Idi on AD yield. The group of enzymes has a 




positive correlation with AD yield. B: Average values of each level of factors Erg19 and IspA on 
AD yield. The group of enzymes has little or no effect on AD yield.  C: The half-normal plot 
indicates the significant factors on AD yield. Factor A, B, D represent Erg12, Erg8 and Idi 
respectively. The abbreviations are as follows. Erg12: mevalonate kinase, Erg8: 
phosphomevalonate kinase, Erg19: diphosphomevalonate decarboxylase, Idi: isopentenyl 
pyrophosphate isomerase, IspA: farnesyl pyrophosphate synthase. 
 
3.2.3 Optimize IspA and Ads levels to enhance AD yield 
One notable conclusion drawn from the Taguchi model prediction was 
that, to maximize AD yield, the activities of the first four enzymes were required 
to be maximized while retaining the activity of the fifth enzyme IspA, at moderate 
levels (Table 3.2). This alluded to the possibility of an inhibitory effect of IspA 
enzyme, since intuitively the yield should increase with increasing enzyme 
concentration. This led us to conduct a set of separate experiments where IspA 
concentrations were optimized, while retaining the other four enzymes at their 
reference levels.  
 
Figure 3.3. Inhibitory effect of IspA and analysis of the precipitates.  
A set of separate experiments was conducted to validate the inhibitory effect of IspA.  This was 
attributed to the precipitation of FPP. A: Fold change in amorpha-4,11-diene (AD) yield when 
increasing IspA and Idi concentrations while keeping other enzymes at reference level. Fold 




change in AD yield was calculated by normalizing against AD yield obtained by reference enzyme 
levels, as indicated by the arrows. Presented data were average of triplicates and standard errors 
were drawn on the plot. B: UPLC-(TOF)MS analysis of the intermediates in the precipitates. 
Presented data were average of triplicates and standard errors were drawn on the plot.  C: SDS-
PAGE analysis of enzymes in the precipitates. The molecular weight of the each band present in 
the protein marker is indicated. The abbreviations are as follows.  Erg19: diphosphomevalonate 
decarboxylase, Idi: isopentenyl pyrophosphate isomerase, IspA: farnesyl pyrophosphate synthase, 
MVA: mevalonic acid, FPP: farnesyl pyrophosphate. 
 
Figure 3.3A showed the fold change in AD yield, with respect to that 
obtained by the reference enzymatic levels, when either Idi or IspA concentrations 
were varied. Idi concentrations were optimized as a control as it displayed a 
positive correlation with AD yield (Figure 3.3A). In contrast, a remarkable 
inhibitory effect was found when IspA activity was increased above its reference 
level (Figure 3.3A). A critical lead at this point of the study was that precipitates 
were formed in the reaction when IspA activity was increased. This interesting 
observation led us to hypothesize that the inhibitory effect of IspA was correlated 
with the precipitation. Interestingly, LCMS analysis revealed that the precipitates 
contained FPP and MVA which are the product of IspA, and the raw material 
respectively (Figure 3.3B). SDS-PAGE indicated that enzymes were co-
precipitated, and therefore, exacerbating the overall productivity of the 
multienzyme reaction (Figure 3.3C).  
 
Table 3.4. Stepwise reaction to identify the cause of precipitation. 
Reaction Precipitation 
Estimated concentration of 
FPP 
Erg12-Erg8-Erg19 No - 









To further identify which factor was the main reason that induced 
precipitation, the multienzyme reaction was analyzed stepwise. Precipitates were 
only visible when FPP was produced (Table 3.4). Therefore, it was hypothesized 
that the negative relationship of the increased activity of IspA and the overall 
productivity may be due to the accumulation of FPP in the context of the system 
examined. In order to test this hypothesis and further improve the AD yield of the 
system, response surface methodology was carried out to optimize the activities of 
IspA and Ads, so as to minimize the accumulation of FPP. The concentration 
ranges of IspA and Ads were chosen to be above and inclusive of the reference 
levels (Table 3.5). The experimental data obtained based on the design was fitted 
to a linear mathematical model (Equation 3.1).  
AdsIspAAD  68.318.0096.0  
Equation 3.1. The linear mathematical relationship generated by Response 





 and adjusted R
2
 values were 0.93 and 0.91 respectively (Table 
3.5), which indicated that the model was suitable to represent adequately the real 
relationships between the factors used. Interpretations from the model coefficients 
suggested a marked agreement with previous observation that IspA level was 
negatively correlated with AD yield. Moreover, the model implied a positive 
correlation between Ads level and AD yield, and Ads had a more pronounced 
effect on AD production. Thus, to validate the model, Ads activity was increased 
twice when compared to the reference enzymatic ratio. Unexpectedly, the 
conversion from MVA to AD was ~100%, which was ~5 fold improvement of 




AD yield as compared to the reference condition (Figure 3.4). This further 
confirmed that Ads was the rate limiting step in the multienzyme synthesis 
reaction for AD production.  
Table 3.5. Coded level combinations for a five-level, two factor response surface 




Run A B AD (mg/L) 
1 1 5 15.9 
2 3 3 8.1 
3 3 3 10.4 
4 5 5 15.6 
5 1 1 3.6 
6 0.17 3 11.9 
7 5 1 3.8 
8 3 0.17 0.3 
9 5.8 3 9.9 
10 3 3 10.7 
11 3 5.8 24.9 
12 3 3 9.5 
    Actual enzyme concentrations corresponding to the coded levels 
    
Coded level variables 
 
 
Variables (mg/L) 1 5 
 
A: ispA 36 180 
 
B: ADS 36 180 
 
Alpha (Rotatable) 1.41 
  
    Analysis of variance 
  

















Figure 3.4 Summary of optimization of amorphadiene production.  
EA: equal activities of the enzyme, which their concentrations in terms of Taguchi coded levels 
are Erg12(1), Erg8(1), tMvd(1), Idi(1), IspA(1) . TOA: optimized enzymatic activities by Taguchi 
orthogonal array method, which their concentrations in terms of Taguchi coded levels are 
Erg12(4), Erg8(4), tMvd(1), Idi(3), IspA(2). This combination of enzyme concentrations was used 
as the reference condition. RSM: response surface design suggested increasing Ads activity. The 
other five enzymes were kept at reference level. 
 
3.2.4 Enhancement Ads specific activity by buffer optimization 
Next, an attempt was made to enhance AD specific yield by examining the 
contribution of ions in the buffer. Potassium ion has recently been shown to 
significantly improve the activity of a terpene synthase by interacting with the  
H1-α loop of the enzyme [158]. Interestingly, a similar structure was found in Ads 
(Figure 3.5).  
 
Figure 3.5 Sequence alignment of H-α1 loop [158] and Ads. 
 
Thus, to test the effectiveness of monovalent ion, we supplemented the 
Ads reaction buffer with potassium ions. Figure 3.6A and B showed the change in 
Ads specific activity and the fold change in AD yield with respect to the reference 
condition respectively. As predicted, Ads specific activity was found to be 




enhanced approximately twice with 100 mM potassium ion (Figure 3.6A). More 
interestingly, the overall AD yield by the reference enzymatic ratio was 
significantly improved about three times in the presence of 100 mM potassium 
(Figure 3.6B). Other monovalent ions, sodium chloride and ammonium chloride, 
were also titrated into the multienzyme reaction. A similar trend was observed 
that, with either 100 mM sodium ion or 50 mM ammonium ion, there was a 
marked three-fold improvement of AD yield (Figure 3.6B).  
 
 
Figure 3.6. Effects of monovalent ions.  
Monovalent ions were used to increase the specific activity of amorpha-4,11-diene synthase (Ads) 
and hence the specific amorpha-4,11-diene (AD) yield of the multienzyme synthesis reaction. A: 
Titration of potassium chloride concentrations, and their effects on Ads specific activity. Presented 
data were average of triplicates and standard errors were drawn on the plots. Student’s t-Test with 
paired two samples for means was used to calculate the p-value in the statistical analysis. B: 
Titration of different monovalent ions concentrations and their effects on AD yield by reference 
enzymatic levels. Fold change in AD yield was calculated by normalizing against AD yield 
obtained by reaction without addition of monovalent ions, as indicated by the arrow. Presented 
data were average of triplicates and standard errors were drawn on the plots. 
 
To further explore the effect of the buffer used, we varied pH from 6 to 
9.1 and magnesium concentrations from 5 mM to 20 mM for AD production with 
reference enzymatic levels. Figure 3.7 showed the fold change in AD yield, with 
respect to the reference condition, when either pH or Mg
2+
 concentrations was 
varied. Remarkably, AD yield increased 3 times when the pH increased from 7.4 




to 8.2, and there was no amorpha-4,11-diene detected when the pH was reduced 
to 6. By keeping pH at 7.4, the optimum Mg
2+
 concentration was found to be 15 
mM, which resulted in a moderate 1.8 fold improvement of AD yield. However, 
no synergistic effect was observed at pH 8.2 and 15 mM Mg
2+
. The optimum 
condition found was at pH 8.2 with 10 mM Mg
2+
, which significantly enhanced 
specific AD yield three times (Figure 3.7).  
 
 
Figure 3.7. Optimization of buffer pH and magnesium concentration.  
Varying buffer pH and magnesium concentrations was found to be helpful to enhance the specific 
amorpha-4,11-diene (AD) yield. Fold change in AD yield was calculated by normalizing against 
AD yield obtained with buffer pH 7.4 and 10 mM Mg2+, as indicated by the arrow. Presented data 


















3.3 Discussion  
In metabolic engineering and synthetic biology, an essential process is the 
in vivo balancing of metabolic pathway flux to achieve optimal productivity. 
Early successes of controlling pathway flux in vivo have been mainly achieved by 
tuning the promoter strength, ribosomal binding site sequences and plasmid copy 
numbers [160]. Controlling enzymatic concentration and activities in vivo is a 
significant challenge where limitations in global cellular and biochemical 
mechanisms including the solubility of overexpressed enzymes are not easily 
predictable [20]. Hence, cell-free enzymatic reaction would be an enabling 
technology that offers an alternative to these challenges. Recently, multienzyme 
synthesis for therapeutic products has been successfully demonstrated [23, 41, 
161]  In this study, the mevalonate pathway together with the downstream plant 
enzyme amorpha-4,11-diene synthase was individually purified and reconstituted 
in a single vessel and the overall biochemical reaction achieved an almost 
complete theoretical yield (~100%, 340 mg/L) of amorpha-4,11-diene production. 
This surpassed the carbon yield of in vivo biosynthesis which was approximately 
15-20% [162].  
One prerequisite for the system is the availability of functional and 
purified enzymes. Most of the recombinant enzymes produced in this study were 
insoluble and thus pose a challenge to obtaining sufficient amounts for in vitro 
reconstitution. When Ads was overexpressed in E. coli, most of the enzyme was 
found in inclusion bodies [163]. This is possibly due to the nature of the enzyme 
which more than 30% of the amino acids of Ads containing hydrophobic 




structures, thus rendering the enzyme less soluble as compared to other pathway 
enzymes. Purification of terpene synthases is challenging, that some active 
enzymes were only recovered from inclusion bodies by in vitro refolding [164-
166]. For Ads, using commercially available detergent to lyse the cells, we were 
unable to recover any functional enzymes. Repeated freeze-thaw method was 
found to be an effective method to improve the recovery of functional and soluble 
Ads for in vitro reaction. 
Although the mevalonate pathway has been extensively optimized in 
engineered microbes, the in vivo mechanistic interactions of the combinations of 
pathway enzymes affecting amorpha-4,11-diene production are currently 
unknown. One advantage of the in vitro multienzyme system is the ability to 
precisely control and modulate the enzymatic activities in the same reaction 
condition. This allows the identification of interacting components or factors 
which can then guide further optimization. Conventionally, trial-and-error method 
was used to optimize the pathway enzyme concentrations. For 6 enzymes, each 
varied at 4 concentrations while keeping the rest at a constant level, there is a 
minimum of 24 reactions to be carried out. This is time-consuming and iterative, 
and sometimes fails to capture the optimum condition. Full factorial analysis 
requires too much experimental effort to be realistically carried out (5
4
=625 
reactions). Therefore, statistical experimental design methodology, in particular, 
Taguchi orthogonal array design was used in this study to rapidly and efficiently 
identify the local optimal ratio of enzymatic activities. Attempts to further 
manipulate the ratio did not result in significant improvement in the yield of AD. 




This approach was rather helpful in identifying the negative effect of IspA which 
was due mainly to the accumulation and precipitation of FPP as well as the 
enzymes. Attempts were made to understand the involvement of MVA in the 
formation of precipitates. There was no obvious precipitates formation when 
MVA but not FPP was present in the reaction, suggesting a stochastic process that 
possibly resulted from the charge interaction between high concentration of MVA 
and Mg
2+
. Similarly, no precipitation was found when enzymes were present 
without FPP. Hence, it was likely that FPP accumulated to sufficiently high levels 
may then precipitate, an observation consistent with a previous report [167]. FPP 
contains a hydrophobic 15-carbon moiety and is involved in post-translational 
lipid modification by protein farnesyltransferases [96, 168]. It is not unexpected 
that Mg
2+
 counterions may shield the negative charges of the pyrophosphate 
moiety resulting in the precipitation of FPP along with the enzymes. By 
increasing Ads activity, the flux of FPP towards AD production would have 
increased, and hence minimizing the accumulation of FPP. A benefit from such an 
increase in metabolite flux is the remarkable increase in the conversion of 
mevalonic acid (~100%). It will be interesting to examine the effect of co-
immobilizing IspA and Ads to improve the channeling of substrate by proximity 
effect in the future.  
By optimizing the buffer conditions, the specific AD yield was further 
enhanced, demonstrating the flexibility of the in vitro system conditions often 
intolerable to cells. Monovalent ions were found to be effective in improving both 
the specific activity of Ads and the specific AD yield by 2 and 3 fold, 




respectively. Monovalent ions are well known to be required for many enzymatic 
activities [169]. Whether the monovalent ions may act as an allosteric activator to 
Ads by binding to specific secondary structures, e.g. H1-α loop of the enzyme 
[158], remains to be verified.  
pH and magnesium ions play a critical role in moderating the enzymatic 
activities. Individual enzyme displayed vast different kinetic property under 
different pH and magnesium concentrations. Literature suggested that purified 
Ads displayed a higher catalytic efficiency when pH was increased in the 
presence of Mg
2+
 [142]. Therefore, the increased productivity of the 
multienzymatic pathway with increased buffer pH would likely be due to the 
enhanced specific activity of Ads in a more alkaline medium and the hypothesis 
remained to be verified.    
 
3.4 Conclusion 
In summary, amorpha-4,11-diene was successfully produced and achieved 
quantitative conversion by a multienzyme, biphasic system. We have 
demonstrated the utility of Taguchi method to efficiently identify the local 
optimum enzymatic ratio and identified the inhibitory effect of IspA, resulting in 
the accumulation of FPP. Further optimization of IspA and Ads activities by 
response surface methodology identified that Ads was a critical factor. By 
increasing the Ads activity, almost 100% conversion from raw materials to AD 
has been achieved. Further buffer optimization of monovalent ions, pH and 
magnesium ions, was able to enhance the specific AD yield 2-3 fold significantly. 




The work-flow demonstrated here will be valuable to produce other isoprenoids in 
an efficient manner.  
 
3.5 Materials and Methods 
3.5.1 Bacteria strains and plasmids 
Bacteria strains and plasmids used in this study were summarized in Table 
3.6. The pET-11a (Stratagene, CA) was modified by replacing the T7 promoter 
with tac promoter to facilitate the transfer of the plasmids among different strains. 
A 5’ SacI site and a 3’ XhoI site were introduced downstream from the 6xHis 
open reading frame. The mevalonate pathway enzymes, namely mevalonate 
kinase (Erg12), phosphomevalonate kinase (Erg8) and pyrophosphomevalonate 
decarboxylase (Erg19), were amplified from S. cerevisiae genomic DNA with 
forward and reverse primers that contain corresponding SacI and XhoI sites. The 
PCR products were ligated into the modified pET-11a vector (Stratagene, CA) 
and transformed into competent E. Coli strain DH10B.  Isopentenyl 
pyrophosphate isomerase (Idi) and IspA were from our previous study [20]. Ads 
gene was codon optimized and synthesized by Genescript with sequences 
encoding C-terminal 6xHis-tag, and subsequently cloned into a modified pBAD-B 
vector (Invitrogen, CA) using 5’ SacI site and 3’ XhoI site. The primers used for 
amplification of the genes were listed in Table 3.7. All the plasmids were 
transformed and harboured from E. coli XL10-gold (Stratagene, CA) and then 
transformed to respectively strains for enzyme overexpression (Table 3.6).   
 




Table 3.6. Bacterial strains and plasmids used in this chapter. 
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Plasmid for overexpression of Ads in E. Coli DH10B This study 
 




Table 3.7. List of primers used for cloning the genes. 

























Underlined text: restriction enzyme site 
 
3.5.2 Expression and purification of Erg12, Erg8, Erg19, Idi and IspA. 
Newly transformed colonies were picked from the agar plate, inoculated 
into 2xPY medium (20 g/L Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH 7) 
containing 100 mg/L ampicillin and grew till stationary phase overnight at 37 
o
C 




in an incubator-shaker (Shin Saeng Shaking Incubator, Finetech, Korea). The 
culture was then further transferred into fresh 2xPY medium (1% inoculation) 
with ampicillin for another 2.5 h at 37 
o
C, till optical density A600 reached 0.6-1.0. 
The enzyme expression was induced with 0.1 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG). Temperature was reduced to 20 
o
C after induction for 
higher solubility of the enzymes [20]. The culture was grown for another 48 h and 
harvested by centrifugation. The cell pellets were stored at -20 
o
C till further use.          
To purify the enzymes, the frozen cell pellets were resuspended in B-
PERII reagent (Pierce, IL), according to the manufacturer’s instruction, and 
vortexed at room temperature for 30 mins to completely lyse the cells. The 
soluble proteins were contained in the supernatant, which was diluted 15 times in 
NPI10 buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) and 
incubated with 200 mg Ni-NTA resin (USB, Affymetrix, CA) at 4 
o
C for 2 h. The 
resin was washed with NPI10 buffer after discarding the binding supernatant, and 
the enzymes were eluted and collected by 400 μl NPI400 (50 mM NaH2PO4, 300 
mM NaCl, 400 mM imidazole, pH 8). The enzymes were further concentrated by 
3K Amicon ultra-0.5 ml centrifugal filter unit (Millipore, MA), and the 
concentrations were measured by Micro BCA protein assay kit (Thermo 
scientific, MA). The purified enzymes were further confirmed by sodium dodecyl 
sulfate-12% polyacrylamide gel electrophoresis (Bio-Rad, CA).     
 




3.5.3 Expression and purification of Ads.  
Bacteria culture was grown in 2xPY medium at 20 
o
C till stationary phase 
after Ads expression was induced with 10 mM L-arabinose. The cells were 
harvested by high speed centrifugation and resuspended in phosphate saline buffer 
(PBS). To purify Ads, cells were lysed by three rapid freeze-thaw cycles by -80 
o
C freezer and 37 
o
C incubator. The released enzyme was separated from cell 
debris by centrifuging at 3000 g for 15 min, and purified by Ni-NTA resin as 
described above.  
 
3.5.4 Enzyme kinetics  
The pathway enzyme kinetics was determined individually by initial rate 
measurements. In brief, the substrates and cofactors were added to 100 mM 
Tris/HCl reaction buffer (pH 7.4), and the reaction was initiated by adding pre-
determined enzyme amount to ensure less than 10% substrate was consumed in 15 
mins at 30 
o
C.  The substrates concentrations were varied in equal steps in 
reciprocal space from 0.1 to 1 mM. The reaction was terminated by adding equal 
volume of 1% ammonium hydroxide and diluted 10 times into cold methanol. 
After high speed centrifugation, the supernatant was subject to UPLC-(TOF)MS 
analysis. Double-reciprocal plots of each enzymatic activity were constructed for 
the determination of Km and Kcat values for the respective substrates. 
 




3.5.5 Multienzyme reaction  
The multienzyme reaction was carried out in a buffer (25 μl) consisted of 
Tris/HCl (100 mM, pH 7.4), MgCl2 (10 mM), (±)mevalonic acid (10 mM), ATP 
(15 mM) and the purified enzymes. The reaction was performed at 30 
o
C with an 
overlay of dodecane phase that contained trans-caryophyllene (50 mg/L) as an 
internal standard. At the end of the reaction, the dodecane phase was diluted 10 
times in ethyl acetate and subject to GCMS analysis. The  (±)mevalonic acid was 
prepared by complete alkaline hydrolysis of 2 M (±)mevalonolactone (Sigma, 
MO) with equal volume of 2 M potassium hydroxide  at 37 
o
C for 1.5 h, and 
neutralized by adding 1 M hydrochloric acid to pH 7   [170].  
 
3.5.6 Experimental design 
Taguchi orthogonal array design and response surface methodology with 
central composite design were calculated using Design Expert® V8 Software 
(Stat-Ease, Inc). Taguchi L16 (4
5
) orthogonal array was constructed which can 
accommodate five control factors corresponding to the five pathway enzymes, 
each varied at four levels of concentrations (Table 3.3). The four enzymatic levels 
were normalized against Ads activity (AA), ranging from 1xAA, 5xAA, 25xAA 
and 100xAA to achieve sufficient coverage. The lowest level was equalized 
enzymatic activity, whereas the highest level was comparable enzymatic 
concentrations. The level of Idi was varied according to IspA. 16 randomized 
experimental runs were conducted to maximize AD yield (Equation 3.2).  The 
specific AD yield (Equation 3.2) was another indicator of the pathway 




productivity but was not considered in the design experiment. The two 
dimensionless readouts were calculated as follows: 
(mg/L) materialraw  5mM on based  yieldlTheoretica
(mg/L)  yield ADActual
  yieldAD                           
(mM) ionsconcentratenzymatic  Total
(mM)  yield ADActual
   yieldDSpecific A                                     
Equation 3.2. The equations to determine the AD and specific AD yield. 
 
Optimizing IspA and Ads activities was carried out by response surface 
methodology with central composite design, which involved the investigation of 
two factors (concentrations of IspA and Ads), each varied at five levels and four 
centre points for replication. The AD production at 6 h was taken as the response, 
before the reaction reached completion and any visible precipitations were 
formed. The experimental data obtained were fitted based on the most suitable 
model suggested by the software.  
 
3.5.7 UPLC-(TOF)MS analysis of mevalonate pathway intermediates 
The analysis was done based on the method developed previously with 
slight modification [42]. In brief, 5 μl samples were injected into a UPLC C18 
column (Waters CSH C18 1.7 μm, 2.1 mm x 50 mm) connected to UPLC (Waters 
ACQUITY UPLC)-(TOF)MS (Bruker micrOTOF II, MA).  Elution was carried 
out with a step change from 100% aqueous solution containing 15 mM acetic acid 
and 10 mM tributylamine (0.5 min) to 10% aqueous solution with 90% methanol 
for another 3.5 min. Electrospray ionization was used and mass spectrometry was 




operated to scan 50–800 m/z in negative mode with 2500 V end plate voltage and 
3200 V capillary voltage. Nebulizer gas was provided in 2 bar, dry gas flow rate 
was 9 ml/min, and dry gas temperature was 200 
o
C. At the assay condition, all the 
intermediates were detected in the form [M-H]
-
. Retention time was subsequently 
determined for each intermediate with respective synthetic standards and the set 
m/z extraction range. The peak area was calculated and subsequently used to 
compute the intermediates concentrations with the software provided by the 
manufacturer. The calibration curves were constructed with synthetic standards 
prepared under similar reaction conditions without enzymes. Linearity of the 




3.5.8 GCMS analysis of amorpha-4,11-diene 
The analysis was carried out based on the modified method developed by 
Martin et al. by scanning three ions; the m/z values are 117, 189 and 204 [170, 
171]. 1 μl sample was injected into HP-5 column (Agilent Technologies 7890A 
gas chromatograph-mass spectrometry, Agilent, CA) with a linear temperature 
increase of 50 
o
C/min from 80 
o
C to 300 
o
C and hold at 300 
o
C for another 
minute. The peak area was calculated and subsequently used to compute the 
amorpha-4,11-diene concentrations with the software provided by the 
manufacturer. Amorpha-4,11-diene concentrations were determined relative to the 
internal standard trans-caryophyllene of known concentration.   




Chapter 4 Unraveling the regulatory behaviour of in vitro 
reconstituted amorpha-4,11-diene synthesis pathway by Lin-log 
approximation  
4.1 Introduction 
In Chapter 3, we have reconstituted and optimized the amorpha-4,11-diene 
(AD) synthesis pathway comprising of mevalonate kinase (Erg12), 
phosphomevalonate kinase (Erg8), diphosphomevalonate decarboxylase (Erg19), 
isopentenyl pyrophosphate isomerase (Idi), farnesyl pyrophosphate synthase 
(IspA) and amorpha-4,11-diene synthase (Ads), as shown in Figure 2.9, for AD 
production. However, the regulatory behavior of the pathway was still unclear, 
especially the interactions of the metabolites with the key enzyme Ads and this is 
important for further in vitro pathway engineering.  
The MVA pathway is mainly present in eukaryotes, archaea and some 
eubacteria and provides the cell with a variety of compounds which are involved 
in multiple cellular processes [118]. Enzymes stem from different species origin 
have unpredictable allosteric metabolic regulatory properties [120]. As mentioned 
in section 2.5.1, a farnesyl pyrophosphate (FPP) resistant mevalonate kinase was 
isolated from Methanosarcina mazei [123], while its counterpart from 
Saccharomyces cerevisiae and Streptococcus pneumonia was highly sensitive 
towards FPP [121] and mevalonate-5-diphosphate (PPMVA) [172, 173] 
respectively. Therefore, the intricacy of metabolic networks and its revolutionary 
diversity renders an intuitive analysis of a biochemical pathway behavior a 
difficult task.  




Mathematical modeling approaches aim to reduce the complexity and 
provide insights for rational engineering, making them an important tool for 
metabolic engineering and synthetic biology [174]. Two main modelling 
strategies have been described in section 2.3.  The conventional kinetics modeling 
governed by Michaelis Menten law is usually difficult to obtain satisfactory 
kinetic parameters and mathematical equations in the context of complex 
enzymatic reactions [175]. Moreover, it requires a priori network structure 
information and extensive parameter tuning to have a more accurate mathematical 
representation of a biochemical pathway [176, 177]. Stoichiometric modeling that 
based on mass balance is a powerful tool to estimate the pathway behavior, 
although it is still heavily dependent on the prior knowledge of regulatory pattern 
of the network [175]. Data-driven modeling such as neural network can be 
applied when mechanistic information is missing. However, time- and cost- 
intensive experiments are required to obtain sufficient data [178, 179]. Recently 
developed canonical modelling method such as Lin-log approximation is more 
promising to predict the regulatory patterns of the biochemical pathway based on 
steady state fluxes. Due to its defined model structure and basis on 
thermodynamic principle of enzyme catalyzed reaction, Lin-log approximation 
requires less number of parameters to be estimated without compromised 
accuracy [81, 180] and technically allows larger perturbations to predict the 
regulatory behavior (up to 20 fold difference) [79]. Therefore, it is highly suitable 
for structure identification for biochemical systems. 




In this Chapter, the Lin-log approximation method was to unravel the 
regulatory behavior of in vitro reconstituted AD synthesis pathway from 
mevalonic acid (Figure 4.1), with the aim of further boosting up the productivity 
of the pathway. The use of reconstituted pathway is advantageous, (section 2.2), 
since it is highly reproducible and open to manipulation by changing 
concentrations of its constituents [181]. The known regulations for the pathway 
are depicted in Figure 4.1with black dashed line. With the strategy used, we 
successfully identified a novel interaction between ATP and Ads (Figure 4.1). 
Subsequently, upon the addition of ATP recycling system, the space- and time- 
yield of the pathway was further enhanced by more than 3 fold. To our best 
knowledge, this is the first investigation into the regulation of the MVA and AD 
synthesis pathway at a multienzymatic system level and the strategy developed 













Figure 4.1. The schematic representation of the amorphadiene synthesis pathway 
with regulations shown.  
The black dash line showed the known feedback regulation for the mevalonate pathway enzymes 
in the literature. The light blue dashed line is the additional regulation that has been found in the 
study for the mevalonate pathway enzymes. The dark blue dashed line showed the novel 
regulations been identified in the study; ATP and pyrophosphate are inhibitory to Ads activity.  
The abbreviations are as follows. Erg12: mevalonate kinase. Erg8: Phosphomevalonate kinase. 
Erg19:  Mevalonate diphosphate decarboxylase. Idi: Isopentenyl diphosphate isomerase. IspA: 













4.2 Results  
4.2.1 Elasticity estimation using the Lin-Log approach 
One important pre-requisite of Lin-log approximation is to establish a 
steady state as the reference state. It is technically difficult to achieve a real steady 
state for in vitro reconstituted system; a quasi- steady state is considered as a 
reasonable approximation [181]. Therefore, enzymatic concentration was 
determined experimentally to ensure minimum fluctuation of the levels of the 
reaction intermediates. The time course of the reaction intermediates has been 
measured and shown in Figure 4.2. They were maintained at approximately the 
same level from 30 mins to 60 mins, and the AD production was almost linear 
during that period of time. Therefore, 30min was taken as the reference time point 
to determine the change in steady-state flux and metabolite concentrations.  
 
 
Figure 4.2. Time course of (A) intermediate concentrations, and (B) 
amorphadiene (AD) production.  
From 30 to 60 min, the metabolite concentrations fluctuate the least, and AD production is linear. 
Therefore, 30min time point was taken to assay the change in the metabolite concentration change 
for Lin-Log approximation. All the data point was done in triplicates, and the standard deviation is 
shown.   




Table 4.1.  Experimental data obtained by perturbation experiments. 
 
Parameters  
Metabolites (μM) Cofactor (A.U.) Flux 
(μM/h) Erg12 Erg8 Erg19 Idi IspA Ads MVA PMVA PPMVA IPP DMAPP GPP FPP ATP 
1 Erg12 0.10 0.20 0.50 0.15 0.15 0.40 2425 356 36 1085 189 11 76 3817 3.1 
2 
 
0.20 0.20 0.50 0.15 0.15 0.40 1806 474 73 891 217 13 93 1840 3.3 
3 Erg8 0.15 0.16 0.50 0.15 0.15 0.40 2100 467 21 718 337 9 70 2209 2.2 
4 
 
0.15 0.24 0.50 0.15 0.15 0.40 2105 375 75 874 340 9 78 1644 2.3 
5 Erg19 0.15 0.20 0.40 0.15 0.15 0.40 2125 401 24 881 374 12 63 1610 2.0 
6 
 
0.15 0.20 0.50 0.15 0.15 0.40 2131 426 31 702 317 7 58 1378 1.8 
7 Idi 0.15 0.20 0.60 0.10 0.15 0.40 2250 429 48 950 266 9 43 1515 1.8 
8 
 
0.15 0.20 0.50 0.20 0.15 0.40 2305 382 44 769 342 13 82 1708 3.1 
9 IspA 0.15 0.20 0.50 0.15 0.10 0.40 2279 430 43 788 384 6 64 1514 3.2 
10 
 
0.15 0.20 0.50 0.15 0.20 0.40 2058 422 31 741 311 7 81 1461 3.1 
11 Ads 0.15 0.20 0.50 0.15 0.15 0.50 2489 402 63 685 419 9 80 2181 3.2 
P a g e  | 74 
 
Subsequently, individual enzyme concentrations were perturbed around 
the pre-determined concentrations to obtain 11 independent measurements shown 
in Table 4.1. The variation in each metabolite concentrations across the 11 
experiments was almost all within 2-3 folds to ensure higher accuracy of Lin-log 
approximation and the total sum of the measured concentrations from each 
experiment was within 10% variation from the initially added substrate 
concentration as shown in Figure 4.3A [80]. Multiple linear regression was 
performed under the ‘maximum connectivity’ assumption to obtain 11 sets of 
elasticities (equation Equation 4.6) [181]. Each had one out of the 11 experiments 
as a reference state. The optimal reference state was evaluated again based on the 
criterion of adjusted coefficient of determinant (Ra
2 
, Equation 4.9 ) [80]. Figure 
4.3B showed that run 9 has the highest Ra
2
 value (0.958) among the 11 
regressions, which indicated that the approximation was sufficient to reflect the 
true relationship between the metabolite concentrations and the steady state flux. 
Thus, the corresponding set of elasticities, with run 9 as reference state, and their 
95% confidence intervals are given in Table 4.2, and was used for subsequent 
analysis.  
 
Figure 4.3. Analysis of the perturbation experiments.  




(A). The sum of metabolite concentrations for each perturbation. The average value is 
approximately 4000µM, which is the same as the initial amount of substrate added. The 10% 
variation boundaries are indicated on the graph. All the perturbation experiments have total 
measured concentration varied with the 10% boundaries of the average value. This showed that 
the measurement was accurate to a large extent.  (B). Adjusted coefficient of determination for 11 
different reference states. “Maximum connectivity” assumption was used. The best reference state, 
run 9, is indicated by the black arrow.  
 
We calculated flux and metabolite concentrations based on the mass 
balance equations derived with Metabolic Control Analysis (MCA) coefficients 
(Equation 4.7 and Equation 4.8), and plotted them against the actual measured 
values in the parity plot (Figure 4.4).  
 
Figure 4.4. Parity plot of the calculated flux and metabolite concentrations with 
the actual measurements.  
All the values are normalized with the reference state (run 9) measurements.  The equations of 
trend lines are given. 





Evidently, Lin-log approximation was able to accurately predict the actual 
measurements to a satisfactory level; the coefficients of all the trend lines between 
the calculated and actual measurements, including flux and metabolite 
concentrations, were close to 1. Majority of the calculated flux and metabolite 
concentrations were within 20% variation of the actual data. Hence, we used the 
lin-log approximation results to further guide our analysis.  
Elasticities would infer to how a metabolite influence a reaction rate 
around the reference state. Usually, positive elasticity means a stimulatory effect, 
and negative elasticity means inhibitory effects [80]. Based on the 95% 
confidence interval, we were able to exclude half of the elasticity values in the 
Table 4.2, which its sign is hard to determine. Relatively larger confidence 
intervals occurred when the enzymatic reaction was directly involved with IPP 
and DMAPP, such as IspA and Idi reaction. Since the two compounds are 
isomers, which are hardly differentiated by chromatographic measurement used, 
an additional acid treatment step was introduced in order to remove acid labile 
DMAPP. Therefore, further measurement error was introduced and exacerbated 
the model accuracy. Moreover, the substrates, products and cofactors of the 
corresponding enzymes, highlighted in blue in Table 4.2, were excluded from 
further analysis. Finally, among the remaining elasticities, those with absolute 
values close to 1 were highlighted in red; they likely suggest interactions with 
biological significance [80]. The negative elasticity of DMAPP on Erg12 
suggested an inhibitory effect. This was in agreement with literature [123], 




lending confidence to the results. It further suggested stimulatory effect of IPP on 
both Erg12 and Erg8. Moreover, interestingly, a strong inhibitory effect of ATP 
on Ads was also suggested. These new relationships required further experimental 
validation in order to confirm whether it was a true biological interaction or 
purely minimization of the least square error [80]. 
 
Table 4.2 . Estimated elasticities at the optimal reference states.  
The 95% confidence interval value is indicated in the bracket. The substrate, product and co-factor 
of the corresponding enzyme is colored in blue. The elasticities that might have biological 
significance are highlighted in red. The p-values have been calculated which all were less than 
0.005. 
Run 9 Enzymes 
Metabolite Erg12 Erg8 Erg19 Idi IspA Ads 
MVA 3.7 ± (0.67) 3.8 ± (0.12) 3.2 ± (3.61) 2.5 ± (5.30) 3.8 ± (7.93) 3.4 ± (2.15) 
PMVA 1.1 ± (0.45) 2.8 ± (0.08) 2.0 ± (2.46) 2.0 ± (3.61) 3.1 ± (5.40) 2.1 ± (1.47) 
PPMVA -0.2 ± (0.07) -0.1 ± (0.01) -0.1 ± (0.370 0.1 ± (0.54) 0.0 ± (0.80) -0.1 ± (0.22) 
IPP 1.2 ± (0.30)** 1.1 ± (0.05)** 1.4 ± (1.61) 1.0 ± (2.36) 2.1 ± (3.53) 1.5 ± (0.96) 
DMAPP -0.5 ± (0.18)** -0.3 ± (0.03) -0.1 ± (0.95) -0.3 ± (1.40) 0.2 ± (2.09) -0.4 ± (0.57) 
GPP -0.3 ± (0.09) -0.1 ± (0.02) -0.1 ± (0.46) -0.2 ± (0.68) -0.4 ± (1.02) -0.2 ± (0.28) 
FPP 1.5 ± (0.20) 1.6 ± (0.04) 1.7 ± (1.11) 0.9 ± (1.63) 1.5 ± (2.43) 1.7 ± (0.66) 
ATP -0.4 ± (0.19) -0.6 ± (0.04) -0.7 ± (1.04) -0.4 ± (1.53) -0.6 ± (2.28) -0.8 ± (0.62)** 
 
4.2.2 Inhibition of Ads by ATP 
To validate the results, we supplemented various metabolites: MVA (5 
mM), IPP (1 mM), DMAPP (1 mM) and ATP (15mM) into the Ads reaction 
assay. A remarkable 10-fold reduction in Ads specific activity was only observed 
with ATP but not other metabolites (Figure 4.5A). Furthermore, to rule out the 




possibility that the marked inhibitory effect of Ads was not a result of non-
specific charge interaction between ATP and Mg
2+
, an essential co-factor for Ads 
activity [142], a range of ATP concentration, from 0 mM to 15 mM was added 
into Ads reaction. More severe inhibition was observed when ATP concentration 
was above 10 mM. Nevertheless, with an addition of 0.2 mM ATP into Ads 
reaction, a concentration far below the Mg
2+
 concentration, a modest yet 
statistically significant (p<0.05) reduction of Ads specific activity was observed, 
as shown in Figure 4.5B. The apparent Ki value, estimated from Morrison 
Equation, was 6.4mM, which was much lower than the amount of Mg
2+
 
supplemented in Ads reaction.  
To further confirm the difference in the Ads activity was real, the 
unreacted substrate (FPP) concentration was also assayed by UPLC-(TOF)MS 
method (section 4.5.4). Figure 4.5B clearly depicted a gradual increase in the 
unreacted FPP concentration when the amount of ATP added into the reaction 
was increased. This increase could not be due to the matrix effect or ion 
suppression of ATP when assayed with UPLC-(TOF)MS, since ATP 
concentration was higher when FPP concentration was high, too. Therefore, it 
strongly suggested that Ads was inhibited by ATP in a specific manner.    





Figure 4.5. Validation of lin-log approximation for Ads reaction.  
(A). Fold change in the specific Ads activity when different metabolites were added separately 
into the Ads reaction. It was obtained by dividing the control ads specific activity (Ctrl), where no 
additives were added.  (B). Ads specific activity when a range of concentration of ATP from 0mM 
to 15mM was added. The amount of unreacted FPP were measured and its integrated area of 
LCMS measurement was used (please refer to section 4.5.4). All the measurement were done in 
triplicates, and their standard deviations were shown. Student t-test with paired two samples for 
means were performed to calculate the p-value in the statistical analysis.     
 
4.2.3 Inhibition of Ads by Pyrophosphate      
To further investigate which of the structure moiety of ATP was 
responsible for the inhibition of Ads, we used another three structurally similar 
compounds. ADP contains the adenosine and ribose moiety, and only differs from 
ATP with one phosphate group. When similar concentration of ADP was 
supplemented into Ads reaction, only 20% reduction in Ads activity was resulted 
(Figure 4.6A). Therefore, it was likely that the inhibition was attributed to the 
effect of the polyphosphate moiety. Therefore, to test the hypothesis, CTP and 
pyrophosphate (Ppi) were used, since both have the polyphosphate structure. 
Indeed, by assaying Ads activity with CTP or Ppi separately, a severe ~10-fold 
inhibition was seen (Figure 4.6A). This result strongly suggested that the 
polyphosphate tail moiety of ATP was responsible for the inhibition of Ads. 
Interestingly, pyrophosphate is the by-product of Ads. Hence, the result further 




suggested a novel product inhibition of Ads. To confirm the results, we titrated 
the Ppi concentration from 0mM to 15mM, and assayed the rate of amorphadiene 
produced. An evident ~30% reduction in Ads specific activity was observed when 
0.2 mM Ppi was added (Figure 4.6B). Its apparent Ki was 0.6mM, which 
implying Ppi as a more potent inhibitor of Ads activity. The unreacted FPP 
concentration accumulated as pyrophosphate concentration increased; it was 
another piece of evidence to support the idea that product inhibition of Ads was 
by Ppi (Figure 4.6B). Therefore, pyrophosphate is a more potent inhibitor of Ads 
than ATP, and it was a specific feedback regulation of Ads instead of a random 




Figure 4.6. Ads activity assay with inhibitors.  
(A). Fold change in Ads specific activity when it was screened with ATP (15 mM), ADP (15 
mM), CTP (15 mM), Pyrophosphate (Ppi, 15 mM). It was calculated by dividing the control Ads 
activity, where no additives were added. (B). Ads specific activity when a range of concentration 
of Ppi from 0mM to 15mM was added. The amount of unreacted FPP were measured and its 
integrated area of LCMS measurement was used (please refer to section 4.5.4 for LCMS 
measurement). All the measurement were done in triplicates, and their standard deviations were 
shown.   
 
4.2.4 Inhibition of the mevalonate pathway enzyme by pyrophosphate 
Due to the structural similarity between ATP and pyrophosphate, we 
further examined whether pyrophosphate would have an inhibitory effect on the 




mevalonate pathway enzymes, since they all of them use ATP as an essential co-
factor. Figure 4.7 clearly showed that all the three enzymes, Erg12, Erg8 and 
Erg19, were inhibited with 10 mM Ppi. Interestingly, Erg12 and Erg8 were more 
sensitive towards the inhibition of pyrophosphate, that a remarkable 10 fold 
decrease in activity is seen. In contrast, Erg19 was less inhibited by the same 
concentration of pyrophosphate; a 2-fold decrease in activity was observed. 
Therefore, these observations demonstrated differential regulatory mechanisms by 
pyrophosphate on the ATP-dependent mevalonate pathway enzymes.  
Lin-log approximation predicted the negative elasticities of DMAPP on 
Erg12 reaction. This was in agreement with previous report in the literature [123]. 
Moreover, it predicted a stimulatory effect of IPP on Erg12 and Erg8. In the 
separate experiment, we observed a more than 5-fold reduction in Erg12 activity 
when either 500 μM IPP or DMAPP was added into the reaction mixture (Figure 
4.7). To our best knowledge, this was the first study showing an inhibitory effect 
of IPP on S. cerevisiae Erg12, although this was also seen for human Erg12 [122]. 
More strikingly, FPP was the most potent inhibitor of Erg12 with ~100 fold 
reduction in activity when only 15 μM of FPP was supplemented into the Erg12 
reaction (Figure 4.7) [121]. Furthermore, no significant enhancement of Erg8 
activity was observed with IPP, an observation that disagreed with Lin-log 
approximation. This was probably a false positive result predicted from the 
assumption of “maximum connectivity”. There were little changes in Erg8 and 
Erg19 activities when downstream diphosphate compounds were added into the 
reaction medium respectively. A slight inhibition of FPP on Erg8 was observed, 




but to a much lesser extent as compared to FPP inhibition on Erg12 (Figure 4.7). 
In contrast, FPP enhanced Erg19 activity mildly and statistically significant 
(Figure 4.7).  The results further suggested different regulation mechanisms of the 
three enzymes although all of them use ATP as phosphate donor. 
 
Figure 4.7. Mevalonate pathway enzyme activities in the presence of downstream 
metabolites.  
Fold change in Erg12, Erg8 and Erg19 activities when downstream diphosphate products, IPP 
(500µM), DMAPP (500 µM), FPP (150 µM), and Ppi (10 mM), were added into their reaction 
medium respectively. It was calculated by dividing its respective control activity, where no 
additives were added into the reaction medium. All the measurements were done in triplicates, and 
their standard deviations were shown. Student t-Test with paired two sample for mean is used to 
calculate the p-value in statistical analysis.   
 
4.2.5 Enhance AD production with ATP recycling and Pyrophosphatase 
In Chapter 3, we have identified Ads as the critical factor that would 
improve the overall productivity of the multienzyme pathway when its activity 
was increased. By discovering the novel regulations of Ads by ATP and 
pyrophosphate, we further examined if the productivity of the multienzyme 
pathway might increase if both ATP and pyrophosphate concentrations could be 
kept low. Therefore, two additional enzymes were introduced in the system, as 
shown in Figure 4.8. 





Figure 4.8. Schematic representation of PyfK and Ppa introduced in addition to 
the amorphadiene (AD) synthesis pathway.  
PyfK is pyruvate kinase which can use PEP as phosphate donor and recycle ADP back into ATP; 
Ppa is pyrophosphatase that can irreversibly hydrolyze pyrophosphate (Ppi) into inorganic 
phosphate (Pi).  
 
Firstly, pyruvate kinase (PyfK) was the commonly used enzyme that uses 
phosphoenolpyruvic acid (PEP) as the phosphate donor that recycle ADP back to 
ATP [182]. With ATP recycling system, catalytic amount of ATP would be 
needed to ensure that all the substrate would be converted. As a proof of concept, 
we first tested the hypothesis with 5mM ATP, which was lower than the apparent 
Ki value. In the future, more robust ATP recycling system could be devised to 
further reduce the initial amount of ATP. The second enzyme was inorganic 
pyrophosphatase (Ppa), which could hydrolyze pyrophosphate to inorganic 
phosphate [55, 183]. Therefore, the toxic by-product could be removed.  The 
enzymes were cloned from E. coli strain Mg1655 genomic DNA and purified by 
immobilized metal affinity chromatography (IMAC) to near homogeneity.  Their 
enzymatic activities have been verified separately (results not shown).  





Figure 4.9. Increasing the in vitro multienzyme production of AD by pyruvate 
kinase and pyrophosphatase.  
(A). Time course of in vitro multienzyme production of AD. PyfK: pyruvate kinase. Ppa: 
pyrophosphatase. (B). FPP concentration at different time point. (C). The total sum of upstream 
metabolite concentration at each time point. It was calculated by adding the concentrations of 
mevalonic acid (MVA), phosphomevalonic acid (PMVA), diphosphomevalonic acid (PPMVA), 
Dimethylallyl pyrophosphate (DMAPP) and Isopentenyl pyrophosphate (IPP).  All the 
measurements were done in triplicates and the standard deviation was shown.  
 
Figure 4.9A showed the time course of AD production under 5 different 
conditions. Evidently, more than 90% of MVA was gradually converted to 
amorphadiene (AD) after 12 h incubation, when the reaction contains 15mM 
ATP. When ATP concentration was lowered to 5mM, it was not sufficient to 
convert all the mevalonic acid (MVA) to AD.  Upon the addition of PyfK which 
recycles ADP back to ATP, there was a remarkable 3-fold kinetic enhancement of 
the multienzyme synthesis system that similar level of conversion (~90%) 
achieved in 4 hours. Unexpectedly, when Ppa which hydrolyzes pyrophosphate 
was mixed with the multienzyme reaction containing 15 mM ATP, a 3-fold 




kinetic enhancement of the production was also observed. This observation 
suggested that Ppa was able to rescue the system from ATP inhibition. Lastly, we 
introduced both PykF and Ppa into the multienzyme synthesis reaction. An 
apparent, albeit mild, improvement in the overall yield of multienzyme synthesis 
was observed as compared to that with either one of the enzymes added.  
To gain a better understanding, concentrations of intermediate metabolite 
were assayed at each time point and the four conditions which resulted >90% AD 
yield were analyzed in Figure 4.9.  As expected, there was an accumulation of 
FPP (~45µM), substrate of Ads, at 4h and 8h when only 15mM of ATP was 
present as compared to other three conditions that PyfK and/or Ppa were added 
(Figure 4.9B). Moreover, the total amount of upstream metabolites 
(MVA+PMVA+PPMVA+IPP+DMAPP) left unreacted at 4h and 8h were at 
similar levels for all four conditions  (Figure 4.9C), indicating that the higher 
concentration of FPP observed was not due to the faster reaction of the upstream 
pathway. This further confirmed that Ads activity was suppressed when high 
concentration of ATP and pyrophosphate were present. Moreover, it further 
suggested that the ATP recycle system was successfully, that the ATP-dependent 
upstream pathway was not limited despite the lower amount of ATP added. In 
contrast, accumulation of upstream metabolites was observed when only 5mM 
ATP was added into the reaction (results not shown).  The interesting observation 
of Ppa being able to reverse the ATP inhibition might be explained by alleviating 
the inhibition effect of pyrophosphate on the upstream pathway enzyme so that 
they consumed ATP in a more efficient manner. This was supported by the 




observation, that with Ppa, there was a slight decrease in upstream metabolites 
concentration as compared to that when Ppa was not added (Figure 4.9C). 
However, this hypothesis remained to be tested. Lastly, the synergistic effects of 
PykF and Ppa were reflected in further reductions in the FPP concentrations, 
especially at 4h (Figure 4.9B).  
 
4.2.6 Enzyme stability in a multienzyme reaction pot 
The experimental design used for estimating elasticities could be used to 
identify the least stable in the multienzyme pathway. This allowed us to access the 
enzymatic stability from a system perspective, since the presence of multiple 
enzymes may have a crowding effect. By pre-incubating the multienzymes at 
30
o
C for a known period of time, the least stable enzyme should have its substrate 
accumulated. Evidently, Figure 4.10A shown that phosphomevalonate (PMVA), 
the substrate of Erg8, was accumulated when the pre-incubation time was 
increased. This suggested that Erg8 could be the least stable or rate-limiting 
enzyme among the 6 enzymes assembled. The decrease in the subsequent 
intermediate levels could be a result of deactivation of Erg8, as less substrates to 
the downstream enzyme were produced. In order to test the stability of Erg8 in the 
reaction condition, we conducted a separate experiment by pre-incubating the 
enzyme alone under the same reaction conditions and found its half-life to be ~50 
min (Figure 4.10B). When 20% glycerol was added, its activity was maintained 
for more than 1h (results not shown). Thus, this enzyme could be the next target 
to engineer so as to enhance its stability under in vitro reaction conditions.  






Figure 4.10. Analysis of the pathway enzyme stability.  
(A). The change in the intermediate metabolite concentrations when the multienzyme was 
incubated at 30oC for 0min, 25min and 50min.  (B). The activity decay of Erg8 after incubating at 
30oC for a period of time. The half-life of the enzyme calculated based on the fitted exponential 
curve is 50min. All the measurements were done in triplicates and the standard deviations were 
shown.   
 
4.3 Discussion 
To better engineer and optimize a biochemical pathway, both in vivo and 
in vitro, understanding the network structure and the interplay among individual 
pathway components is paramount. However, by conventional trial-and-error 
approach would be time-consuming and ineffective to reach an optimal solution. 
The beauty of mathematical modelling is to reduce the experimental efforts and 
efficiently identify the likely optimal range. An ideal mathematical model for a 
biochemical pathway would be able to capture the mechanistic information of the 
multienzyme system, and allow the biologists to analyse and interpret the 
biological meaning of the parameters estimated. To obtain such model requires 
undue experimental and computation efforts, since many examples have shown 
that even kinetics information was abound for individual enzyme but would not 
result in a satisfactory mathematical representation of the pathway, and 




furthermore some information may be contradictory to each other [184]. Recent 
developed Lin-log formalism reduces the model complexity and permits 
identifying the biochemical structure around a reference state. It is an extension of 
metabolite flux analysis method that allows large perturbations around a reference 
state [79], and was sufficiently capable to unravel the regulatory behaviour of an 
in vitro system [184]. Therefore, we harnessed the benefit of the modelling 
technology which enabled the identification of a novel inhibitory effect of ATP on 
Ads.  
The inhibition of ATP was more apparent when its concentration was very 
high. Therefore, when multienzyme system was initiated, high ATP concentration 
would inhibit Ads activity, resulting in little or no amorphadiene conversion at the 
start, even though there was already accumulation of FPP at higher concentration 
(results not shown). This may be detrimental to the whole multienzyme system, 
since we reported in the previous chapter that accumulation of FPP would lead to 
precipitation and prevent efficient catalysis of the pathway enzymes. There are 
three hypotheses that could account for the inhibition of ATP on Ads. Firstly, the 
phosphate of ATP is complexed with Mg
2+
, and hence depleting the availability 
of divalent ions for Ads catalysis. Secondly, there may be a structural similarity 
between FPP and ATP, since FPP was identified to competitively occupy the ATP 
binding site of several enzymes including mevalonate kinase (Erg12) [120]. 
Moreover, there was a glycine rich region identified near the catalytic site of Ads. 
The glycine cage has been reported to bind the nucleotide portion of ATP in the 
literature [185]. This might provide a docking site for ATP and prevent the entry 




of FPP.  Lastly, ATP entails a pyrophosphate moiety, which is a by-product of 
Ads.  From our results, it was likely that the polyphosphate moiety of ATP was 
responsible for the inhibition effect, since ADP containing the same nucleotide 
group did not elicit significant inhibition. Hence, a novel feedback regulation of 
Ads by its product pyrophosphate was identified. Ads belongs to the important 
class of enzyme, terpene synthase, that is responsible for the diversity of 
terpenoids [12]. Hence it might be interesting to examine if the inhibitory effect 
was a universal phenomenon to terpene synthases, in particular, sesquiterpene 
synthases.  
In addition to the novel finding of an inhibitory effect of ATP and 
pyrophosphate on Ads, regulation of Erg12 by downstream metabolites including 
IPP, DMAPP, GPP and FPP were also observed [123]. To our best knowledge, 
we were the first to observe the novel inhibition of S.cerevisae Erg12 by IPP, 
similar to that reported for the human form of Erg12 [122].  We attempted to 
examine the mechanism of IPP inhibition on Erg12, and found both IPP and 
DMAPP were uncompetitive inhibitors, determined by lineweaver burk plot, to 
the substrate mevalonic acid (MVA); they were possibly able to compete with 
ATP binding pocket and reduce the enzyme efficacy. S. cerevisea Erg8 activity 
was reported to be inhibited by high concentration of ATP [126]. This was 
effectively reflected by the lin-log approximation.  However no inhibition of 
downstream metabolites, albeit minute inhibition of FPP, was observed for Erg8 
catalyzed reaction. The false positive results drawn from Lin-log approximation 
could be due to the assumption made by “maximum connectivity”. Further 




optimization of Lin-log approximation could be carried out with a priori 
information to strengthen the predictability of the model.   
We further examined the inhibition of pyrophosphate (Ppi) on the ATP-
dependent mevalonate pathway enzymes. All the three enzymes were affected by 
Ppi but the extent of inhibitioin varied among the three enzymes. This interesting 
observations reiterated the diversity of enzymes, and the uniqueness of ATP 
binding pocket that each enzyme entails that makes the prediction of inhibition 
less obvious.   
By unraveling the regulation of the amorphadiene synthesis pathway, we 
were able to rationally engineer the multienzyme pathway with two additional 
enzymes: PyfK that recycles ATP and Ppa that hydrolyze pyrophosphate. This 
further enhanced the kinetics of the multienzyme system by 3 fold. We have done 
a theoretical calculation that if Ads is the rate limiting step, which means the 
production of AD is solely dependent on the activity of Ads, to catalyze all 5mM 
mevalonic acid to AD, it would only require 3-4h. (Refer to the previous chapter 
for Ads activity, which is 0.05s
-1
, and approximately 3µM of Ads is added). 
Hence, our results demonstrated that, with PyfK and Ppa, the multienzyme system 
can reach ~90% conversion at 4h, and hence is kinetically optimal. Further 
optimization may require engineering Ads to alter its catalytic efficiency.  
Another application of the assembled pathway has enabled us to identify 
the least stable enzyme along the pathway. The stability of enzymes may change 
when its environment changes. When multiple enzymes are present, some 
enzymes may lose its activity faster due to aggregation, or a stabilizing effect may 




be resulted due to crowding effect. Therefore, by assembling the pathway together 
and measure its steady state metabolite profile change may provide a more 
accurate depiction of how enzyme stability may be affected in a multienzyme 
condition. With that, we have identified the second enzyme, Erg8, as likely to be 
the least stable enzyme, and should be the target of further optimization. 
  
4.4 Conclusion 
In summary, we have identified a novel inhibition of ATP on Ads, and it 
was due to the presence of polyphosphate moiety in ATP, that is structurally 
similar to Ads byproduct, pyrophosphate. It was further confirmed that 
pyrophosphate is a potent product inhibitor of Ads. Moreover, high concentration 
of pyrophosphate would inhibit the ATP-dependent mevalonate pathway 
enzymes, although with different extent of inhibition. After unravelling the 
regulation of the amorphadiene synthesis pathway, we introduced the ATP 
recycling system and pyrophosphatase into the multienzyme system, and was able 
to enhance the time yield of the system by 3-fold. According to our theoretical 
calculation, the system was kinetically optimized. The study emphasized the 
importance of understanding the pathway regulations and the advantages of in 
vitro multienzyme system. With which, we were able to rationally design targeted 
engineering strategies to overcome the challenge, and enhance the productivity. 
We believe the method employed here may be useful for other in vitro 
reconstituted system beyond the scope of this study.   
 




4.5 Materials and Methods 
4.5.1 Bacteria strains and plasmids 
The bacteria strains and plasmids for the amorphadiene synthesis pathway 
enzymes were the same as Chapter 3. The Bacteria strains and additional plasmids 
used in this chapter were summarized in Table 4.3. The cloning of the two 
additional plasmids were as described [186]. Briefly, Pyruvate kiase (PyfK, EC 
2.7.1.40) and inorganic pyrophosphatase (Ppa, EC 3.6.1.1) were amplified from 
E. coli MG1655 strain genomic DNA. The vector backbone was amplified from 
pBAD-B plasmid (Invitrogen, CA). The primers used for amplification of the 
genes were listed in Table 4.4. The PCR products were treated by 0.3% Iodine at 
70
o
C for 5min to chemically cleave the phosphorothioate bond. Then ethanol 
precipitation step was carried out to purify and concentrate the treated DNA. The 
insert and vector were mixed at approximately 1:1 molar ratio, and then annealed 
with heating at 80
o
C for 5min and gradually cooling down to 20
o
C with a ramp 
rate of 0.1
o
C/s.  Then 1µl of mixture with final DNA concentration of ~100ng/ µl 
was transformed into E. coli XL10-gold (Stratagene, CA) to self ligate the insert 
and vector together. The colonies formed were examined by colony PCR with 
forward primer targeting the vector and the reverse primer targeting the gene of 
interest. The colony harbouring the correct plasmid was then grown till optical 
density reached 2 and then was harvested to purify the plasmids. The plasmids 
were then transformed to respectively strains for enzyme overexpression (Table 
4.3).   
 




Table 4.3. The bacteria strain and plasmids used in Chapter 4. 
Name Description 
Reference 
E. coli BL21-Gold (DE3) F– ompT hsdS (rB
– mB
–) dcm+ Tetr gal 
λ(DE3) endA Hte 
Stratagene 
E. Coli DH10B araD139 Δ(ara-leu)7697 fhuA lacX74 galK 
(Φ80 Δ(lacZ)M15) mcrA galU recA1 
endA1 nupG rpsL Δ(mrr-hsdRMS-mcrBC) 
NEB 
E. Coli XL10-Gold Tetr D(mcrA)183 D(mcrCB-hsdSMRmrr) 
173 endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F9 proAB lacIqZDM15 
Tn10 (Tetr) Tn5 (Kanr) Amy 
Stratagene 
pBAD-His-PyfK Plasmid for overexpression of PyfK in E. 
coli DH10B 
This study 




Table 4.4. The CLIVA primers used in Chapter 4. * indicated the 
phosphorothioate modification.  








4.5.2 Expression and purification of PyfK and Ppa. 
Purification of the amorphadiene synthesis pathway enzymes were the 
same as described in Chapter 3. Expression and purification of the two additional 
enzymes were described as follows. Newly transformed colonies were picked 
from the agar plate, inoculated into 2xPY medium (20 g/L Peptone, 10 g/L Yeast 
extract, and 10 g/L NaCl, pH 7) containing 100 mg/L ampicillin and grew till 




stationary phase overnight at 37 
o
C in an incubator-shaker (Shin Saeng Shaking 
Incubator, Finetech, Korea). The culture was then further transferred into fresh 
2xPY medium (1% inoculation) with ampicillin for another 2.5 h at 37 
o
C, till 
optical density A600 reached 0.6-1.0. The enzyme expression was induced with 10 
mM L-arabinose. Temperature was reduced to 20 
o
C after induction for higher 
solubility of the enzymes [20]. The culture was grown for another 48 h and 
harvested by centrifugation. The cell pellets were stored at -20 
o
C till further use.          
To purify the enzymes, the frozen cell pellets were resuspended in B-PERII 
reagent (Pierce, IL), according to the manufacturer’s instruction, and vortexed at 
room temperature for 30 mins to completely lyse the cells. The soluble proteins 
were contained in the supernatant, which was diluted 15 times in NPI10 buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) and incubated with 
200 mg Ni-NTA resin (USB, Affymetrix, CA) at 4 
o
C for 2 h. The resin was 
washed with NPI10 buffer after discarding the binding supernatant, and the 
enzymes were eluted and collected by 400 μl NPI400 (50 mM NaH2PO4, 300 mM 
NaCl, 400 mM imidazole, pH 8). The enzymes were further concentrated by 3K 
Amicon ultra-0.5 ml centrifugal filter unit (Millipore, MA), and the 
concentrations were measured by Micro BCA protein assay kit (Thermo 
scientific, MA). The purified enzymes were further confirmed by sodium dodecyl 
sulfate-12% polyacrylamide gel electrophoresis (Bio-Rad, CA).     
 




4.5.3 Multienzyme reaction  
The multienzyme reaction was carried out in a buffer (25 μl) consisted of 
Tris/HCl (100 mM, pH 7.4), MgCl2 (10 mM), (±)mevalonic acid (10 mM), ATP 
and the purified enzymes. If not indicated otherwise, the amount of amorphadiene 
pathway enzymes were added according to the optimum enzyme levels found in 
Chapter 3. PyfK and Ppa were both added in excess at the final concentration of 
50mg/L. The reaction was performed at 30 
o
C with an overlay of dodecane phase 
that contained known concentration of trans-caryophyllene as an internal 
standard. At the end of the reaction, the dodecane phase was diluted 10 times in 
ethyl acetate and subject to GCMS analysis. Equal volume of ice cold methanol 
was added to stop the reaction. Half of the stopped reaction mixture was further 
diluted with MeOH and 0.1% ammonium hydroxide, and injected into UPLC 
column for measurements. Another half of the stopped reaction mixture was used 
to determine the concentrations of IPP and DMAPP. In order to differentiate the 
isomer IPP and DMAPP, an acid treatment step was carried out to degrade the 
acid labile DMAPP [187]. In brief, equal volume of 2M HCl was mixed with 
stopped reaction mixture, and then incubated at 37
o
C for 10min. Then the reaction 
was stopped with 1% acetic acid. It was further diluted in methanol before UPLC-
(TOF)MS analysis. To determine the enzyme stability, the enzymes were first 
mixed together according to the concentration of the optimal steady state 
determined for Lin-log approximation (run 9). Then they were incubated at 28
o
C 
for 0min, 25min and 50min respectively, before the mixture of substrate and co-
factors were added to initiate the reaction.  The  (±)mevalonic acid was prepared 




by complete alkaline hydrolysis of 2 M (±)mevalonolactone (Sigma, MO) with 
equal volume of 2 M potassium hydroxide  at 37 
o
C for 1.5 h, and neutralized by 
adding 1 M hydrochloric acid to pH 7 [170].  
 
4.5.4 UPLC-(TOF)MS analysis of mevalonate pathway intermediates 
The analysis was done based on the method developed previously with 
slight modification [42]. In brief, 5 μl samples were injected into a UPLC C18 
column (Waters CSH C18 1.7 μm, 2.1 mm x 50 mm) connected to UPLC (Waters 
ACQUITY UPLC)-(TOF)MS (Bruker micrOTOF II, MA).  Elution was carried 
out with a step change from 100% aqueous solution containing 15 mM acetic acid 
and 10 mM tributylamine (0.5 min) to 10% aqueous solution with 90% methanol 
for another 3.5 min. Electrospray ionization was used and mass spectrometry was 
operated to scan 50–800 m/z in negative mode with 2500 V end plate voltage and 
3200 V capillary voltage. Nebulizer gas was provided in 2 bar, dry gas flow rate 
was 9 ml/min, and dry gas temperature was 200 
o
C. At the assay condition, all the 
intermediates were detected in the form [M-H]
-
. Retention time was subsequently 
determined for each intermediate with respective synthetic standards and the set 
m/z extraction range. The peak area was calculated and subsequently used to 
compute the intermediates concentrations with the software provided by the 
manufacturer. The calibration curves were constructed with synthetic standards 
prepared under similar reaction conditions without enzymes. Linearity of the 








4.5.5 GCMS analysis of Fanesyl pyrophosphate (FPP) and amorpha-4,11-
diene (AD) 
To measure the FPP concentration, a hydrolysis reaction was carried with 
acid phosphatase (Sigma, MO) according to the manufacturer’s instruction. In 
short, FPP was incubated with acid phosphatase at 37
o
C for 10min, and was 
stopped by extracting the product farnesol (FOH) with 3 volumes of ethyl acetate. 
The standard curve of FPP was constructed with synthetic standards that known 
concentration of synthetic FPP was treat with acid phosphatase and then subjected 
into GCMS analysis. AD analysis was carried out based on the modified method 
developed by Martin et al. by scanning three ions; the m/z values are 117, 189 and 
204 [170, 171]. For both FPP and AD, 1 μl sample was injected into HP-5 column 
(Agilent Technologies 7890A gas chromatograph-mass spectrometry, Agilent, 
CA) with a linear temperature increase of 50 
o
C/min from 80 
o
C to 300 
o
C and 
hold at 300 
o
C for another minute. The peak area was calculated and subsequently 
used to compute the FPP and AD concentrations with the software provided by 
the manufacturer. FPP concentration was determined based on the external 
standard curved constructed. Amorpha-4,11-diene concentrations were 
determined relative to the internal standard trans-caryophyllene of known 
concentration.   
 
 




4.5.6 Lin-log modelling 
The lin-log modelling was done based on the previous study demonstrated by Wu 
et al [80]. It was modified from metabolic control analysis (MCA).  The important 
MCA parameters and relations for linear pathway were summarized in Table 4.5 
and Table 4.6. 
Table 4.5. Definition of MCA parameters [188].   
Elasticity with respect to xm 
 
Elasticity with respect to ej 
 
Elasticity with respect to cr 
 
Flux control coefficient 
 
Metabolite control coefficient 
 
Flux response coefficient 
 









Table 4.6. MCA relations for a linear pathway. [80] 
All the equation below are for matrix operations. J
o
 is the steady state flux. S is 





the elasticity matrix for dependent metabolite and independent metabolite 
respectively. i is a unit vector.  




Metabolite control coefficient 
 
Flux control coefficient 
 
Metabolite response coefficient 
 
Flux response coefficient 
 
 
An important parameter in MCA is elasticity (Equation 4.1), which 
reflects the kinetic property of individual enzyme towards a dependent metabolite 




In the Lin-log approximation, the nonlinear relationship between reaction 
rate and the reaction components, namely the enzymes and the metabolites were 
shown in Equation 4.2, where the reaction rate vi was assumed to be proportional 
to the enzyme level ei and a linear sum of logarithms of m dependent (x) and r 
independent (c) metabolite concentrations. pi,m and qi,r are estimated coefficients 




The rationale behind the logarithmic concentration terms has its origin in 
the concept that the rate of a chemical reaction is proportional to the reaction 




affinity when the reaction is close to equilibrium [189]. The affinity term is 
linearly proportional to the logarithmic term of the reactant concentration.  
A reference state can be introduced in Equation 4.2, as shown in Equation 4.3 that 






) and independent (cr
o
) 
metabolite concentrations were all modified with the “o” symble to show they are 




Therefore, by the definition of elasticity (Equation 4.1) and the reaction 
rate (Equation 4.3), it can be expressed in terms of enzymes and the coefficients at 




Combining Equation 4.2, Equation 4.3, and Equation 4.4, the coefficients 




When a multienzymatic reaction system is considered, Equation 4.5 can be 












) can be estimated by linear regression 







) and reaction rate (v/v
o
) around a steady 
state. After obtaining the elasticities, the control coefficients listed in Table 4.5 
can be calculated based on the relationship given in Table 4.6. With the control 
coefficients, Lin-log approximation could give an analytical solution of the steady 
state mass balances of the metabolic network; the steady state flux (Equation 4.7) 
and dependent metabolite concentrations (Equation 4.8) could then be re-






To determine the optimal steady state, the criteria of adjusted coefficient 
of determinant, aR
2
, is used, which is calculated as follows, where SSE is the sum 
of square error and SST is the sum of square total, N is the number of 
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Chapter 5 Co-immobilization of Multienzymes for amorpha-4,11-
diene synthesis   
5.1 Introduction 
In Chapter 4, the amorphadiene synthesis pathway was further optimized 
to achieve near theoretical productivity. However, free enzymes usually suffer 
from low enzymatic stability and require cost- and time- consuming purification 
processes. Immobilization of the enzymes is an attractive biorenewable approach 
offering advantages in enhanced stability, volume specific biocatalyst loading, 
recyclability, simplified downstream processing and is often the key to optimizing 
the operational performance of an enzyme in industrial processes [86, 190]. Many 
parameters contribute to the success of immobilized enzyme technology and 
continual efforts to optimize attachment chemistries of the enzyme onto 
compatible surfaces combined with modern analytical tools to improve activity 
and stability has gained recent attention [191]. As a rule of thumb, the enzyme 
cost in commercial applications should not exceed more than a few percent of the 
total production costs [86].  For example, 600kg of 6-aminopenicillanic acid (6-
APA) is produced for every kg of immobilized penicillin G amidase, and the 
specific yield is 11,000kg/kg enzyme for food production [192]. Therefore 
operational stability of the biocatalysts is critical to ensure the economic viability 
of the process. Immobilization is able to enhance the enzymatic stability [193, 
194]; aggregation due to random Brownian motion of the enzymes was reduced. 
Moreover, the enzymes are easily separated from the products and reused 
continuously for subsequent cycles of catalysis [195]. Therefore, the specific yield 
is enhanced. In addition, immobilization would be able to concentrate the 




otherwise diluted enzymes [196]. Hence kinetic efficiency might be enhanced as a 
consequence of substrate channeling and close proximity of the catalytic sites 
[197, 198].  
A myriad of exciting immobilization strategies have been developed, due 
to the synergistic growth of material research and biotechnology. As reviewed in 
chapter 2, cross-linked enzyme aggregates (CLEA), DNA-directed 
immobilization (DDI) are promising technologies to co-immobilize multienzymes 
in an elegant way. However, the methods lacked the control over the orientation 
of the enzymes, which has been shown to be critical to enzymatic activities at 
interface [99, 100, 195]. Therefore, adsorption via site-directed interaction 
between the insoluble support and the enzymes is attractive, and it is simple, 
cheap and causes no or little damage to enzyme [199].  Among them, 
immobilized metal affinity chromatography (IMAC) technology is a facile 
approach of immobilizing enzymes. Enzymes can be easily engineered with 
polyhistidine-tag, and one-step protein purification and immobilization is 
achieved to avoid expensive protein purification [200, 201].  Moreover, enzymes 
immobilized via IMAC technology has minimal impact on enzymatic 
conformation and reflects solution phase enzymatic activities [99, 202].  
In this chapter, the pathway enzymes for amorpha-4,11-diene biosynthesis 
were co-immobilized on Ni-NTA modified solid surface (Figure 5.1). Initial 
attempt to recycle the co-immobilized AD synthesis pathway did not yield 
satisfactory productivity and recyclability. This was likely attributed to the 
presence of high concentration of ATP and pyrophosphate, as identified in chapter 




4. Therefore, when pyruvate kinase and inorganic pyrophosphatase were added to 
remove the inhibitors, both the rate of production and overall AD yield were 
improved by 3 and 2.5 fold respectively. Further guided by the regulatory 
topology of the multienzyme pathway, a rationally designed, novel bi-modular 
system was implemented, which a further 25% improvement in AD yield was 
observed and a near quantitative conversion of the substrate after 12h was 
achieved. The multienzymes can be effectively reused for more than 7 cycles of 
reaction. Taken together, approximately 2.2g/L of amorphadiene could be 
produced within 4 days, which is a greater than 6-fold enhancement of AD 





Figure 5.1. Schematic representation of the co-immobilized multienzymes.  
The enzymes were arranged in tandem, and the intermediates were shown. The black circle in the 
graph represent the co-factor ATP. The abbreviations are as follows. Erg12: mevalonate kinase, 
Erg8: phosphomevalonate kinase, Erg19: diphosphomevalonate decarboxylase, Idi: isopentenyl 
pyrophosphate isomerase, IspA: farnesyl pyrophosphate synthase.Ads: amorpha-4,11-diene 
synthase. MVA: mevalonic acid. PMVA: phosphomevalonic acid. PPMVA: diphosphomevalonic 
acid. IPP: Isopentenyl pyrophosphate. DMAPP: Dimethylallyl pyrophosphate. FPP: Farnesyl 
pyrophosphate. AD: Amorpha4,11-diene. 
 




5.2 Results  
5.2.1 Immobilize enzyme on Ni-NTA functionalized beads 
The overexpressed enzymes were engineered with hexahistidine tag (his6-
tag). Therefore, they can be conveniently purified and immobilized by 
immobilized metal affinity chromatography (IMCA) [98], which the surface of 
solid resin was functionalized with nickel-chelated nitrilotriacetic acid (Ni-NTA). 
Since the immobilization process is reversible, a facile dilution method was used 
to decrease concentration of imidazole and immobilize purified enzymes. For 
convenience, we used enhance green fluorescence protein (eGFP; Figure 5.2B) as 
a model protein to monitor the efficiency of the immobilization method. From 
Figure 5.2A, almost all the eGFP proteins were adsorbed onto the solid resin, 
when 5µg of protein was mixed with 1mg of resin (an optimal protein to resin 
ratio recommended by manufacturer). By measuring the residual fluorescence in 
the supernatant, the immobilization yield was determined to be greater than 90%. 
We have increased the protein to solid resin ratio twice, the immobilization yield 
was still above 90%, suggesting a high protein immobilization capability of the 
resin. For the subsequent experiments, the optimal enzyme to resin ratio 
(5ug:1mg) was used so that the surface was not saturated.    
The dilution method was subsequently applied to immobilize the enzymes 
involved in the biosynthesis of amorphadiene (AD synthesis pathway). 
Mevalonate kinase (Erg12) is the first enzyme in the pathway, and is used as an 
exemplary enzyme to determine the immobilization yield and activity yield 
(section 5.5.2 ). From Figure 5.2C, more than 90% of Erg12 was immobilized 




after mixing with the resin for 10 min at room temperature and the activity yield 
had reached a plateau at 10 min. There was a decrease in the immobilized Erg12 
activity, approximately 30% activity remained after immobilization, possibly due 
to adverse interfacial phenomenon that has previously been reported [203]. 
Nevertheless, the enzyme was efficiently immobilized onto the Ni-NTA grafted 
solid support, and 10min mixing time will be used subsequently to co-immobilize 
the multiple enzymes.  
 
 
Figure 5.2. Immobilizing his6-tag enzyme onto Ni-NTA functionalized solid resin.  
(A). Demonstration of immobilizing eGFP onto Ni-NTA resin by dilution method. The 
concentrations were determined by its fluorescence intensity. (B). The standard curve of eGFP 
concentration against its fluorescence intensity (Ex=490nm, Em=500nm). NPI-40 and NPI-400 
were two buffers that contained sodium chloride (N), phosphate (P) and imidazole (I). 40 and 400 
refer to 40mM and 400mM imidazole concentration. The standard curve showed a good linearity 
between the fluorescence and concentration of the eGFP protein. It was used to calculate the 
concentration of eGFP in the solution. (C). The immobilization and activity yield of Erg12. For 
definition of the two terms, please refer to materials and methods (Section 5.5.2).  
   




5.2.2 Production of Amorpha-4,11-diene 
The AD synthesis pathway enzymes were assembled and co-immobilized 
according to the enzymatic ratio identified previously (Chapter 3) for amorpha-
4,11-diene (AD) production (Figure 5.3, system I). SDS PAGE analysis showed 
that majority of the enzymes were co-immobilized onto the solid support with 
greater than 90% yield, (Figure 5.4A, lane 3-4).  
 
 
Figure 5.3. Schematic representation of the co-immobilized systems.  
System I (iR6): randomly co-immobilize the 6 pathway enzymes on Ni-NTA grafted solid 
support. System II (iR8): randomly co-immobilize the 6 pathway enzymes together with pyruvate 
kinase (PyfK) and inorganic pyrophosphatase (Ppa) onto Ni-NTA grafted solid support. System III 
(2x iR4): bi-modular system that the 8 enzymes were divided into two groups: the ATP dependent 
mevalonate pathway enzymes were co-immobilized with PyfK that can recycle ATP; the 
downstream enzymes was co-immobilize with Ppa that can hydrolize pyrophosphate.   
 
Amorphadiene was successfully produced with the co-immobilized 
system, and could reach approximately 40% AD yield after 12 h incubation 
(Figure 5.4B). The recyclability of system I was very poor. Less than 10% AD 
yield was retained after 5 cycles of reaction (Figure 5.4C). LCMS analysis 
indicated that FPP was accumulated at 12h in the first cycle of reaction (Figure 




5.4B), suggesting Ads reaction was inhibited due to the presence of high 
concentration of ATP and pyrophosphate in the reaction mixture, as discovered in 
Chapter 4. Therefore, the two additional enzymes, pyruvate kinase (PyfK) and 
inorganic pyrophosphatase (Ppa), were introduced to co-immobilize with the 
pathway enzymes in a random fashion (Figure 5.3, system II). Remarkably, AD 
yield was enhanced to 80% after 12h incubation, a 2 fold enhancement as 
compared to system I (Figure 5.4B). This was probably attributed to the enhanced 
Ads activity, as FPP concentration was significantly reduced which is more than 6 
fold lower than system I. Surprisingly, the productivity of system II was 
maintained at greater than 60% after 7 cycles of reactions (Figure 5.4C). Judging 
from the trend, the enzymes can be reused for more cycles of reactions. This is 
probably correlated to the minimized amount of FPP left unreacted in the 
reaction, which will induce precipitation (Chapter 3) and deactivate the enzymes. 
The improved system productivity spurred us to optimize the spatial 
arrangement of the multiple enzymes. A novel bi-modular reaction system was 
proposed, as shown in Figure 5.3, System III. Since the mevalonate pathway 
enzymes are ATP dependent, they are co-localized with PyfK which can recycle 
ATP. The downstream enzymes produce pyrophosphate (Ppi) are co-localized 
with Ppa that can hydrolyze Ppi. We hypothesize that by segregating Ads from 
PyfK, the local ATP concentration would be lowered around Ads by substrate 
channeling effect, since the ATP regenerated by PyfK can be effectively 
consumed by the mevalonate pathway enzymes before it is diffused to the 
external reaction medium.  Similarly, by bringing Ads in close proximity with 




Ppa, Ppi would be hydrolyzed immediately.  As a result, an enhanced productivity 
would be expected. The concept was successfully illustrated as an improved AD 
yield was observed for system III that approximately 100% conversion was 
achieved in the first cycle of reaction. This was a 2.5 and 1.25 fold improvement 
as compared to system I and II respectively (Figure 5.4B). Moreover, System III 
was kinetically enhanced as AD was produced in a higher rate than the other two 
systems (~ 50% enhancement as compared to system II at 4 hour, Figure 5.4B). 
The enhanced rate of reaction was probably due to the further reduction in FPP 
concentration, as negligible amount of FPP was detected by LCMS in system III. 
However, to our disappointment, AD yield was gradually decreased to ~67% after 
7
th
 cycle of reaction without any appreciable enhancement as compared to system 
II (Figure 5.4C).  
 
Figure 5.4.  Production of amorpha-4,11-diene by co-immobilized AD synthesis 
pathway.  
(A). SDS page analysis of the enzymes. Lane 2 is  the total enzyme before immobilization. Lane 
3-8: the residual enzymes in supernatant after immobilizing. Lane 9-14: the enzymes that were 




still immobilized on the solid support after 7th cycle of reaction. Its concentration was diluted with 
equal volume of NPI400, which is half of that loaded in lane 2. (B). The AD yield produced by the 
three systems at 4h and 12h. The FPP concentration was measured by LCMS at 12h. (C). The AD 
yield at each cycle of 12h reaction.  All the measurements were done in triplicates, and the 
standard errors were shown.  
 
 
In order to evaluate the decrease in the AD yield after repeated use of the 
multienzymes, LCMS (Figure 5.5) analysis were conducted to access the 
accumulated metabolites at the end of 7
th
 cycle of reaction. Surprisingly, apart 
from FPP, IPP/DMAPP was accumulated to a high level for all three systems. 
This was probably due to the leakage of farnesyl pyrophosphate synthase (IspA) 
from the Ni-NTA resin, as reflected by SDS PAGE that IspA was hardly detected 
(Figure 5.4A, Lane 9-13). Moreover, the mevalonate pathway enzymes were less 
efficient for both system II and III, as the substrate MVA and PMVA were found 
to be accumulated. This could be due to the inactivation of PyfK that was not able 
to continuously supply ATP to the system. The hypothesis remained to be tested. 
Nevertheless, the immobilized multienzyme system was successfully 
recycled. Approximately 2.2g/L AD was produced in 4 days. This translated to 
approximately 80%  overall AD yield and a significant more than 6 fold 
enhancement in AD specific yield as compared to free enzymatic system.  
 






Figure 5.5. UPLC-(TOF)MS analysis of the reaction intermediates in the 7
th
 cycle 
of reaction.  
All the measurements were done in triplicates, and the standard errors were shown.  
 
5.3 Discussion 
Co-immobilization of the enzymes is an attractive technology to develop 
the in vitro multienzymatic biosynthetic platform for industrial application. In 
addition to the advantages associated with the single enzyme immobilization, 
multienzyme co-immobilization can achieve spatial arrangement of the multi-
biocatalysts by artificially varying the inter-enzymatic distance. A number of 
reports have described the benefits of substrate channeling where the 
intermediates were efficiently shuffled towards product when the in-tandem 
enzymes were brought in close proximity [18, 196, 198]. More importantly, the 
toxic intermediates can be removed effectively to prevent them from inactivating 
the pathway enzymes [18]. We applied the concept of co-immobilization to the 
AD synthesis pathway, and designed a bi-modular system to boost the 
productivity from 40% to 100%. The in situ removal of the byproduct 
pyrophosphate and recycling of ATP were found to improve the recyclability of 




the system. Since there were less inhibitors accumulated along the pathway, the 
activity of the enzymes should be preserved longer, and hence the specific yield 
could be further enhanced. In the future, more innovative and stable ATP 
recycling system can be used. One interesting idea is to use a coupled pyruvate 
oxidase and acetyl kinase system to directly use pyruvate and phosphate as the 
starting materials to regenerate ATP via the formation of high energy compound 
acetyl phosphate [204]. In such a way, the phosphate formed after hydrolyzing 
pyrophosphate by inorganic pyrophosphatase can be used as energy source to 
replenish ATP in the system. Therefore, the in vitro system should achieve self-
sustainability. Furthermore, DNA-directed immobilization technique can be 
explored to further program and address the enzymes rationally to enhance the 
substrate channeling effect.             
One limitation of the co-immobilized system when using IMAC is the 
steric hindrance of the liquid and solid interface. The high interfacial energy 
might inactive the enzymes and hampers the diffusion of the substrates to the 
reaction site. Therefore, the turnover rate of the system may be reduced, as seen 
for immobilized Erg12. Therefore, modification of the surface with a spacer, such 
as polyethylene glycol (PEG), might provide a means to overcome such  










In summary, a recyclable multienzymatic platform was established for AD 
production. The productivity of the system was systematically improved from 
40% to ~100%, with the knowledge that high concentrations of ATP and Ppi 
inhibited Ads activity. The platform could be effectively reused for more than 7 
cycles of reactions with AD yield maintained at more than 60%. Thus, the 
specific yield of the system was significantly improved for more than 6 fold as 
compared to the free enzymatic system.  
 
5.5 Materials and Methods 
5.5.1 Expression and purification of the enzymes 
The bacteria strains and plasmids for the amorphadiene synthesis pathway 
enzymes were the same as Chapter 3 and Chapter 4.  The purification methods 
were the same as described in the previous chapters. The enhanced green 
fluorescence protein (eGFP) was from the previous study [20]. Its concentration 
was determined with Micro BCA protein assay kit (Thermo scientific, MA). The 
standard curve of eGFP was constructed between its florescence (λex=490, 
λem=510nm) and known concentration. Different buffer was used to dilute the 
eGFP enzymes, to exclude any background fluorescence.  
 




5.5.2 Immobilize His6-tag enzymes by dilution 
The purified proteins were contained in NPI400 buffer (50 mM NaH2PO4, 
300 mM NaCl, 400 mM imidazole, pH 8) which was diluted 10 times with 
phosphate saline buffer. Then the enzyme was immobilized onto Ni-NTA grafted 
resin (USB, Affymetrix, CA) at a ratio of 5µg enzyme per mg of resin, and vortex 
at room temperature for 10min. Then the supernatant was carefully remove after 
centrifuging the mixture. Portion of the supernatant was subject to dodecyl 
sulfate-15% polyacrylamide gel electrophoresis (Bio-Rad, CA), to measure the 
residual amount of the protein. To determine the amount of enzymes 
immobilized, the resin was resuspended in NPI400 buffer, and both the resin and 
enzymes were loaded into SDS page gel.  When immobilizing mevalonate kinase 
(Erg12), the yield was determined by measuring its kinetic activity before it was 
immobilized (Atp), the activity on the solid support (Aim) and the residual activity 
in the supernatant (Are). Then the immobilization yield and activity yield was 











5.5.3 Co-immobilized Multienzyme reaction  
There were three systems of co-immobilized multienzymes (Figure 5.3). 
For system II and III, the enzymes were co-immobilized by directly mixing the 
enzymes with the solid resin in the ratio as stated above. For system III, the two 
groups of enzymes were mixed with corresponding amount of resin according to 
the ratio separately, and then combined the co-immobilized enzymes into one-pot. 
Subseqeuntly, the multienzyme reaction was initiated upon the addition of 
substrates (10 mM), (±)mevalonic acid contained in a buffer (50 μl) consisted of 
Tris/HCl (100 mM, pH 7.4), MgCl2, ATP. If not indicated otherwise, the amount 
of amorphadiene pathway enzymes were added according to the optimum enzyme 
levels found in Chapter 3. PyfK and Ppa were both added in excess at the final 
concentration of 50mg/L. The reaction was performed at 30 
o
C with an overlay of 
dodecane phase that contained known concentration of trans-caryophyllene as an 
internal standard. At the end of the reaction, the dodecane phase was diluted 10 
times in ethyl acetate and subject to GCMS analysis. At each time point, a volume 
of reaction mixture was drawn and equal volume of 1% NH4OH and 8 volumes of 
ice cold methanol were added to stop the reaction and subjected to UPLC-
(TOF)MS column for measurements. At the end of each cycle of reaction, the 
immobilized enzymes were separated from the aqueous solution by centrifuging 
at 10,000 g for 5min, and the supernatant was carefully removed. Then the solid 
support was washed with 50µl of NPI10 with 20% glycerol, and the wash buffer 
was removed by repeating the centrifuging step. Then the resin was resuspended 
in NPI10 for the next cycle of reaction.  The (±)mevalonic acid was prepared by 




complete alkaline hydrolysis of 2 M (±)mevalonolactone (Sigma, MO) with equal 
volume of 2 M potassium hydroxide  at 37 
o
C for 1.5 h, and neutralized by adding 
1 M hydrochloric acid to pH 7 [170].  
 
5.5.4 UPLC-(TOF)MS analysis of mevalonate pathway intermediates 
The analysis was done based on the method developed previously with 
slight modification [42]. In brief, 5 μl samples were injected into a UPLC C18 
column (Waters CSH C18 1.7 μm, 2.1 mm x 50 mm) connected to UPLC (Waters 
ACQUITY UPLC)-(TOF)MS (Bruker micrOTOF II, MA).  Elution was carried 
out with a step change from 100% aqueous solution containing 15 mM acetic acid 
and 10 mM tributylamine (0.5 min) to 10% aqueous solution with 90% methanol 
for another 3.5 min. Electrospray ionization was used and mass spectrometry was 
operated to scan 50–800 m/z in negative mode with 2500 V end plate voltage and 
3200 V capillary voltage. Nebulizer gas was provided in 2 bar, dry gas flow rate 
was 9 ml/min, and dry gas temperature was 200 
o
C. At the assay condition, all the 
intermediates were detected in the form [M-H]
-
. Retention time was subsequently 
determined for each intermediate with respective synthetic standards and the set 
m/z extraction range. The peak area was calculated and subsequently used to 
compute the intermediates concentrations with the software provided by the 
manufacturer. The calibration curves were constructed with synthetic standards 
prepared under similar reaction conditions without enzymes. Linearity of the 








5.5.5 GCMS analysis of amorpha-4,11-diene (AD) 
AD analysis was carried out based on the modified method developed by 
Martin et al. by scanning three ions; the m/z values are 117, 189 and 204 [170, 
171]. 1 μl sample was injected into HP-5 column (Agilent Technologies 7890A 
gas chromatograph-mass spectrometry, Agilent, CA) with a linear temperature 
increase of 50 
o
C/min from 80 
o
C to 300 
o
C and hold at 300 
o
C for another 
minute. The peak area was calculated and subsequently used to compute AD 
concentrations with the software provided by the manufacturer. Amorpha-4,11-
diene concentrations were determined relative to the internal standard trans-
caryophyllene of known concentration.   
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Chapter 6 In vitro biosynthesis of Artemisinic acid and 
Dihydroartemisinc acid by cytochrome p450 system 
6.1 Introduction 
The conversion of amorphadiene to dihydroartemisinic acid which can 
then be chemically synthesized to artemisinin is an important step in producing 
artemisinin [149]. The first step of this conversion is the oxidization of 
amorphadiene to artemisinic alcohol and then to artemisinic aldehyde and 
subsequently to artemisinic acid. This bioconversion is by the cytochrome p450 
system from Artemisia annua (Figure 6.1A) which consists of cytochrome p450 
enzyme (CYP450) and its electron supply partner cytochrome P450 reductase 
(CPR) [146]. Despite the successful production of 25g/L of artemininc acid in a 
lab-scale reactor [3], the yield is still less than the highest amorpha-4,11-diene  
(AD) titer reported, which was approximately 40g/L [162]. The co-
overexpression of CYP450 with AD synthesis genes in cells is known to inhibit 
the upstream AD production, a phenomenon that was observed similarly in our 
lab too.   
To overcome the limitation of cellular production of artemisinin 
precursors, a hybrid in vivo and in vitro platform for artemisnic acid production is 
demonstrated in this chapter. Amorphadiene and CYP450 were separately 
produced in E. coli and yeast cells, respectively. Subsequently whole cell 
biocatalysis was carried out to convert AD to artemisnic acid.  In this way, 80% 
of amorphadiene was effectively converted to artemisnic acid. Therefore, the new 
platform developed is a powerful tool for cytotoxic product production and 
definitely have wide application in biotechnology and biosynthesis. 





6.2.1 Genetic optimization of cytochrome p450 
As a membrane bounded enzyme, CYP450 was targeted to the inner 
membrane of E.coli by the first 29 amino acids at N terminal of the protein with a 
membrane binding sequence (MBS). It has previously been shown that the 
enzyme might not be functionally optimal inside bacteria with this naive MBS.  
So we replace the sequence partially (first 6, 15, 22 or 29 amino acids) with a 
short leading sequence from Bovine CYP450, which has been shown to help with 
the expression of other CYP450 in E.coli [205] (Figure 6.1B). In addition to the 
native CPR from Artemisia annua (CPRaa), another CPR from Taxus baccata 
which has been successfully introduced to E.coli for the oxidization of another 
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Figure 6.1. protein engineering of cytochrome p450 system.  
(A), the reaction catalyzed by the cytochrome p450 system (CYP450) (B), scheme of protein 
engineering for cytochrome p450 system. Abbreviations: Artemisia annua cytochrome p450 
enzyme (Native-CYP), short membrane binding sequence from Bovine cytochrome p450 enzyme 
(BOV), engineered Artemisia annua cytochrome p450 enzyme with the first 6, 15, 22 or 29 amino 
acid removed (6-CYP, 15-CYP, 22-CYp, 29-CYP), Artemisia annua cytochrome P450 reductase 
(CPRaa), Taxus baccata cytochrome P450 reductase (CPRtb). (C), the production of artemisinic 
alcohol and artemisinic aldehyde by engineered cytochrome p450 systems. TM2-dxs, TM3-iDF, 
TM1-ADS, MG1655 strain producing amorphadiene with DXP pathway was used as the parent 
strain to harbor the cytochrome p450 systems. 





MG1655 strain overexpressing the DXP pathway was used as the parental 
strain to test the performance of the different engineered CYP450 strains. In all 
tested strains, the major product of CYP450 system was artemisinic alcohol 
(AOH), and only very tiny amount of artemisinic acid (AA) could be detected. 
The overall conversion of amorphadiene (Figure 6.1C) showed that BOV15-CYP-
CYPaa (CYP15) was the best strain and was used for further analysis. However, 
the maximum yield was only about 5% of the amorphadiene yield (300mg/L for 
DXP pathway).It appeared that some major bottlenecks still exist for the function 
of this plant CYP450 system inside E.coli. Other parameters such as growth 
condition and co-factor supply system (NADPH-FMN-FAD) could be further 
explored to optimize the system.  
 
6.2.2 Overexpressing CYP71AV1 in E. coli strains for whole cell biocatalysis 
As CYP450 is membrane bounded, the overexpression of this enzyme 
may affect growth of E.coli as well as the production of amorphadiene. 
Furthermore, it was very difficult to adjust and optimize the reaction conditions 
for high yield in vivo. To overcome those difficulties, we explored the in vitro 
bioconversion of amorphadiene using CYP450. These were produced separately 
and then mixed together in a cell free system (Figure 6.2A). 
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Figure 6.2.in vitro biosynthesis of cytochrome p450 system.  
(A), illustration of in vitro biosynthesis process consist of amorphadiene extraction and CYP450 
system extraction. (B), demonstration of in vitro biosynthesis. Samples were collected at 2h after 
reaction (28oC, pH7). 
  
Amorpha4-11-diene (AD) was firstly purified and extracted by solid phase 
with C18 beads and then eluted using hexane. The hexane solvent was then 
removed by evaporation and the AD was dissolved in DMSO which was miscible 
with the reaction in aqueous phase. Approximately 50% of the AD produced in 
vivo could be recovered by this method. By supplementing AD into the whole cell 
(final O.D. 10-20) catalyzed reaction mixture at 28
o
C, pH7, conversion of AD to 
AOH was successful (Figure 6.2B).  
To further optimize the in vitro reaction, several E. coli strains were 
screened to select the best strain for functional expression of CYP15 by 
monitoring the bioconversion of exogenously added AD (Figure 6.2A). We 
observed severe growth inhibition for M15 strain when CYP15 was induced, 
which suggested cytotoxicity of the gene product (Figure 6.3A). Among the 
strains screened, BL21 strain displayed the highest yield and cell viability, 
although only ~7% conversion from AD to AOH was observed (Figure 6.3A) in 
two hours. Prolonging the reaction time to 12 hours did not further enhance the 




yield significantly, which showed that the reaction was stalled completely after 
the conversion reached certain level. We have verified that this loss of activity 
was not due to the inactivation of the CYP15 enzyme, as shown in Figure 6.3C 
that similar level of conversion was reached even though the whole cell 
biocatalysts was pre-incubated at 28
o
C for two hours. Therefore, this suggested 
that enzyme inactivation was unlikely. Subsequently, we supplemented the 
reaction with essential co-factors, such as iron(III) chloride, FMN/FAD and a 
NADPH recycling system with in-house produced glucose dehydrogenase (GDH) 
from Bacillus Megaterium. However, little improvement of final yield was 
observed. This observation was similar to tobacco, a plant cell. The conversion of 
AD to AA was incomplete, even though CYP71AV1 was successfully 
overexpressed [148]. Hence, the intracellular environment may be important to 
ensure activity of CYP15. 
 
 
Figure 6.3 in vitro whole-cell CYP15 enzyme reaction.  
(A), Different bacteria strains were screened for the best host for CYP15 expression and activity. 
(B), The time course of BL21 whole cell CYP15 biotransformation. The abbreviations are as 
follows. UI is uninduced cells. I is induced cells. (C), investigation of heat inactivation of whole 
cell CYP15 biocatalysis. (D). Additives screening to enhance the conversion yield of BL21 whole 
cell CYP15 biotransformation. 




6.2.3 Overexpressing CYP71AV1 in S.cerevisae W303 strain for whole cell 
biocatalysis 
Baker yeast is a better host to express plant P450 enzymes, and they are 
widely used for industrial biotechnology [206]. Therefore, we overexpressed the 
CYP15 enzyme in the wild type W303 strain. Although hardly any visible protein 
band could be seen on SDS page gel (Figure 6.4A), production of AA was 
observed when mixing the whole cell (final O.D. ~20) with AD at 28
o
C, pH7 for 
two hours, as shown in Figure 6.4B. It clearly indicated that only the cell 
harbouring the plasmid p416-TEF-CYP15 was able to catalyze three consecutive 
oxidation of AD into AA.   
 
 
Figure 6.4 in vitro production of artemisinic acid (AA) by yeast W303 whole cell 
CYP15.  
(A), SDS PAGE gel of yeast expression CYP15. The red-arrow indicate the expected sized of 
CYP15, which could not be seen on the gel. Glu: glucose medium. Gal: galactose medium. (B), 
Demonstration of the production of acid. (C), the total amount of oxidized products produced 
when the substrate concentration was increased linearly from 1x AD (~400mg/L), 2x AD 
(800mg/L) to 3xAD (1.2g/L). The integrated area (A.U.) from GCMS analysis was reported. (D), 
the product distribution profile for three different initial substrate concentrations. The 
abbreviations are as follow. AD: amorphadiene. AOH: artemisinic alcohol. AO: artemisinic 
aldehyde. AA: artemisinic acid.   
 




When the substrate AD concentration increased linearly from 400mg/L to 
1.2g/L, more products accumulated after 12h of incubation in a linear fashion 
(Figure 6.4C), where about 40-50% of the final oxidized product was AA (Figure 
6.4D). The product distribution was fairly similar despite the initial concentration 
of substrate; they mainly consisted of AOH and AA. By detailed analysis of the 
reaction kinetics, the substrate concentration was saturated at 2xAD which was 
~800mg/L (~4mM). A two fold decrease in total percentage of conversion at 
10min was observed when the initial AD concentration was at 3x AD (~1.2g/L 
AD / ~6mM AD) (Figure 6.5A). However, the final conversion yield at 12h was 
approximately the same (~70%) for all three different initial substrate 
concentrations (Figure 6.5B). One plausible explanation was that the enzymatic 
catalysis sites were saturated with AD, and thus depriving subsequent oxidation of 
alcohol to aldehyde and acid. This implied that CYP15 would release each 
intermediate oxidation product from its catalysis pocket and allowing them to 
diffuse to the next reaction site for further oxidation. It was further supported by 
the observation that AOH and AO were both detected in the product pool, too. 
Hence, the rationale way to improve the conversion further was to increase the 
available biocatalyst sites. One way was to enhance the turnover rate of 
CYP71AV1. Literature suggested that glucose may affect biocatalysis efficiency 
when resting E. coli cells were used [107], since glucose would affect the co-
factor availability. Therefore, by supplementing 10mM glucose into the reaction 
medium, a slight enhancement, ~50% increment in kinetics, was observed for all 
three different initial AD feeding (Figure 6.5A). However, it did not change the 




substrate saturation concentration; the percentage of converted product at 10min 
still decreased at 3x AD concentration. Neither did glucose change the final 
product distribution profile. The final AA yield was about 40-50% for all the three 
initial AD concentration. Therefore, we increase the biocatalyst yield in order to 
increase the catalytic efficiency.  
Another noteworthy observation was that CYP15 activity was lost after 
the yeast cells were lysed by shaking with glass beads (Figure 6.5B); less than 
10% conversion was achieved when the cell lysate was used. This might be due to 
the disruption of the membrane fraction of the enzyme, or could be due to the 
change of environment leading to the loss of activity.     
 
 
Figure 6.5 analysis of kinetics of CYP15 biotransformation.  
Percentage of AD being converted to downstream oxidized products, including AOH, AO and 
AA, after incubating at 28oC for(A) 10mins and (B) 12 hours. Both reaction conditions with (glu) 
and without glucose (w/o glu) were shown. The abbrevations are as follows: 1x AD: ~400mg/L 
amorphadiene. 2x AD: ~800mg/L amorphadiene. 3xAD: ~1.2g/L amorphadiene. Lysate: cells 
were lysed with glass beads.  
 
The yeast plasmid p416-TEF used is a low copy number (1-2 copies) 
centromeric expression vector with a constitutive strong promoter. Therefore, a 
high copy number 2µ-based plasmid pYES260-Gal1 was used instead. The 
additional benefit associated with the latter vector was the promoter is tightly 
regulated by Gal1, and hardly any leaky expression was observed when the cells 




were grown in glucose medium. Thus, it would avoid any toxicity effect 
associated with the gene product during cell growth and control gene transcription 
when cells attain certain biomass. When the yeast cells were transformed with the 
new plasmid, the growth profile did not alter significantly (Figure 6.6A). 
Therefore, this high copy plasmids did not exert undue metabolic burden to the 
host cell. More than 50% improvements in AA yield was achieved (from 50% to 
80% overall conversion), with W303 strain harbouring pYES-Gal1-CYP15 




Figure 6.6 Improving the CYP15 enzymatic yield by use of high copy-number 
plasmid pYES-Gal1.  
(A), the growth curve of the W303 strain harbouring both p416-TEF-CYP15 (pTEF) and pYES-
Gal1-CYP15 (pYES) plasmids. (B), comparison of product distribution between two vector 
systems. The abbreviations are as follows.  AD: amorphadiene. AOH: artemisinic alcohol. AO: 
artemisinic aldehyde. AA: artemisinic acid.  percentage of AD being converted to downstream 
oxidized products, including AOH, AO and AA, after incubating at 28oC for(C) 10mins and (D) 
12 hours. Both reaction conditions with (glu) and without glucose (w/o glu) were shown. The 
abbreviations are as follows. 1x AD: ~400mg/L amorphadiene. 2.5xAD: ~1g/L amorphadiene. 




The increase in the conversion yield was likely to be attributed to the 
enhanced enzyme expression. However, the percentage conversion at 10min was 
still low when 1g/L AD was added (2.5x AD) (Figure 6.6C). Glucose was not 
effective to improve the rate of conversion, although an enhancement of 
conversion rate was observed at low initial AD concentration (400mg/L, 1xAD). 
Therefore, it was likely that specific competitive inhibition by substrate accounted 
for the lagged conversion efficiency, since the same binding pocket was used for 
all three steps of oxidation. However, despite the reduced kinetics at the start of 
the reaction, ~80% conversion could be achieved after 12h incubation (Figure 
6.6D).  Approximately 800mg/L artemisinc acid could be produced, calculated 
based on using the AD standards. 
 
6.2.4 Overexpressing CYP71AV1 in S.cerevisae BY4741 strains for whole cell 
biocatalysis 
In view of the low cell density of W303 cells (final O.D was about 2), we 
explored another yeast strain BY4741. Moreover, the uptake of NADPH by W303 
strain was limited, as supplementing NADPH directly into the reaction medium 
did not enhance the productivity of the whole cell biocatalysis (results not 
shown). This indicated that the lysed cells were not useful. Therefore, 
permeabilized whole cell biocatalysis might be an alternative solution, so as to 
allow the ease of uptake of reaction substrates and additives across the 
membranes. Instead of enzyme-dependent or organic-solvent-treatment 
permeabilization, we set to explore yeast cells with thin cell walls.  CWP1 and 




CWP2 encode the two major mannoproteins of the outer cell wall; deletion of the 
two genes caused increased yeast sensitivities to genotoxic chemicals [207]. 
Ergosterol, as the predominant sterol component in the cell membrane, can affect 
membrane permeability. Deletion of Erg6 gene was not lethal but could alter 
membrane permeability [207]. Thus, BY4741 cells with each of these three genes 
deleted (denoted as dCWP1, dCWP2, dERG6) were obtained from Euroscarf 
(Frankfurt, Germany) to overexpress CYP15 and used for subsequent studies.  
BY4741 strains grew much faster and to a higher cell density than W303 
strain in glucose medium, and single gene deletion did not affect cell growth 
(Figure 6.7A). All four phenotypes were explored for the catalytic conversion of 
AD (~500mg/L) to AA. All of them were able to achieve more than 70% 
conversion within 12 hours. BY4741 cells harbouring pYES-Gal1 plasmid was 
more productive than the strain carrying p416-TEF, where AA was almost the 
sole product in the oxidized products (Figure 6.7B). Among the four phenotypes, 
dCWP2 strain displayed the highest conversion yield, albeit there was very slight 
enhancements. This suggested that transporting AD across yeast cell wall may not 
be a bottleneck. We further compared the kinetics of dCWP2 strain and BY4741 
strain with and without additives in the medium. Rationally, with thinner cell 
wall, additives might be easier to diffuse through the membrane and more 
effectively speed up the catalytic reaction. As reasoned, when glucose was 
supplemented in the reaction medium, dCWP2 strain exhibited a more significant 
change (~3 fold enhancement) in rate of conversion as compared to the wild type 
BY4741 (~2 fold) at 1h (Figure 6.7C). Moreover, when initial AD concentration 




was increased from 500mg/L (1x AD) to 1g/L (2x AD), the percentage of 
oxidized products in dCWP2 strain at 1h increased from 12% to 20%, 
respectively (Figure 6.7C). In contrast, 10% of oxidized products were produced 
with BY4741 strain in both initial AD concentrations. Therefore, dCWP2 strain 
displayed a more competitive advantage than wild type BY4741, and was used for 
further downstream reaction medium optimization.  
Buffer optimization was carried out, by screening a panel of important 
additives. NADPH is the external co-factor that drives the chain event of electron 
transfer. Supplementing glucose into the reaction medium resulted in a positive 
enhancement in the yield and was likely to be due to the enhanced amount of 
NADPH. Other additives were also explored to enhance the final yield of acid. 
The electron shuttle enzyme CPRaa used FMN/FAD system to transfer the 
electron to the iron-sulfur center of P450 enzyme.  Depletion of the co-factors 
may result in the loss of enzymatic activities. Thus, more FMN/FAD was 
supplemented in the reaction medium. Moreover, reactive peroxide will be 
formed in the course of the reaction, which is detrimental to the enzymatic 
activity. L-proline [208] and L-ascorbic acid are singlet oxygen species 
scavengers . By supplementing these additives into the reaction medium, further 
50% enhancement in the final acid yield was observed (Figure 6.7D). A 
combinatorial optimization of additive concentrations could be explored to 
examine any synergistic effect so as to further boost up the CYP15 enzyme 
efficiency in future studies. 






Figure 6.7 in vitro production of artemisinic acid (AA) by yeast BY4741 whole 
cell CYP15.   
(A), growth curve of BY4741 strain and BY4741 strain with CWP2 gene deleted. (B), comparison 
of product distribution between pYES-Gal1 and p416-TEF vector systems. The abbreviations are 
as follows.  AD: amorphadiene. AOH: artemisinic alcohol. AO: artemisinic aldehyde. AA: 
artemisinic acid. (C), Comparison of the CYP15 conversion efficiency between BY4741 (BY) 
strain and BY4741 strain with CWP2 gene deleted (dCWP2). Percentage of AD being converted 
to downstream oxidized products, including AOH, AO and AA, after incubating at 28oC for 1 
hour. Both reaction conditions with and without glucose were shown. The abbreviations for the x-
axis label is as follows. 1x AD: ~500mg/L amorphadiene. 2xAD: ~1g/L amorphadiene. (D), 
screening of additives to enhance the final AA yield when dCWP2 whole cell CYP15 was used. 
 
6.2.5 Production of dihydroartemisinc acid (DHAA) 
Research showed that the precursor of Artemisinin is DHAA instead of 
AA [152]. Therefore, it is more desirable to produce DHAA enzymatically. In the 
process of optimization, we observed that ~70% of oxidized products were 
outside the cell, regardless of the phenotype (Figure 6.8A). Hence, it served as an 
avenue for us to use the auxiliary pathway externally that further converted AOH 
to dihydroartemisinc acid (DHAA) through three consecutive enzymatic steps: 
alcohol dehydrogenase (Adh1), double bond reductase (Dbr2) and aldehyde 
dehydrogenase (Aldh1).  The advantage is that the three auxiliary enzymes could 




be individually overexpressed in separate hosts to its maximum yield. As shown 
in Figure 6.8B, high amount of enzymes were obtained when the genes were 
overexpressed with 0.1mM IPTG. Therefore, by mixing the cell lysates with the 
dCWP2 cells expressing CYP15, a tiny amount of DHAA, ~20% of AA, was 
successfully produced (Figure 6.8C), and the characteristic MS peak was identical 
to that preciously reported [151]. There is a need to fine tuning the enzyme 
amount, as literature suggest that Dbr2 is likely the bottleneck step for high 




Figure 6.8 auxiliary reaction for dihydroartemisinc acid (DHAA) production.  
(A), the distribution of acid in the pellet and reaction supernatant when different BY4741 strains 
were used for whole cell catalysis. (B), SDS page analysis of Mg1655 (DE3) lysate 
overexpressing Adh1, Dbr2 and Aldh1 respectively. The inducer IPTG concentration was 
indicated in the table, which is 0mM, 0.01mM and 0.1mM. The abbreviations are as follows. 
Adh1: alcohol dehydrogenase. Dbr2: double-bond reductase. Aldh1: aldehyde dehydrogenase. S: 
soluble fraction of cell lysate. I: insoluble fraction of cell lysate. (C). demonstration of the 
production of DHAA. 
 
 




6.2.6 Exploring different reaction formats: hybrid in vivo-in vitro and total in 
vitro synthesis 
Purified AD (~1g/L) was fed into the growing cells at different growth 
stages of BY4741 and dCWP2 strains. Interestingly, the addition of AD to cells 
induced to overexpress CYP15 gene resulted in severe growth retardation in wild 
type BY4741 but not dCWP2 (Figure 6.9A and B). This could be due to the 
toxicity of AA produced [210], where dCWP2,  cells with thinner cell wall, were 
able to get rid of this toxic products faster. Although this is an attractive 
hypothesis to be tested, there was no significant enhancement in the conversion 
yield between the two phenotypes (Figure 6.9C). The toxic effect was less 
obvious when the substrate was introduced at mid-exponential growth phase, 
suggesting other mechanism may be involved in the growth retardation observed 
when AD was fed at early exponential phase.  
Lastly, total in vitro synthesis was carried out, which the upstream total 
enzymatic AD synthetic pathway was also added, (Chapter 3), into the reaction 
mixture. Total in vitro synthesis was able to further convert more than 50% AD to 
oxidized products (Figure 6.9D). More AOH was present in the oxidized 












Figure 6.9 Different reaction format for AA production.  
Growth curve of (A) BY4741 and (B) BY4741 with CWP2 gene deleted. Purified AD (final 
concentration ~1g/L) was fed into the living cells at different growth stage: 0h (early exponential 
phase), and 7h(mid-exponential phase). 2% Galactose (Gal) medium was used to induce the 
expression of CYP15, whereas no expression of CYP15 when the cells were grown in 2% glucose 
medium (Glu). (C), percentage of AD being converted to downstream oxidized products, 
including AOH, AO and AA, after the cells were grown in 28oC for 10hours. (D), The product 
distribution of total in vitro synthesis method using 5mM mevalonic acid at 28oC for 12h. The 
dCWP2 cells grown in Glu condition was used as control to quantify the amount of AD produced 
by multienzyme synthesis, whereas the dCWP2 cells grown in Gal condition was used to further 
catalyze the conversion from AD to AA. The abbreviations are as follows.  AD: amorphadiene. 

















Selective oxidation and reduction of the undecorated hydrocarbon 
backbone of amorphadiene is a difficult task [150]. It is metabolized by the 
membrane bound enzyme cytochrome p450 monooxygenase (CYP71AV1), 
which is a class of important heme containing enzyme that enabled 
functionalization of AD to bioactive Artemisinin [146]. The enzyme was 
discovered recently and much is still unknown; for example, the enzyme has not 
been kinetically characterized. Our initial attempt to overexpress and purify the 
membrane bound enzyme from E. coli was not successful. No apparent protein 
band was shown on the SDS page gel, after the host E. coli cells were cultured at 
20
o
C for 24h (results not shown). It was likely to be due to the cytotoxicity of the 
gene product which may have resulted in the loss of plasmid. Moreover, 
CYP71AV1 in E. coli was unable to catalyze the three consecutive oxidation 
reactions and displayed extremely low activity. In light of this, an engineered 
substrate promiscuous p450BM, an enzyme from Bacillus Megaterium that display 
high kinetic efficiency in E. coli, was used to convert amorphadiene to artemisinic 
epoxide (section 2.5.3) [150].  In contrast, S. cerevisiae was a better host to 
overexpress cytochrome p450 [211]; yeast whole cell biocatalysis has been 
applied for the production of many important fine chemicals [206]. CYP71AV1 
showed a very high catalytic efficiency when overexpressed in yeast and 
artemisinic acid was effectively produced. This could be due to the difference in 
the intracellular redox environment between E. coli and S. cerevisiae [212]. The 
conversion rate of CYP71AV1 was reduced at high initial concentration of AD, 




possibly due to the saturation of catalytic sites. Therefore, controlled pulse 
addition of AD could be explored to overcome the challenge. Moreover, the 
enzymatic yield could be increased when high copy number plasmid was used to 
overexpress the enzyme. 80% conversion yield was achieved from 1 g/L AD, 
which corresponded to 800mg/L artemisinic acid produced in a small scale. The 
titer was comparable to the highest yield reported to date and that was produced in 
a shaking flask [3]. The productivity was expected to be further improved by co-
expressing the auxiliary enzymes, Adh1 and Aldh1.  
 
6.4 Conclusion 
In summary, a hybrid in vivo and in vitro system was established to 
produce dihydroartemisinic acid and/or artemisinic acid, by which the production 
of amorpha-4,11-diene (AD) would not be affected by the downstream 
overexpression of cytotoxic P450 enzyme. The conversion of AD to downstream 
oxidized products was systematic optimized through enhanced protein expression 
and choice of more robust yeast strain. So far 80% of AD can be effectively 
converted to downstream acid, which will be further optimized by introducing 











6.5 Materials and Methods 
6.5.1 Bacteria strains and plasmids 
The microbial strains and plasmids used in this study were summarized in 
Table 6.1. The pET-11a (Stratagene, CA) was modified by replacing the 
ampicillin with kanamycin maker. Adh1, Aldh1 and Dbr2 genes were codon 
optimized and synthesized by Genescript, and they were cloned into the modified 
pETK-11a plasmid by CLIVA method as described in Chapter 4 [186]. To modify 
the N-terminal of CYP15, different PCR primers were designed to target at 
different site of the open-reading frame. Then CLIVA was used to ligate the 
truncated gene into pCL plasmid. The CYP71AV1 with the first 15 amino acid 
being truncated displayed the highest enzymatic activity. Therefore, the 
corresponding gene was amplified by the primers (Table 6.2), and ligated into 
shuttle vector p416-TEF, and pYES-Gal1 respectively. Both plasmids carried the 
Ura3 auxotrophic marker. The plasmids were transformed into and amplified in E. 
coli DH10B strain. Then the purified plasmid was transformed into the yeast 
strains with lithium acetate mediated method developed by Gietz et al. [213].  The 
colonies were formed after incubating at 30
o
C for 3-4 days. Then colony PCR was 
carried out to confirm the presence of the plasmid. The correct colony was then 
grown in selection medium lacking uracil till stationary phase for whole cell 
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dCWP1 BY4741; Mata; his3D1; leu2D0; met15D0; ura3D0; 
YKL096w::kanMX4 
 
dCWP2 BY4741; Mata; his3D1; leu2D0; met15D0; ura3D0; 
YKL096w-a::kanMX4 
 
dErg6 BY4741; Mata; his3D1; leu2D0; met15D0; ura3D0; 
YML008c::kanMX4 
 
BY4741 MATa; his3Δ 1; leu2Δ 0; met15Δ 0; ura3Δ 0 
 
p416-TEF-CYP15 Low copy plasmid used to overexpress CYP15 in yeast 
pYES-Gal1-CYP15 High copy plasmid used to overexpress CYP15 in yeast 
pETK-Adh1 Plasmid used to overexpress Adh1 in Mg1655 (DE3) 
pETK-Aldh1 Plasmid used to overexpress Adh1 in Mg1655 (DE3) 
pETK-Dbr2 Plasmid used to overexpress Dbr2 in Mg1655 (DE3) 
pCL-CYP15 Plasmid used to overexpress CYP15 in E. coli strains 
 
Table 6.2. The primers used in Chapter 6. 











6.5.2 Yeast growth and protein expression 
10ml culture of was grown in synthetic medium lacking uracil (20g/L 
Glucose, 6.7g/L drop-out base (USbiological, MA), 2g/L drop-out mix without 
uracil (USbiological, MA)), till stationary phase at 28
o
C, 300rpm in an incubator-
shaker (Shin Saeng Shaking Incubator, Finetech, Korea).  The yeast growth was 
monitored by the optical density at A600. For cells harbouring p41-TEF plasmid, 
the culture was directly harvested for downstream biotransformation, since TEF is 
a constitutive promoter.  For cells harbouring pYES-Gal1 plasmid, CYP15 
expression was induced with one step change of glucose synthetic medium to 2% 
galactose synthetic medim (20g/L Galactose, 6.7g/L drop-out base (USbiological, 
MA), 2g/L drop-out mix without uracil (USbiological, MA)). In brief, the cells 
were grown in glucose medium till OD600 reach approximatel 2. Subsequently, the 
cells were harvested by a brief centrifugation at 3000 g for 5min. The supernatant 
was carefully decanted and the culture was diluted with fresh galactose medium to 
OD600 = 0.5. Then, the culture was allowed to grow at 28
o
C for 6h till OD600 is 
about 2 and used for subsequent biocatalysis.   
 
6.5.3 Amorpha-4,11-diene purification 
The microbial production of amorphadiene (AD) via mevalonate pathway 
has been optimized by promoter engineering and medium optimization 
(unpublished work). Approximately 2-4g/L of AD could be produced by E. coli 
Mg1655 strain carrying the mevalonate pathway genes and Ads gene in a 100ml 
culture growing in 2xPY medium supplemented with 10g/L glucose in 3 days.  




The production was initiated with 0.01mM IPTG when the cell has grown till 
OD600=0.6, and 2g C18 beads were added simultaneously to capture the AD 
produced. At the end of production, the beads were allowed to sediment, and the 
bacteria culture was removed by carefully discarding the medium containing the 
cells. Then the beads were resuspend in deionized water, and packed into a 
chromatography column (Bio-Rad, CA). The beads were washed with 3 bed 
volumes of deionized water twice to remove any bacterial contamination. Then 
the AD was eluted with equal bed volume of hexane (~1ml) three times. It was 
then subjected to GCMS analysis to determine the extraction efficiency. Usually, 
more than 50% capture AD could be eluted with first hexane elution. The hexane 
was further evaporated by vacuum concentrator, and AD was mixed with DMSO 
which would be miscible for whole cell Biocatalysis.  
 
6.5.4 Yeast whole cell Biocatalysis and product extraction  
Approximately 1ml, OD600 2, yeast cells were collected and mixed with 
AD in a 100µl reaction containing 100mM Tris-HCL, 10mM MgCl2 and additives 
as indicated in the text. The reaction was carried out in a 2ml GC vial, sealed with 
screwed cap to prevent evaporation of AD. The AD evaporation was minimized 
when it was dissolved in DMSO and mixed with yeast cells, as similar level of 
AD was detected before and after incubation at 28
o
C for 12h in the control 
reaction mixture. 20µl of the reaction mixture was drawn at designated time point. 
It was acidified with 10% 2M HCl, and 100µl of ethyl acetate containing 
200mg/L octylbenzoic acid was added to extract amorphadiene and its oxidized 




products. 5mm glass beads were added to lyse the yeast cells and facilitate the 
extraction process. After vortexing at room temperature for 10min, the organic 
solvent layer was separated from the aqueous phase by centrifugation at 15,000 g 
for 10min. Then organic solvent was derivatized with TMS-diazomethane 
(Sigma, MO) and 10% methanol and subjected to GCMS measurement.     
 
6.5.5 GCMS analysis of AD, AOH, AO and AA 
1 μl sample was injected into HP-5 column (Agilent Technologies 7890A 
gas chromatograph-mass spectrometry, Agilent, CA). The gas chromatography 
oven temperature was programed with an initial fast linear temperature increase 
of 80 
o
C/min from 80 
o
C to 200 
o







C and hold at 300 
o
C for another minute. Scan 
mode was used to detect the compounds. With that temperature profile, 
amorphadiene (AD), artemisinic alcohol (AOH), artemisinic aldehyde (AO) and 
artemisinic acid (AA) were eluted at 3.86min, 5.04min, 4.70min and 5.14min 
respectively. The peak area was calculated with the software provided by the 
manufacturer. AD concentrations were pre-determined relative to the internal 
standard trans-caryophyllene of known concentration. Then the conversion yield 
was calculated based on the peak areas of the compounds as Equation 6.1, and the 
yield of AA was determined based on the total amount of AD added at the start of 
the reaction.  
  
Equation 6.1 
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Chapter 7 Multi-biocatalytic synthesis of 2C-methyl-D-erythritol 
2,4-cyclodiphosphate (MEC) via the non-mevalonate pathway 
7.1 Introduction 
The mevalonate-independent pathway or 1-deoxy-D-xylulose-5-phosphate 
(DXP) pathway (Figure 7.1) demonstrates the complexity and diversity of natural 
metabolic networks where two distinctive pathways are involved in synthesizing 
the same 5 carbon molecule, isopentenyl pyrophosphate (IPP). Both pathways co-
exist in plants. Interestingly, the DXP pathway was found to be the sole pathway 
in unicellular green algae [214]. Similarly, many pathogenic bacteria can only 
synthesize essential metabolic products via the DXP pathway, including the 
quinone co-factors for respiration [215]. Therefore, the enzymes in this pathway 
can serve as multiple, valuable drug targets to screen and develop anti-bacterial 
agents [116, 216]. This concept has been validated with fosmidomycin, a well-
known antibiotic, which is a potent inhibitor of 2-C-methylerythritol-4-phosphate 
reductase (Dxr), the second enzyme along the DXP pathway [217, 218].   
The DXP pathway is superior stoichiometrically as compared to the MVA 
pathway in synthesizing isoprenoids [219]. It produces less by-products and the 
co-factors are better balanced [219].  Recent efforts in metabolic engineering to 
enhance the flux through the DXP pathway have identified new bottlenecks, 
which are the last two enzymatic steps catalyzed by (E)-4-hydroxy-3-methyl-but-
2-enyl phyrophosphate synthase (IspG) and (E)-4-hydroxy-3-methyl-but-2-enyl 
phyrophosphate reductase (IspH) [42, 220, 221]. In vitro analysis showed that 
these two oxygen-sensitive enzymes shared many similar features, such as they 
both contain [4Fe-4S] prosthetic group [222-224]. In our lab, we have established 




a robust and reliable liquid chromatography and mass spectrometry coupled assay 
to detect the DXP pathway intermediates in vivo and discovered that 2-C-methyl-
D-erythritol 2,4-cyclopyrophosphate (MEC), the substrate of IspG, accumulated 
intracellularly and effluxed out of E. coli [42]. This provided the insight that 
endogenous IspG and IspH were kinetically inefficient in shuffling MEC towards 
isoprenoids production downstream. More intriguingly, the production of 
amorpha-4,11-diene, a sesquiterpene, was suppressed when  IspG and IspH were 
overexpressed [186]. Therefore, understanding the mechanisms and limitations of 
these two enzymes would be valuable to overcome the bottlenecks and further 
boost up the productivity of the DXP pathway. In addition, a better understanding 
would facilitate the design of novel antimicrobial drug leads against IspG and 
IspH. In order to investigate the biochemical properties of the two enzymes, there 
is a need to produce large quantity of MEC, the natural substrate of IspG [225]. 
Both chemical synthesis [225] and free enzymatic synthesis methods [41] have 
been reported previously. However, the former method resulted in exceptionally 
low yield (<10% from the starting material) and the latter method appeared to be 
useful for small scale production and the enzymes used were non-recyclable 
thereby increasing the cost of production.  
In this study, a recyclable multienzymatic platform to produce MEC in 
vitro by co-immobilized DXP pathway enzymes was explored. Initially, the 
production of MEC (~50% yield within 1hr) was found to be in a free 
multienzymatic system, consistent with previous reports [41]. An attempt was 
then made to produce MEC by co-immobilized DXP pathway enzymes and this 




was found to perform poorly. Further investigation showed that immobilized Dxs 
was inactivated when immobilized. By co-immobilizing the DXP pathway 
starting from Dxr, high yield of MEC (~50% of DXP was converted to MEC) was 
observed within 10 minutes. The accumulation of DXP to a comparable level as 
MEC in both free and co-immobilized enzymatic formats spurred us to investigate 
possible regulations of Dxr. We found that the enzyme was highly reversible and 
sensitive to NADP+ concentration. By coupling Dxr with glucose dehydrogenase 
(GDH) that regenerates NADPH from glucose, almost all the DXP was eventually 
converted to MEP. Further optimization is still on-going to optimize the 
multienzymes system on the solid platform.   
 
 
Figure 7.1. Schematic representation of the DXP pathway. 
 





7.2.1 Enzymatic purification and quantification 
The genes encoding each enzyme were amplified from E. coli genomic 
DNA. They were subcloned into either pET-11a or pBAD-B vector with 
engineered N-terminal hexahistidine tags (His6-tag).  Solubility of the enzymes 
was examined to determine the optimal strain to overexpress the enzymes (Table 
7.3) [20]. All the pathway enzymes were purified by immobilized metal affinity 
chromatography (IMCA) to near homogeneity, as validated by SDS-PAGE 
(results not shown).  Initial velocity measurements were carried out to determine 
the steady-state kinetics of the enzymes (Table 7.1).   As the substrates for 4-
diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE) and 2-C-methyl-D-
erythritol 2,4-cyclodiphosphate synthase (IspF) were not available, the kinetics 
parameters were extracted from literature [226, 227]. From the enzyme kinetics 
analyses, Dxs displayed the lowest catalytic efficiency among all the pathway 
enzymes, implying a potential kinetic bottleneck in the pathway. An initial 
attempt was made by mixing equal concentration of the five enzymes in one pot at 
37
o
C for 2 hours. MEC was successfully produced with an overall conversion of 
50% from the starting materials (pyruvate and glyceraldehyde-3-phosphate). This 
means that on average, each step of enzymatic reaction was able to achieve about 








Table 7.1. Purification and characterization of individual pathway enzymes from 
bacterial culture. 






































420 (ATP)  





4.6.1.12 16897.54 339  1.01 33 
* MW is calculated based on the primary amino acid sequence. 
# Yield refers to the final protein yield after purification  
The italic values were adapted from literature. IspE kinetics was assayed at 30oC [226]. IspF kinetics was 
assayed at 20oC [227].  
 
7.2.2 Production of MEC by co-immobilized DXP pathway enzymes 
The initial success with free multienzymatic synthesis prompted us to 
attempt to conduct the synthesis with co-immobilized multienzymes. Since all the 
DXP pathway enzymes have a his6-tag, they can be anchored onto Ni-NTA 
functionalized surface. In Chapter 5, the established immobilization protocol was 
used here to immobilize the expressed enzymes directly from cell lysates.  After 




the cells were disrupted by glass beads, the lysate was prepared with 
approximately equal concentration of individual enzyme. The mixture was then 
diluted in phosphate saline buffer (PBS) and incubated with Ni-NTA modified 
silicon beads at 4
o
C for 2 h. The unbounded protein was then washed away with 
PBS. In order to compare the performance of the immobilized multienzymes 
system with the free enzyme system, the beads with bound enzymes were divided 
into two equal parts. To one part, NPI400 buffer (50 mM NaH2PO4, 300 mM 
NaCl, 400 mM imidazole, pH 8) was added to elute the enzymes from the beads, 
and to the other part, equal volume of NPI10 (50 mM NaH2PO4, 300 mM NaCl, 
10 mM imidazole, pH 8) was added. From Figure 7.2, almost all the enzymes 
were released from the beads (lane 3) in NPI400 buffer, whereas the enzymes 
were captured on beads in NPI10 buffer (lane 8). The amount of enzymes were 
comparable between the two systems. 
 
Figure 7.2 SDS PAGE of dxp pathway enzymes in free enzymatic and 
immobilized enzymatic formats.  
Lane 1 and 5: cell lysate mixture before incubating with Ni-NTA beads. Lane 2 and 6, supernatant 
after incubating with Ni-NTA beads. Lane 3 and 7, enzymes in eluent after either NPI400 or 
NPI10 was added. Lane 4 and 8, enzymes in eluent and on beads after either NPI400 or NPI10 
was added.  
 




Synthesis of MEC was conducted at 37
o
C and pH 7.4 (100mM HEPES 
buffer) in a mixture  (25µl) containing pyruvate (5mM), DL-GAP (10mM), ThDP 
(1mM), NADPH (5mM), CTP (5mM), ATP (5mM), MgCl2 (10mM).  The 
reaction was initiated by the addition of the pathway enzymes, either in free or 
immobilized enzymatic format. A time course study revealed that the synthesis of 
MEC saturated within 1 hour (Figure 7.3). Approximately 50%, namely 2.5mM 
of MEC was produced with free enzymes. However, less than 10% of MEC was 
produced with the immobilized enzymes. The extremely low yield prompted a 
further investigation into possible bottleneck(s) in the co-immobilized enzymatic 
system.   
 
Figure 7.3. Time course of in vitro synthesis of MEC by free or co-immobilized 
DXP pathway enzymes.  
All the measurements were done in triplicates with the standard errors drawn on the plots.  
 
7.2.3 Immobilized Dxs activity was reduced 
One hypothesis was that Dxs activity was reduced after immobilization, 
since it was the first committed step and possibly subjected to interfacial diffusion 
limitations [41, 191, 229].  To test the hypothesis, Dxs was immobilized onto the 
Ni-NTA beads, and was separated into free and immobilized format as described 




above. Its reaction was conducted at the same reaction condition in the mixture of 
pyruvate (5mM), DL-GAP (10mM), ThDP (1mM) and MgCl2 (10mM).  The time 
course study clearly demonstrated that immobilized Dxs was approximately 10 
times less efficient in catalysis as compared to free Dxs (Figure 7.4).  
 
Figure 7.4. Time course of Dxs reaction in either free or immobilized form.  
All the measurement were done in triplicates with the standard errors drawn on the plot.  
 
This observation led us to investigate if it was due to mass transport 
limitation [191] or interfacial enzyme inactivation [230]. To decouple the two 
possible effects, the kinetic behavior of Dxs prior to and following immobilization 
was examined.  The apparent Michaelis Menten parameters would provide insight 
into the plausible barrier on the reduced Dxs efficiency. Generally, the apparent 
Km would increase if diffusion was a limitation, and Vmax would decrease if the 
enzyme was inactivated. From Table 7.2, the maximum reaction rate, Vmax, for 
immobilized Dxs was significantly lower than free Dxs (~10 fold lower), whereas 
Km was slightly decreased after immobilization (~2 fold lower). Therefore, it 
strongly suggested that immobilized Dxs was less active at the liquid-solid 
interface.     
 











/ µM 466.9 313.9 
V
max 
/ µM/min 275.1 24.2 
 
Interestingly, no appreciable activity difference between immobilized and 
free IspD was observed (Figure 7.5A), suggesting that the reduced immobilized 
Dxs efficiency was likely an enzyme-dependent inactivation rather than a general 
mass transport phenomenon. Furthermore, when assembling the DXP pathway 
from Dxr (the second pathway enzyme) instead of Dxs, the production of MEC 
proceeded with similar rates between co-immobilized and free enzymes (Figure 
7.5B). This observation provided further evidence that immobilized Dxs activity 
was severely impaired serving as the major bottleneck for the use of co-
immobilized DXP pathway enzymes.  Future work might involve bi-modular 
production of MEC, whereby DXP would be produced with soluble Dxs first, and 
then converted to MEC with downstream co-immobilized DXP pathway enzymes.  
 
Figure 7.5. Time course of A. IspD reaction both in free and immobilized forms; 
B. assembled Dxr, IspD, IspE and ispF reaction both in free and co-immobilized 
forms.  
All the measurements were done in triplicates and the standard errors were drawn on the plot.  




7.2.4 DXP was accumulated in the multienzymes synthesis reaction 
Another intriguing observation was that DXP was accumulated to a 
comparable level as MEC in the multienzymes reaction medium (Figure 7.6A). 
Moreover, Dxr was unable to convert the accumulated DXP in the multienzymes 
reaction mixture when additional purified Dxr (4µg) and NADPH (1mM) were 
supplemented (Figure 7.6B).  The initial hypothesis was that DXP enantiomers 
were produced by substrate promiscuous Dxs [231]. However the hypothesis was 
rejected because about 50% chemically synthesized, enantiopure DXP was also 
left unreacted when it was used as the starting material. Hence, this alluded to the 
possible regulation of Dxr activity. 
 
 
Figure 7.6 A. Time course of accumulation of DXP in the multienzyme reaction 
both in free and immobilized forms.  
All the measurements were done in triplicates and the standard errors were drawn on the plot. B. 
The metabolite levels before and after adding fresh Dxr enzymes. It showed no significant 
difference in DXP level, suggesting that Dxr activity was inhibited by the mixture of metabolites. 
 
To test the hypothesis, the products and by-products of the multienzymes 
pathway were supplied to the Dxr reaction separately.  By monitoring the Dxr 
activity photometrically at 340nm, we noticed a slight drop in the initial rate of 
reaction when NADP+ was added (Figure 7.7A).  NADP+ was the by-product of 




Dxr, suggesting a possible reversible reaction mechanism. To verify the 
observation, glucose dehydrogenase (GDH), cloned from Bacillus Megaterium 
genomic DNA, was added into Dxr reaction to recycle NADPH. In the presence 
of GDH, catalytic amount of NADPH was sufficient to achieve almost 100% 
conversion of DXP to MEP, as shown in Figure 7.7B. However, without GDH, 
majority of DXP was left unreacted even when sufficient amount of NADPH was 
added into the reaction medium. Therefore, the accumulation of DXP in the 
multienzymes synthesis was due to the reversible nature of the Dxr reaction [228]. 
GDH is essential to recycle NADPH and drives the reaction to completion. Work 
is ongoing to further optimize the multienzymes reaction with GDH to enhance 
the MEC yield.  
 
Figure 7.7. The Dxr reaction with downstream metabolites.  
A. different downstream products and by-products supplemented into the reaction medium. The 
activity was monitored by absorbance at 340nm; B. coupled with or without gluose 
dehydrogenease and in low (0.1mM) or high (0.5mM) NADPH. All the measurements were done 
in triplicates and the standard errors were drawn on the plot.   
 
7.3 Discussion 
The DXP pathway has drawn tremendous interest recently, since the 
pathway enzymes are uniquely essential constituents of many pathogenic 
microorganisms, and thus are excellent targets for developing antimicrobial 




agents [116, 227, 229]. MEC has been synthesized from glucose using purified 
enzymes [41, 55]. In this study, the aim was to explore the use of a co-
immobilized multienzymes platform for both MEC biosynthesis and for future 
antimicrobial drug screening.  
The initial hypothesis was to increase the enzymatic efficiency via co-
immobilization and substrate channeling. Since the in vitro enzymes are diluted 
and dispersed, a stark contrast to nature, co-localization is a way to bring enzymes 
into close proximity and hence increases local substrate concentration [85, 232]. 
However, this proposal was not successfully realized as the first commited 
enzyme, Dxs, was severely inactivated at the liquid-solid surface. This was 
probably due to the incorrect orientation of the Dxs on the solid support. Since the 
his6-tag was engineered at N-terminal of Dxs, where the active site is located, 
anchoring the enzyme onto the solid support might render the active site 
inaccessible to the reactants. Attempts have been made to re-engineer Dxs with C-
terminal his6-tag. However, little or no activity was detected when the C-terminal 
of Dxs was modified.  An alternative solution would be to modify the solid 
support with inert spacer, such as polyethylene glycol [203]. Dxs was discovered 
more than a decade ago, and has been extensively characterized [233, 234]. It has 
a promiscuous substrate binding pocket that is able to accept a range of substrates 
[235, 236]. Moreover, detailed mechanistic insights have revealed that GAP and 
pyruvate exhibit substrate inhibition [237], and IPP is a product inhibitor of Dxs 
[238]. These studies suggest that Dxs is highly susceptible to inactivation and is a 
known bottleneck of the DXP pathway [131, 239]. More recently, an alternative 




enzymatic route has been discovered in E. coli and Arabidopsis that 
phosphorylates 1-deoxy-D-xylulose to DXP [240, 241]. Moreover, in the field, 
there is some disagreement as to the identity of the first enzymatic reaction of the 
DXP pathway, as some suggested Dxr as the first committed step instead of Dxs 
[229, 238, 239, 242].  
The accumulation of DXP in the multienzymes reaction spurred us to 
investigate whether Dxr was regulated by downstream metabolites. Similar to this 
observation is that we have observed DXP also accumulates in vivo by using the 
LCMS method developed [42].  DXP accumulation may also due to Dxr activity 
as it is highly reversible and the equilibrium is biased in favour of the substrates 
[228]. With the aid of glucose dehydrogenase, the NADP+ level can be kept at 
minimal level and shifting the equilibrium towards MEP formation.  
Dxr is the second pathway enzyme, and fosmidomycin is a specific 
inhibitor of the enzyme. The drug has been demonstrated to cure rodent malaria 
caused by Plasmodium vinckei [243]. Interestingly, a new family of enzyme has 
been discovered in Brucella abortus that confers Dxr like (Drl) enzymatic 
activity[244].  This was likely the reason that certain bacteria have developed 
drug resistance through changes in biochemical pathway by re-routing and 
evolving new enzymatic functions. Therefore, a combination of antibacterial 
drugs that inhibit multiple enzymes simultaneously would limit the chance of 
developing drug resistance. However, to screen a library of compounds usually 
consists of hundreds of thousands of chemicals, the cost of preparing the target 
proteins would be high. Therefore, enzyme recycling and the use of miniaturized 




devise, such as immobilized microfluidic enzyme reactor (IMER) [245], would 
have a great impact to reduce the cost incurred. We believe the technology 
developed here would have industrial importance and could be applied as a 
recyclable platform for drug screening. 
7.4 Conclusion 
In summary, we are in the process of developing a recyclable platform that 
co-immobilize the DXP pathway enzymes for MEC biosynthesis and 
antimicrobial drug screening. Since Dxs was found to be severely inactivated at 
the liquid-solid interface, we aimed to develop a two stage reaction whereby Dxs 
reaction would be performed in solution, and Dxr, ispD, ispE and ispF would be 
co-localized on Ni-NTA functionalized surface. With that approximately 50% 
yield was achieved within 1 hour. The yield can be further optimized with 
auxiliary reaction such as glucose dehydrogenase to drive the reversible Dxr 
reaction to completion.   
7.5 Materials and Methods 
7.5.1 Bacteria strains and plasmids 
Bacteria strains and plasmids used in this study were summarized in Table 
7.3. The DXP pathway enzymes, namely 1-Deoxy-D-xylulose 5-phosphate 
synthase (Dxs), 2-C-methylerythritol-4-phosphate reductase (Dxr), 4-
diphosphocytidyl-2-C-methyl-D-erythritol synthase (IspD), 4-diphosphocytidyl-2-
C-methyl-D-erythritol kinase (IspE), and 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase (IspF) were amplified from E. coli genomic DNA with 




his6-tag. A 5’ SacI site and a 3’ XhoI site were introduced downstream from the 
6xHis open reading frame. The PCR products were ligated into the modified 
pBAD-B (Invitrogen, CA) and pET-11a vector (Stratagene, CA) and transformed 
into competent E. Coli strain DH10B [20]. All the plasmids were transformed and 
harboured from E. coli DH10B and then transformed to respectively strains for 










Table 7.3. The bacteria strains and plasmids used in Chapter 7. 
Name Description 
Reference 
E. coli BL21-Gold 
(DE3) 
F– ompT hsdS (rB
– mB
–) dcm+ Tetr gal λ(DE3) endA 
Hte 
Stratagene 
E. Coli DH10B araD139 Δ(ara-leu)7697 fhuA lacX74 galK (Φ80 
Δ(lacZ)M15) mcrA galU recA1 endA1 nupG rpsL 
Δ(mrr-hsdRMS-mcrBC) 
NEB 
E. Coli XL10-Gold Tetr D(mcrA)183 D(mcrCB-hsdSMRmrr) 173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F9 proAB 
lacIqZDM15 Tn10 (Tetr) Tn5 (Kanr) Amy 
Stratagene 
pBAD-His-Dxs Plasmid for overexpression of Dxs in E. coli XL10 
[20] 
pET-His-Dxr Plasmid for overexpression of Dxr in E. coli BL21 
pET-His-IspD Plasmid for overexpression of IspD in E. coli BL21 
pET-His-IspE Plasmid for overexpression of IspE in E. coli BL21 
pET-His-IspF Plasmid for overexpression of IspF in E. coli BL21 
 




7.5.2 Enzyme expression and purification 
Newly transformed colonies were picked from the agar plate, inoculated 
into 2xPY medium (20 g/L Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH 7) 
containing 100 mg/L ampicillin and grew till stationary phase overnight at 37 
o
C 
in an incubator-shaker (Shin Saeng Shaking Incubator, Finetech, Korea). The 
culture was then further transferred into fresh 2xPY medium (1% inoculation) 
with ampicillin for another 2.5 h at 37 
o
C, till optical density A600 reached 0.6-1.0. 
The enzyme expression was induced with 10mM L-arabinose for Dxs and 0.1 
mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) for the other four pathway 
enzymes. Temperature was reduced to 20 
o
C after induction for higher solubility 
of the enzymes [20]. The culture was grown for another 48 h and harvested by 
centrifugation. The cell pellets were stored at -20 
o
C till further use.          
To purify the enzymes, the frozen cell pellets were resuspended in B-
PERII reagent (Pierce, IL), according to the manufacturer’s instruction, and 
vortexed at room temperature for 30 mins to completely lyse the cells. The 
soluble proteins were contained in the supernatant, which was diluted 15 times in 
NPI10 buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) and 
incubated with 200 mg Ni-NTA resin (USB, Affymetrix, CA) at 4 
o
C for 2 h. The 
resin was washed with NPI10 buffer after discarding the binding supernatant, and 
the enzymes were eluted and collected by 400 μl NPI400 (50 mM NaH2PO4, 300 
mM NaCl, 400 mM imidazole, pH 8). The enzymes were further concentrated by 
3K Amicon ultra-0.5 ml centrifugal filter unit (Millipore, MA), and the 
concentrations were measured by Micro BCA protein assay kit (Thermo 




scientific, MA). The purified enzymes were further confirmed by sodium dodecyl 
sulfate-12% polyacrylamide gel electrophoresis (Bio-Rad, CA).     
7.5.3 Enzyme kinetics  
The pathway enzyme kinetics was determined individually by initial rate 
measurements. In brief, the substrates and cofactors were added to 100 mM 
HEPES reaction buffer (pH 7.4), and the reaction was initiated by adding pre-
determined enzyme amount to ensure less than 10% substrate was consumed in 15 
mins at 37 
o
C.  The substrates concentrations were varied in equal steps in 
reciprocal space from 0.1 to 1 mM. For Dxr, the enzymatic activity was 
monitored photometrically at 340nm. For Dxs and IspD, the reaction was 
terminated by adding equal volume of 1% ammonium hydroxide and diluted 10 
times into cold methanol. After high speed centrifugation, the supernatant was 
subject to UPLC-(TOF)MS analysis. Double-reciprocal plots of each enzymatic 
activity were constructed for the determination of Km and Kcat values for the 
respective substrates. 
7.5.4 Multienzyme reaction  
The multienzyme reaction, starting from Dxs, was carried out in a buffer 
(25 μl) consisted of HEPES (100 mM, pH 7.4), MgCl2 (10 mM), 
(±)Glyceraldehyde 3-phosphate (10 mM), pyruvate (5mM), Thiamine 
pyrophosphate (ThPP, 0.5mM), NADPH (5mM), CTP (5mM), ATP (15 mM) and 
the purified enzymes. The reaction was performed at 37
o
C. At the end of the 
reaction, the reaction was terminated by adding equal volume of 1% ammonium 




hydroxide and diluted 10 times into cold methanol. The multienzymes reaction 
starting from Dxr was conducted at the same reaction condition in a buffer (25µl) 
consisted of HEPES (100 mM, pH 7.4), MgCl2 (10 mM), 1-Deoxy-D-xylulose 5-
phosphate (DXP, 1mM), NADPH (1mM), CTP (1mM), ATP (1 mM) and the 
purified enzymes.  
To co-immobilize the pathway enzymes, the cells were disrupted by glass 
beads, and the cell lysate mixture was prepared with approximately equal enzyme 
concentration of individual enzyme. The mixture was then diluted in phosphate 
saline buffer (PBS) and incubated with Ni-NTA grafted silicon beads at 4
o
C for 2 
h. The unbounded protein was washed away with PBS. Subsequently, the beads 
with bound enzymes were divided into two equal parts. To one part, NPI400 
buffer (50 mM NaH2PO4, 300 mM NaCl, 400 mM imidazole, pH 8) was added to 
elute the enzymes from the beads, and to the other part, equal volume of NPI10 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8) was added. Then 
predetermined amount of enzymes were added into the reaction mixture to initiate 
the reaction.  
7.5.5 UPLC-(TOF)MS analysis of DXP pathway intermediates 
The analysis was done based on the method developed previously with 
slight modification [42]. In brief, 5 μl samples were injected into a UPLC C18 
column (Waters CSH C18 1.7 μm, 2.1 mm x 50 mm) connected to UPLC (Waters 
ACQUITY UPLC)-(TOF)MS (Bruker micrOTOF II, MA).  Elution was carried 
out with a step change from 100% aqueous solution containing 15 mM acetic acid 
and 10 mM tributylamine (0.5 min) to 10% aqueous solution with 90% methanol 




for another 3.5 min. Electrospray ionization was used and mass spectrometry was 
operated to scan 50–800 m/z in negative mode with 2500 V end plate voltage and 
3200 V capillary voltage. Nebulizer gas was provided in 2 bar, dry gas flow rate 
was 9 ml/min, and dry gas temperature was 220 
o
C. At the assay condition, all the 
intermediates were detected in the form [M-H]
-
. Retention time was subsequently 
determined for each intermediate with respective synthetic standards and the set 
m/z extraction range. The peak area was calculated and subsequently used to 
compute the intermediates concentrations with the software provided by the 
manufacturer. The calibration curves were constructed with synthetic standards 
prepared under similar reaction conditions without enzymes. Linearity of the 
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Chapter 8 Conclusion and recommendation of future works 
8.1 General Conclusion 
Cell free synthesis is a re-emerging powerful technology for biomolecules 
and small molecules production. In this thesis, production of isoprenoids and its 
precursors via cell-free synthesis has been demonstrated by assembling both the 
mevalonate and non-mevalonate pathways. A summary of main findings in the 
thesis is shown in Figure 8.1. A substantial portion of the thesis was dedicated to 
the optimization of amorpha-4,11-diene (AD) production using the mevalonate 
pathway. Through which, it repeatedly demonstrated that the key limiting step 
was amorpha-4,11-diene synthase (Ads). Firstly, its enzymatic turnover rate was 
more than 2 orders of magnitude lower than the other pathway enzymes. 
Secondly, its substrate farnesyl pyrophosphate precipitated in the presence of 
magnesium, an essential ion for the enzymatic reactions (chapter 3). Lastly, Ads 
activities were inhibited by high concentration of ATP and its by-product 
pyrophosphate (Ppi) (chapter 4 and 5). Equipped with thorough understanding of 
Ads behaviour, we devised specific strategies to improve Ads activities through 
buffer optimization and removal of inhibitors (ATP regeneration and 
pyrophosphatase to hydrolyse Ppi). Consequently, the production of AD was 
improved from less than 5% conversion in 12h to approximately 100% 
conversion in 4h, which approached the theoretical rate of reaction based on Ads 
activity. This was a remarkable enhancement of time and space yield. We further 
demonstrated the production of AD on solid platform with the intention to recycle 
the pathway enzymes. By designing a novel bi-modular reaction system, the 




productivity of the solid platform was able to maintain after 8 cycles and 
approximately 2.2g/L AD could be produced in a small scale.  
 
 
Figure 8.1 Schematic diagram summarizing the main findings in the thesis.  
The work mainly focused on establishing and optimizing the mevalonate pathway in vitro to 


















8.2 Future studies 
8.2.1 Crystal structure of amorpha-4,11-diene synthase and rational protein 
engineering 
As demonstrated in the thesis, Amorpha-4,11-diene synthase (Ads) is the 
main rate limiting step. Increasing its activity has shown to improve both in vitro 
and in vivo AD yield. Despite the improvement of its specific activity with buffer 
optimization, Ads still displayed remarkably low enzymatic efficiency. One 
plausible hypothesis was that the hydrophobic product was released slowly into 
aqueous medium. Doping the medium with amphiphilic substances such as 
detergent and ionic liquid was not found to be helpful. On the contrary, they 
prevented FPP from accessing the Ads catalytic site, since FPP is amphiphilic and 
would bind to detergent-like molecules. Therefore, rational protein engineering 
would be more desirable approach to improve Ads activity at molecular level. The 
structurally optimized Ads will be applicable to both in vitro and in vivo AD 
synthesis.  To this end, structural information of Ads will provide useful 
information in determining the key amino acids that interact with both the 
substrate and product. Subsequently, in silico tools will be explored to aid re-
modeling of the catalytic site of Ads, which will then be verified experimentally.  
 
8.2.2 Increase Ads enzyme yield by in vitro re-folding 
As shown in Chapter 3, Ads is entirely insoluble when overexpressed in E. 
coli. Although repeated freeze-thaw is able to release some soluble Ads into the 
lysis medium, majority of Ads enzymes were lost as insoluble aggregates. To 




recover Ads from the inclusion bodies, in vitro protein re-folding is 
recommended. Initial attempt has been carried out, and found that commonly used 
chaotropic agent such as 8M urea was unable to recover Ads from the inclusion 
body. Instead, alkaline solution (pH=12.5) with 2M urea was used to partially 
dissolve Ads. Lowering urea concentration is favourable, since it will not totally 
disrupt the partially folded polypeptide chains which resemble native secondary 
structure [246]. Ionic liquid can be explored in the future to treat the inclusion 
body to enhance Ads polypeptide chain solubility. Subsequently, on column 
refolding will be carried out to in situ remove extraneous proteins and refold Ads. 
Combinations of natural and artificial chaperons as well as additives (Table 8.1) 
will be optimized to drive the equilibrium toward the correctly folded enzymes. 
The refolding efficiencies can be determined and compared by measuring the total 
activity recovery (Equation 8.1).  
 
Equation 8.1.Refolding efficiency is determined by the percentage of total activity 
recovered after refolding.  
The abbreviations are as follows. mr is the mass of refolded soluble protein. Ar is the specific 
activity of refolded protein. mt is the total protein recovered from inclusion body. An is the specific 
activity of the native protein by standard purification. 
 
Table 8.1 Lis of commonly used additives for protein refolding. 
Additives Concentrations used Effect 
Glycerol, sucrose 100mM to 2.5M Stabilizer 
L-Arginine 100mM to 2.5M Stabilizer 
Mg2+ 75mM Salt 
GSSG/GSH 0.01mM to 10mM Redox reagents 





bromide (CTAB) + β-
cyclodetrin (β-CD) 
2.4mM (CTAB) 5mM (β-CD) 
Artificial 
chaperone [247] 




8.2.3 Scale-up cell free synthesis 
The application of cell free synthesis has always been questioned for its 
capability to scale up, due to the cost incurred to purify enzymes and the use of 
expensive co-factors. The recent breakthrough demonstrated by Zawada et al. 
[249] quelled the myth. They have successfully scaled up cell-free synthesis to 
100L by using cell lysates and produced 700mg/L human granulocyte 
macrophage colony-stimulating factor. This was the first ever industrially relevant 
cell-free protein synthesis reaction.  Therefore, in the future, semi-in vitro 
synthesis with cell lysates containing overexpressed enzymes will be used to 
scale-up the multienzymes biosynthesis. It allows a higher degree of freedom to 
manipulate the production pathway enzymes than in a living cells, since cell 
viability is no longer a limiting factor. The balancing of pathway components can 
be better controlled without high cost incurred. Preliminary data suggested that 
AD can be synthesized through semi-in vitro method. The yield can be further 
improved when Ads activity is optimized. Accurate quantification and 
manipulation of enzyme amount will be realized via advanced mass spectroscopy 
technology.  A combination of chaperons can be co-expressed with the pathway 
enzymes to enhance their stability. To avoid dilution of the pathway enzymes, 
they can be co-localized by facile means such as IMAC to increase the local 




enzyme concentrations. Specific biochemical pathways can be activated to 
regenerate co-factors. Moreover, since the product formed could be in situ 
removed by the second organic layer (e.g., dodecane), continuous feeding of 
substrates to the cell lysates mixture is feasible. Thus, the cell lysate mixture can 
be effectively recycled.  
 
8.2.4 DNA-directed assembly of multienzymes 
DNA directed assembly technology is advancing by leaps and bounds. 
With the drastic improvement of DNA synthesis technology, using DNA as a 
novel biomaterial has become a reality. Due to the defined dimension of 
oligonucleotide and specific base pairing, it is possible to generate almost any 
geometries and structures. However, the real application of DNA directed 
assembly technology is still limited. Despite the ample applications of DNA 
microarray, DNA directed assembly of cascade enzyme reactions is still in its 
infancy. Therefore, there is a great potential to adapt our in vitro system onto the 
platform. We have shown that by dividing the pathway enzymes into two modules 
would enhance the productivity of the system.  Tuning the inter-enzyme distance 
at submicron level would result in much higher precision and is expected to 
further enhance the specific yield of the system. 
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